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NEUROIMMUNE CROSSTALK: A ROLE FOR NEUROPEPTIDE Y IN 
INFLAMMATORY BOWEL DISEASE 
by 
Henry H. Ruiz 
Adviser: Professor Susan D. Croll 
Neuropeptide Y (NPY) is a 36-amino acid peptide widely expressed in the central and 
peripheral nervous systems. In addition to other cells, NPY is also synthesized and co-
released from sympathetic nerve fibers functioning as a potent sympathetic 
neuromodulator. NPY has been implicated in playing important roles in the regulation of 
energy balance, appetite, anxiety, vascular tone, and immune cell functioning. In 
addition, immune cells of both the innate and adaptive immune systems express 
functional NPY receptors. Some immune cells can produce and secrete NPY, and genetic 
alteration of these receptors results in altered immune cell functioning. Its direct 
association with the immune system, its presence in sympathetic neurons innervating 
primary and secondary immune organs and its close association with vasculature, make 
NPY a candidate for mediating, at least in part, the neuroimmune crosstalk.  The gene 
expression results presented here suggest that DSS is a valid model of human IBD and 
that pain-related behavior in the open field is closely associated with DSS-induced gene 
changes. Furthermore, the data suggest that NPY signaling via its Y1 receptor plays some 
regulatory role in the immune process induced by DSS. Y2 receptor antagonism resulted 
in a mild attenuation of immune activity but also slightly attenuated pain-related behavior 
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in the open field. In sum, it appears that NPY signaling via its Y1 and Y2 receptors plays a 
role in various features of DSS induced disease. 
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The Involvement of the Nervous System in Inflammatory Disease 
 
 The nervous and immune systems are two distinct body systems that have 
traditionally been thought to underlie very distinct functions and diseases.  Recent 
research has revealed more crosstalk between the two systems than was previously 
appreciated.  The role of neuroimmune interactions in both normal physiology and 
pathophysiology is becoming increasingly apparent, but research more fully elucidating 
the mechanisms and breadth of these functions is in its infancy.  One system that is 
gaining increased attention in this regard is the autonomic nervous system.  Because the 
autonomic nervous system innervates the vasculature and most peripheral organs, it has 
the potential to be involved in a wide range of physiological conditions.  It is for this 
reason that many laboratories have launched into research programs designed to better 
understand the role of the autonomic nervous system in immune diseases.  The current 
paper will introduce work being done to understand some of the potential mechanisms of 
autonomic nervous system involvement in immune disease. 
The Autonomic Nervous System 
The autonomic nervous system represents just one component of the nervous 
system.  The nervous system encompasses two major systems; the central nervous system 
(CNS), which is made up of the brain and spinal cord, and the peripheral nervous system 
(PNS), which is made up of all nerves and ganglia outside the CNS. The peripheral 
nervous system is further subdivided into two subsystems: the somatic nervous system, 
which includes sensory and motor fibers, and the autonomic nervous system (ANS). The 
	  	  
2	  
ANS is further subdivided into three components. The two major components that often 
work in harmonic opposition to one another: the sympathetic nervous system (SNS) and 
the parasympathetic nervous system (PaNS) with the third being the enteric nervous 
system (ENS) and compromising neurons controlling the functions of the gastrointestinal 
system.  Through mainly opposing mechanisms, the SNS and the PaNS play major roles 
in maintaining an organism’s internal environment at homeostatic balance.  This 
maintenance occurs automatically, and is usually outside the voluntary control of the 
organism. 
 Some of the functions mediated by the SNS include pupil dilation, stimulation of 
hormonal release from glands, inhibition of digestion and constriction of blood vessels all 
characteristic of the “fight or flight” response. The PaNS on the other hand mediates the 
opposing effects, such as pupil constriction, stimulation of digestion and blood vessel 
dilation. Signaling for both systems originates in the CNS and is carried out by clusters of 
neurons known as preganglionic cells. For both the SNS and PaNS, the neurotransmitter 
secreted by preganglionic cells is acetylcholine (Ach). The preganglionic cells then 
project to postganglionic cells which project throughout the body to signal autonomic 
regulation.  The neurotransmitter released by postganglionic cells is different for the two 
branches of the autonomic nervous system, with PaNS cells releasing Ach onto target 
organs whereas SNS signaling is mediated by the catecholamine, norepinephrine (NE).  
These two systems must work as negative feedback mechanisms in order to maintain 
homeostatic balance and healthy functioning. 
 There is growing evidence that ANS disruption is often associated with 
pathological states. Several cardiovascular (Abboud et al, 2012), murine inflammatory 
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(Elenkov et al., 2000), human inflammatory diseases such as inflammatory bowel disease 
(Belai et al.,1997; Furlan et al., 2005), primary Sjögren syndrome (pSS), rheumatoid 
arthritis (RA) and systemic lupus erythematosus (SLE) have been linked to alterations in 
ANS functioning (Stojanovich et al., 2007).  The observation that ANS dysfunction is 
associated with several immune disease states has contributed to the perspective that the 
immune and nervous system interact, and may be capable of modulating each other's 
activity.  
Though there has been evidence of nerve fibers innervating immune organs such 
as the lymph nodes for more than a century, only in the last forty years have there been 
attempts to elucidate the connection between the brain and the immune system or the 
neuroimmune connection (Elenkov et al., 2000).  This relatively recent integration of 
fields of study has provided a great amount of insight into the mechanisms by which the 
CNS and immune system communicate, with a large body of literature pointing to the 
crucial involvement of the ANS as the key mediator for this cross system communication 
(Nance & Sanders, 2007).  
The Immune System 
 The immune system is an important line of defense for an organism’s body to be 
protected against foreign bodies. In addition to this internal line of defense, the body also 
has other defense mechanisms. In the CNS, protection is largely mediated by bone 
encompassing the brain and spinal cord and a protective vascular barrier known as the 
blood brain barrier (BBB), which forms a tight selective vascular barrier. The PNS is 
largely unshielded from the general circulation and is vulnerable to infiltration by 
external factors. The skin is the body’s largest organ in charge of keeping foreign 
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substances out of the body. In addition, the epithelial lining of organs exposed to outside 
agents, such as gastrointestinal organs or lung alveoli are designed to provide a barrier to 
unrestricted passage of foreign substances.  At times, however, these barriers can be 
broken as is the case during lesions or antigen infiltration in compromised barriers such 
as in the nasal passages or the gastrointestinal (GI) track. When this occurs, cells that 
make up the immune system, which are constantly surveying the internal state of the 
body, begin an immune response.   
 There are two main components of the immune system that work in concert to 
identify and destroy foreign threats to the body: the innate and adaptive immune systems.  
The innate immune response is mediated by cells that rapidly respond to any foreign 
threat detected in the body.  This response does not lead to long lasting immunity and is 
not specific to any individual antigen. The innate immune response is mainly mediated by 
innate leukocytes (neutrophils, eosinophils, basophils, monocytes and macrophages) 
(Murphy, 2012). Upon recognition of a body or substance as foreign, immune cells 
become activated and begin a phagocytic process resulting in the degradation and 
removal of the substance. This response can and often does result in inflammation, an 
important component of most immune responses.  
 Inflammation is a phenomenon first identified by Cornelius Celsius nearly 2000 
years ago when it was clinically described by its four cardinal signs of redness and 
swelling with heat and pain (rubor et tumor cum calore et dolore) (Scott, 2004).  
Inflammation is characterized by the presence of immune cells in the affected region, and 
its symptoms are thought to be mediated by the immune cells themselves.  In addition to 
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the innate immune system, inflammation is also associated with responses of the adaptive 
immune system.  
 An adaptive immune response is initiated when antigens are able to evade the 
innate immune system or be incompletely cleared by the innate response.  Dendritic cells 
are thought to be primary players in the transition between innate and adaptive responses. 
The adaptive immune response is primarily carried out by T and B-lymphocytes. T-Cells 
can be further subdivided into effector or helper T-Cells. Effector T-Cells can perform 
three main functions: 1) destroying cells expressing a protein antigen through cytotoxic 
responses, 2) activating macrophages and other immune cells for antigen removal or 3) 
regulatory where they help control immune responses by suppressing other immune cells. 
Helper T-Cells (Th) enhance the phagocytic function of macrophages and activate B-
Cells by presenting the antigen on their cell surface to be recognized by B-Cells 
(Murphy, 2012).  B-cells express large numbers of receptors on their cell surface and 
each B-cell has a different combination of receptors.  In this manner, each B-Cell is 
programmed to respond to only a very select set of antigens, but there can be millions of 
potential antigen receptors circulating in the body at any given time to encounter antigens 
that have bypassed innate immunity. Upon activation of a B-Cell receptor, that cell 
begins a cloning process to divide and create more cells that express the same antigen 
receptor. When activated, B-Cells can differentiate into plasma cells that release antibody 
(Abs) proteins, which bind to foreign antigens, targeting them for immune attack.  
 It is clear that both the innate and acquired immune systems are crucial for the 
protection and maintenance of an organism’s health.  However, when these systems fail 
to maintain homeostatic harmony or become dysregulated in concert, immune diseases 
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such as autoimmunity can occur. Autoimmunity refers to the immune system’s inability 
to distinguish foreign antigens from self-antigens (antigens associated with the body’s 
own tissue), leading to autoimmune diseases characterized by tissue damage (Murphy, 
2012). Currently, there are more than 80 chronic autoimmune illnesses affecting an 
estimated 5-8% of the American population, rapidly increasing in prevalence and 
affecting women and minorities disproportionally (NIH, 2005). In light of the debilitating 
nature of these diseases, it is of importance to elucidate the mechanisms responsible for 
the development and progression of these diseases.  A solid line of support for the 
involvement of the neuroimmune pathway in inflammatory diseases comes from clinical 
and experimental studies showing altered SNS function during the active phase of the 
disease (Boisse et al., 2009) and no difference from controls during stable disease phases 
(Flachenecker et al., 2001). Irregular SNS activity in humans is highly associated with 
autoimmune diseases such as systemic sclerosis and Raynaud’s phenomenon (Pancera et 
al., 1999) and these observations have also been corroborated in experimental models 
(Kasselman et al., 2006).  
 The relevance for neuroimmune crosstalk in autoimmune and inflammatory 
diseases has received much attention over the past four decades. Kasselman et al. (2006) 
and Pancera et al. (1999) both presented results suggesting that sympathetic dysfunction 
plays a crucial role in the development of perivascular inflammation and in autoimmunity 
respectively. Though the link between the CNS and SNS in these diseases has been 
established (Nance & Sanders, 2007), the question remains as to what underlying 
mechanisms are responsible for the induction of these pathological states.  Emphasis is 
currently being placed on the neurotransmitters and neuromodulators of the SNS as 
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potential therapeutic targets. These include the catecholamines (epinephrine, 
norepinephrine), regulatory neuropeptides particularly from the Y family and their 
respective receptor subtypes. 
Neuropeptide Y  
Neuropeptide Y (NPY) is a neuropeptide widely expressed in both the CNS and 
PNS, which may play a role in neuroimmune cross talk (Bedoui et al., 2003).  NPY is a 
36 amino acid peptide sequenced within the last three decades and part of the larger Y 
peptide family consisting of NPY, peptide YY (PYY) and pancreatic polypeptide (PP) 
(Tatemoto, 1982).  NPY is synthesized and released by neurons that, in the PNS, are 
predominantly sympathetic neurons. Upon NPY release, its signals are mediated via G-
protein coupled receptors (GPCRs).  GPCRs are seven transmembrane domain 
metabotropic receptors commonly found throughout the nervous system but also found in 
other tissues.  There are five types of GPCRs for NPY (Y 1,2,4,5,6), each with a distinct 
pattern of distribution in the brain and periphery (Dumont et al., 1993; Jönsson-Rylander 
et al., 2003). These activated GPCRs initiate a downstream cascade via the Gi subunit 
resulting in the inhibition of cyclic adenosine monophosphate (cAMP) production from 
adenosine triphosphate (ATP) thereby altering second messenger cascade signaling 
(Lobaugh & Blackshear, 1990). 
 In the CNS, NPY signaling has been associated with food intake, energy balance 
and anxiolytic effects and in the periphery it modulates metabolic (Li et al., 2012), 
gastrointestinal and renal functioning as well as being a potent vascular constrictor and 
sympathetic modulator (Michel et al., 1998).  Recently, the role of NPY as a mediator of 
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the sympathetic link between the neuroimmune crosstalk has been explored and has 
generally been well supported. 
 Evidence for the idea of neuroimmune crosstalk being mediated by the SNS 
comes from observations that noradrenergic sympathetic fibers innervate the major 
peripheral immune organs including the thymus, bone marrow, spleen, and primary 
lymph nodes (Felten et al., 1985; Ericsson et al., 1987; Madden et al., 1997). In addition 
to the direct innervation of lymphatic tissue by the SNS, the presence and potential 
synthesis (Ericsson et al., 1987) of several neuropeptides including NPY at these immune 
organs has been reported (Felten et al., 1985). Furthermore, it has been observed that 
NPY is co-transmitted in large vesicles with catecholamines (CA) such as norepinephrine 
(NE) and epinephrine (E) in sympathetic fibers but not sensory fibers innervating the 
lymph nodes (Fink & Weihe, 1988).  It is thought that these fibers contribute to the 
regulation of immune cell functioning (Straub et al., 2000). Taken together, the fact that 
sympathetic fibers carrying signals from the central nervous system via neurotransmitters 
such as NE and E and neuromodulators such as NPY innervate and have synaptic-like 
connections on immune organs suggests that this mechanism serves as a control and 
feedback mechanism between the brain and the immune system.  
Neuropeptide Y and Immunity 
NPY has also been demonstrated to play a crucial role in the direct modulation of 
the neuroimmune crosstalk at the cellular level. Sympathetic fibers releasing NPY have 
synaptic-like connections with immune cells (Phillips et al., 2012), and NPY receptors 
have been observed on those cells (Bedoui et al., 2002; Straub et al., 2000). It is widely 
accepted that the release of catecholamines and NPY from sympathetic terminals, is 
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dependent on the stimulation pattern. That is, NE is preferentially released during 
stimulation representative of baseline sympathetic functioning whereas NPY release 
dominates sympathetic signaling during sympathetic hyperactivity (Bedoui et al., 2002). 
In addition, activated monocytes, macrophages and B-lymphocytes secrete NPY, further 
implicating this neuropeptide in the modulation of immune responses (Schwarz et al., 
1994).  
 The nature of NPY’s involvement during immune responses is dependent on the 
cell type and Y receptors expressed (Wheway et al., 2005). Several studies point to the 
expression of different Y receptors on different immune cell populations with Y1, Y2 and 
Y5 expression being most often reported (Bedoui et al., 2002; Dimitrijevic et al., 2005; 
Mitic et al., 2011). Peripheral blood granulocytes such as neutrophils, eosinophils and 
basophils affect immune responses via Y1, Y2 and Y5 receptors. In addition, Y2 and Y5 
receptors appear to influence the adherence properties of granulocytes whereas Y2 and Y1 
are reported to be important in regulating phagocytic activity (Mitic et al., 2011). Though 
there is clear evidence from multiple laboratories on the involvement of NPY in immune 
functioning, these observations have been shown to vary between in vitro and in vivo 
studies. Mitic et al. reported that in vivo, NPY decreases inflammatory cell adherence and 
phagocytosis via Y2/5 and Y1/2 receptors respectively as determined by pharmacological 
manipulations. In vitro however, the same authors report that NPY mediated 
enhancement of both adhesiveness and phagocytic properties of immune cells that are 
mediated by the Y1 receptor (Mitic et al., 2011). The authors attribute these differential 
effects between the in vivo and in vitro assays to the possibility that in the in vivo 
experiment, Dipeptidyl peptidase-4 (DPP4) or CD26 activity may be cleaving NPY into 
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an isoform not recognized by the Y1 receptor but with high affinity to the Y2 receptor. 
This explanation is supported by reports that Y2 receptor activation suppresses 
phagocytic activity by immune cells (Dimitrijevic et al., 2005). An alternative 
explanation comes from observations that during insult with the endotoxin 
lipopolysaccharide (LPS) and in the presence of NPY, monocyte migration is reduced at 
early time points (4 hrs.) but then NPY enhances migration 72 hrs. after insult (Nave et 
al., 2004). Mitic et al. observations took place on the same day of NPY treatment but the 
specific time points were not provided. Additionally, Nave et al. demonstrated that in 
vivo, NPYs enhances monocyte, macrophage and T-lymphocyte adhesion via its Y2 
receptor. Y2 receptor selective antagonism resulted in a decreased macrophage 
mobilization whereas selective agonism of the same receptor enhanced macrophage 
mobilization. Furthermore, these authors demonstrated that Y2 receptor expression on 
PBMCs is only apparent following activation by LPS. These observations are in conflict 
with Mitric et al. who report the Y2 receptor to suppress cell adhesion in vivo. This 
discrepancy in findings may be partially explained by Nave at al. observation that Y2 
receptor expression does not begin until some time after PBMCs become activated. 
However, there is still a need for more in vivo studies to replicate and assessed these 
findings.  
 NPY has also been implicated in the mobilization of leukocytes as the application 
of exogenous NPY increases the adherence of macrophages and T-Cells (Nave et al., 
2004) and other immune cells. Mobilization of natural killer (NK) cells, monocytes and 
B-lymphocytes is modulated by NPY via its Y1 and Y5 receptors as demonstrated by 
pharmacological agonism and antagonism of each of these receptors (Bedoui et al., 2002) 
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as well as Y2 receptors for monocytes, macrophages and T-Cells (Nave et al., 2004). 
Because these leukocytes were only reported to express the Y1 receptor, it was suggested 
that the Y2 and Y5 receptor mediated modulation of leukocyte mobilization occurs via an 
indirect pathway (Bedoui et al., 2002). However, Nave at al., demonstrated that Y2 
receptors though not expressed at baseline, upon immune cell activation, their 
transcription is initiated and the same could be the case for the Y5 receptor, however, this 
question has yet to be addressed. In vitro, Y1 activation was shown to inhibit leukocyte 
mobilization while Y5 facilitates leukocyte mobilization to affected areas (Bedoui et al., 
2002). In a different in vivo model of immunological responses (septic shock), it was 
demonstrated that monocyte mobilization initially decreases after insult (4 hrs.) but three 
days later monocyte count is significantly increased only in the NPY treated groups. In 
addition, on the fourth day, there is a 60% monocyte increase compare to the third day 
and 600% increase when compared to the 4 hr. time point suggesting a continuously 
increasing monocyte perfusion in the presence of NPY (Nave et al., 2004).  
 In macrophage-dependent models of degradation and phagocytic activity, NPY 
has been demonstrated to be necessary for activation and proper functioning of 
macrophages and NPY knock out mice show impaired APC functioning (Wheway et al., 
2005), a phenomenon shown to be dependent on the receptor subtypes activated 
(Dimitrijevic et al., 2005). Dimitrijevic et al. showed that in the phorbol myristate acetate 
(PMA) model of macrophage degradation, the observed increases in oxidative stress by 
NPY are mediated by Y1 and Y2 receptors. However, in the zymosan-stimulated 
macrophage model, Y2 and Y5 receptors mediated the suppression of the NPY-induced 
oxidative stress. Y5 also mediated oxidative stress suppression in the PMA model 
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(Dimitrijevic et al., 2005). It is therefore apparent that the regulatory role of NPY in 
neuroimmune signaling is not homogenous but rather varies with cell type and the Y 
receptors expressed and activated. 
 Similar to the heterogeneous response of NPY depending on cell type and 
receptors expressed, NPY signaling in neuroimmune crosstalk is differentially modulated 
depending on sympathetic tone.  NPY levels have often been reported to be altered in 
SNS-dependent inflammatory and autoimmune diseases such as RA, SLE, pSS, 
fibromyalgia and inflammatory bowel diseases but decreased in other diseases (Bedoui et 
al., 2003).  Sympathetic innervation of lymphatic organs is necessary to regulate cytokine 
release as demonstrated by increases in pro- and anti-inflammatory cytokine release from 
animals exposed to chemical sympathectomy and reversal of this effect by 
pharmacologically preventing chemical sympathectomy (Kruszewska et al., 1995).   
Sympathetic tone and NPY significantly interact to alter leukocyte mobilization. 
In vivo and in vitro studies looking at different doses of epinephrine in the presence of 
NPY have provided insight into the role of NPY under different levels of sympathetic 
tone. Low and moderate sympathetic tone in the presence of NPY enhances the 
mobilization of leukocytes such as NK, monocytes and B-lymphocytes while high 
sympathetic tone in the presence of NPY inhibits these effects (Bedoui et al., 2002). In 
addition, and as is expected from high sympathetic tone resulting in increased NPY 
levels, administration of high levels of NPY results in enhanced mobility of NK cells, 
monocytes and T-cells while low levels of NPY result in inhibition of these effects 
(Bedoui et al., 2001). Both of these studies suggest a direct modulation of immune cell 
mobilization by the sympathetic system. Though these findings appear contradictory in 
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that Bedoui et al. (20002) found high sympathetic tone in the presence of NPY to inhibit 
leukocyte mobilization and Bedoui et al. (2001) found that high levels of NPY (as would 
bee expected in high sympathetic tone) showed increased leukocyte mobilization, the 
difference may lay in the baseline levels of NPY. That is, when NPY is already present, it 
may modulate a protective role and inhibit leukocyte migration whereas during high 
sympathetic tone, elevations in NPY drive leukocyte mobilization. Hence, it could be that 
at baseline sympathetic conditions, NPY plays a regulatory role whereas high levels of 
NPY during sympathetic hyperactivity may initiate proinflammatory cascades.  
Sympathetic tone also has modulatory effects on macrophage-dependent cytokine release. 
Under low sympathetic tone, catecholamine signaling is largely mediated by the α-
adrenoreceptors while high sympathetic tone preferentially activates β-adrenoreceptors. 
Under low sympathetic tone, NPY enhances the inhibitory effects of NE on cytokine 
release as measured by the macrophage production of the proinflammatory cytokine 
interleukin 6 (IL-6). However, under high sympathetic tone or direct pharmacological 
stimulation of β-adrenoreceptors, NPY enhances the proinflammatory macrophage-
dependent cytokine IL-6 release (Straub et al., 2000). These results indicate that in part, 
sympathetic activity determines the role of NPY on neuroimmune crosstalk particularly 
via macrophage-dependent proinflammatory cytokine release. 
 In line with the data supporting a role for NPY in immune disease, preliminary 
data from our laboratory suggests that peripheral NPY Y1 receptor antagonism in an 
experimental autoimmune model results in decreased inflammation of some peripheral 
organs often affected in human autoimmune diseases (Ruiz et al., 2011). NPY has also 
been implicated in mediating neurogenic dermal inflammation in other immune models 
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(Naveilhan et al., 2001). Naveilhan et al. looked at capsaicin-induced inflammation 
(neurogenic), mustard oil induced inflammation (mixed: neurogenic and non-neurogenic 
component) and carrageenan induced inflammation (non-neurogenic). These authors 
observed a complete amelioration of dermal neurogenic inflammation, a partial 
suppression of dermal inflammation in the mixed model and no difference in the non-
neurogenic model for mice lacking the Y1 receptor. These findings suggest that dermal 
inflammation with neurogenic components is largely mediated by the Y1 receptor. 
Another major inflammatory area where the Y1 receptor has been largely implicated is in 
inflammatory bowel disease.  
Inflammatory Bowel Disease 
Inflammatory bowel disease (IBD) is a category of diseases characterized by 
chronic or recurring immune responses leading to inflammation of the gastrointestinal 
tract. IBD symptoms include diarrhea, cramping abdominal pain, fever, bloody stool and 
often, significant weight loss. Due to its detrimental effects, IBDs impose a burden on 
patients affecting interpersonal and intrapersonal relationships as well as posing a 
problem for other family members and the family’s financial status. Ulcerative colitis 
(UC) and Crohn’s disease are the two primary and most common types of IBD. Crohn’s 
disease was first described by the German surgeon Wilhelm Fabry (also known as 
Guilhelmus Fabricus Hildanus) in 1623 and later on described and named in the United 
States by the physician Burril B Crohn. The British physician Sir Samuel Wilks first 
described UC nearly two centuries later in 1859 (Baumgart and Carding, 2007a).  
Though many centuries has passed since the first description of the primary IBDs, 
there is currently a need for a global clinical diagnostic criterion to allow for consistent 
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and accurate disease classifications. Stemming from this issue, current epidemiology IBD 
studies though informative may not be providing the most precise global incidence and 
prevalence of IBD.  With this in mind, there is a large body of literature providing 
informative patterns about IBDs that may aid in unveiling the etiology for these diseases, 
which has yet to be uncovered. 
Epidemiology of IBD 
Crohn’s disease and UC symptoms and clinical diagnosis is most commonly 
observed during late adolescence and early adulthood with a mean age range from 33.4 to 
45 and a median of 29.5 years of age. IBD diagnosis in children under the age of 18 is 
estimated to be about 10% and has not risen in recent years. Thought this is the general 
pattern, some reports suggest a bimodal age distribution with some cases appearing in the 
later years of life (Loftus, 2004).  According to the center for disease control (CDC), 
There are marginal sex differences in the incidence of IBD. Women have a tendency to 
experience Crohn’s disease more often whereas UC tends to be more frequently observed 
in men (Sonnenberg, 1989, Loftus, 2004). A more pronounce difference in IBD incidence 
is observed with ethnic and geographical differences. Historically, IBD has been more 
often observed in Caucasians than minorities, however, these differences have been 
narrowing with time with recent reports showing the prevalence of Crohn’s disease 
among African Americans being two thirds that of whites (Baumgart and Carding, 
2007a). Geographically, there are also differences in the epidemiology of IBD. 
Historically, IBD has most often been observed in developed, more industrialized nations 
than in underdeveloped countries pointing to a potential contribution to disease 
development by urbanization (Lakatos, 2006).  However, it is not fully clear whether this 
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observed pattern might be driven by improvement of diagnosis or increased development 
in the less urbanized countries. Regional changes in the epidemiology of IBD traces back 
tot eh 1930’s when IBD incidence rates began to climb in the United States, a patterned 
mimicked by Northern and western European countries in the 1950’s with UC increases 
preceding Crohn’s disease by an average of 17.5 years (Lakatos, 2006). One of the latest 
available meta-analysis on IBD incidence indicates 19.2 and 24.3 cases per 100,000 
people with UC and 20.2 and 12.7 cases per 100,000 people with Crohn’s disease in 
North America and Europe respectively. The same report shows prevalence rates of 249 
and 319 per 100,000 people for UC and Crohn’s disease respectively in North America.  
These same statistics for other regions including Asia, Middle East and South America 
are several orders of magnitude lower. Furthermore, incidence of UC and Crohn’s disease 
has been significantly increasing over time (Molodecky et al., 2012).  Extrapolating these 
estimates suggests that IBD currently affects as many as 1.4 million people in the United 
States. While the regional differences in IBD epidemiology point to an important 
environmental contribution, twin studies have provided strong evidence for a substantial 
role of genetics.  
Studies looking at twin concordance rates are scarce in the literature but the 
reports available show a high degree of consistency. In general and as would be expected 
from a strong genetic component, monozygotic twins show significantly greater rates of 
concordance than dizygotic twins. Monozygotic twins showed 44.4-50% concordance 
rates for Crohn’s disease and 6.3-18% for UC as well as an increased probability of IBD 
development by first-degree relatives, the rates for dizygotic twins were not different 
from the general population rates (Orholm et al., 2000; Halfvarson et al., 2003).  These 
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findings suggest a strong genetic component to IBD, which is stronger in Crohn’s 
disease. Taken together, the life-long debilitating nature of IBD along with its severe 
socioeconomic impact on the worldwide younger population, it becomes apparent that an 
effective therapeutic treatment for IBD should be sought out in light that the current 
treatments have failed to retain effectiveness across time.  
Clinical Presentation and Treatments for IBD 
Although both UC and Crohn’s disease share clinical manifestation overlap, there 
are major presentation differences between these diseases. UC and Crohn’s disease both 
present with similar clinical symptoms including bloody diarrhea, abdominal pain, 
passage of pus and mucus, weight loss and fever as well as bowel obstruction which is 
most often reported in Crohn’s disease patients. To distinguish these diseases, objective 
endoscopic, radiologic and histological analyses are required (Baumgart and Sandborn, 
2007b). Objective studies of Crohn’s and UC patients have revealed a differential 
inflammatory pattern for these diseases in the gastrointestinal tract. UC is characterized 
by an inflammatory patterns that is limited to the colon whereas Crohn’s disease patients 
suffer from inflammatory patches that can localize at any place along the tract with the 
most distal areas (away from the mouth) more commonly affected.  
Current treatments for IBD fall under four major categories: aminosalicylates 
(mesalizine, sulfasalazine, olsalazine), corticosteroids (hydrocortisone, budesonide), 
immune modifiers (infliximab), and antibiotics (metronidazole, ampicillin, ciprofloxin).  
Aminosalicylates (mesalizine and sulfasalazine for UC and Crohn’s respectively) appear 
to be the most effective and first-line therapies for mild to moderate IBD (Baumgart and 
Sandborn, 2007b). With more complicated cases, the specific treatment has to be tailored 
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to the individual and appears to be largely based on trial and error. The current rates of 
induction of disease remission attest to the lack of efficacy of the current treatments with 
about 60% of IBD patients showing a chronic intermittent course of disease progression 
(with rate being slightly higher for Crohn’s disease patients).  Eventually, a large 
proportion of IBD patients require surgical removal of the affected areas such as 
colectomy (removal of the colon). However, this surgical procedure appears to only be 
efficacious in UC patients. Though the quality of life for IBD patients is not optimal, life 
expectancy for UC is normal and only slightly reduced in Crohn’s disease (Baumgart and 
Sandborn, 2007b). Nevertheless, with increasing insight to the etiology of IBD, there is a 
need for more efficacious treatments to become available.  
Potential Risk Factors for IBD 
One risk factor that has been associated with IBD is appendectomy or the removal 
of the appendix.  Several meta-analysis and large cohort studies have reported that 
patients who undergo an appendectomy had a 69% reduce rate of developing UC. For 
patients at risk for Crohn’s disease, appendectomy was not beneficial and rather 
increased the chances of disease development. Oral contraceptive intake by women has 
been linked to increased risk for developing IBD. This is particularly true for women who 
have used oral contraceptives for long periods of time. Some reports estimate between 
30-40% greater likelihood of developing IBD when using oral contraceptives.  Diet also 
appears to play a key role in the development and prevention of IBD. Patients who 
engage in high sugar, chocolate and fat dietary patterns have an increased risk for 
developing IBD with fiber, fruits ad vegetables showing a protective role in IBD. 
Perinatal and childhood factors also have been linked to an increased risk for IBD.  
	  	  
19	  
Maternal contraction of the measles virus as well as attenuated live measles vaccine has 
been inked to a three-fold likelihood of developing IBD. In addition, breastfeeding 
appears to have a protective effect against the development of IBD (Loftus, 2004). This 
protective effect of breastfeeding may be linked to the immunoregulatory actions of 
lactoferrin, a protein found in high concentrations in breast milk, which has been found to 
attenuate experimental colitis by increasing production of anti-inflammatory cytokines 
and reducing levels and synthesis of proinflammatory cytokines (Togawa et al., 2002). 
Another major risk factor for IBD development is smoking history.  The earliest report 
linking cigarette smoking to IBD was reported in 1982 by Harries et al. who found that 
patients with Crohn’s disease were more likely to smoke than patients suffering from UC. 
This original report established the relationship between smoking and IBD but left the 
question unanswered as to what the nature of this relationship is, since then, several 
reports have shed light on this relationship. Current smokers have a significantly reduced 
risk of developing UC, former smokers on the other hand showed an increased risk of 
developing UC even if cessation happened for a long time. Furthermore, in one study, 
45% of patients who resumed smoking showed clinical improvement, similar findings 
have been reported from UC patients treated with transdermal nicotine patches. However, 
this pattern does not hold for Crohn’s disease patients. On the other hand, smoking has 
been associated with a two-fold increase risk and worsening of disease for this patient 
population (Loftus, 2004). Thought the reports on the effectiveness of nicotine in treating 
IBD have been mixed, there is an emerging theory that can explain this phenomenon.  
Wang et al., in 2004 showed that a specific nicotinic receptor subtype has anti-
inflammatory actions, however, the specific pathways were not known at the time. 
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Recently, it has been reported that a specific nicotinic receptor subtype (α7 nAchR) 
involved in autonomic nervous system regulation of immunity plays a major role in 
inhibiting the production of proinflammatory cytokines known to be involved in IBD 
(Anderson and Tracey, 2013).  Hence, it can be conceived that the nicotine in cigarette 
smoke may directly regulate the immune system. 
IBD and Immunity  
The homeostatic balance of the immune systems is perturbed in patients suffering 
from IBD. Though no known cause has been elucidated, for some time it has been known 
that both types of IBD manifest with increased cellular infiltration in inflamed regions, a 
phenomenon that is more accentuated in Crohn’s disease (Furgeson et al., 1975).  
Cellular infiltrates, the first line of immune defense, tends to be compromised of 
granulocytes and other immune cells that play important roles in the initiation and 
execution of phagocytosis (Beeken et al., 1987). However, this observation may depend 
on the stage of disease. Marks et al. (2006) reported an overall decrease in neutrophil 
accumulation following trauma to the intestines in patients suffering from Crohn’s 
disease. Furthermore, these researchers noted that this hyporesponsiveness of neutrophils 
is generalized as the same pattern is observed following skin trauma and it is not limited 
to neutrophils since cultured macrophages from these patients demonstrated reduced 
responsiveness to stimulatory agents. Hence, it is yet to be determined whether IBD 
causes a decrease in granulocyte availability or if the disease is a result of this observed 
deficiency. The large mobilization of immune cells during inflammatory phases of IBD 
and the alteration in responsiveness of these cells have led to the theory that IBD may be 
driven by penetration of intestinal flora into the intestines. Under normal conditions, 
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bacteria are recognized when immune cells identify the pathogen associated molecular 
pattern (PAMP) via pathogen recognition receptors (PRR). Upon recognition, PPRs 
activate membrane bound Toll-like receptors (TLR) and cytoplasmic nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLR). Activation of TLRs and NLRs 
results in the activation of the transcription factor nuclear factor (NF)-κB thereby 
initiating the production of inflammatory cytokines for bacteria removal. In support of 
this hypothesis are observations that IBD patients have defective intestinal epithelium 
(Geremia et al., 2013) and that NOD2 mutations are common in patients with Crohn’s 
disease leading to inadequate NF-κB activation and inability to fight off intruding 
bacteria (Ogura et al., 2001). An alternative role for NOD2 comes from reports that 
NOD2 regulates TLR2, which in turn regulate Th1 inflammatory responses (Watanabe et 
al., 2004). Based on these observations, the reported alterations in NOD2 observed in 
Crohn’s disease patients may results in disinhibition of the Th1 inflammatory response 
characteristic of this disease (Fichtner-Feigl et al., 2005) and would explain the 
hyperreactive inflammatory profile observed during acute IBD.   
 Autoantibodies have been observed in patients with IBD suggesting the 
involvement of the adaptive immune system in these diseases. Adaptive immunity is 
largely driven by T-cells that can differentiate into Th1, Th2 or the more recently 
recognized Th17 profiles.  UC has often been characterized as demonstrating a Th2 
profile with overproduction of cytokines such as Interleukin 4, 5, 10, which are 
associated with the induction of eosinophil accumulation.  Crohn’s on the other hand has 
been associated with a Th1 profile characterized by overproduction of tumor necrosis 
factor (TNF), interferon gamma (IFN-γ) and Interleukin 2 and 12. Though autoantibodies 
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have been observed in samples from IBD patients including from colon samples and 
serum, neither disease meets the criteria to be considered typical autoimmune diseases 
(Wen and Fiocci, 2004).  These autoantibodies have been reported to be against epithelial 
cells and to cross-react with Escherichia coli. This observed cross-reaction between 
bacteria and self-antigens suggests that IBD is associated with a faulty adaptive immune 
system.  In addition to wrong targeting of epithelial cell in IBD, several reports have 
observed the presence of autoantibodies against epithelial cell-associated components 
(ECAC), more specifically against goblet cell glycoproteins (Aronson et al., 1983).  This 
observation is validated by findings that mucin-producing cells (goblet cells) are depleted 
in humans suffering from IBD (McCormik et al., 1990) and in experimental models of 
IBD (Elson et al., 1995). Two mucin layers made from MUC2 glycoproteins provide 
protection from intestinal flora, one loose outer layer in direct contact with the lumen and 
where bacteria colonize and a more rigid inner layer completely devoid of bacteria 
(Johansson et al., 2008).  In an experimental model of IBD, Johansson et al. (2010) found 
that disruption of the outer mucus layer results in colonic permeability that allows for 
bacteria to infiltrate the colon mucosa after 12 hours of treatment administration, a time 
period that well precedes inflammation.  These results suggest that IBD may be in part 
due to gastrointestinal epithelial barrier disruption leading to bacteria infiltration 
initiating an uncontrollable immune response, a phenomenon postulated by other as being 
driven by high salt diets (Kleinewietfeld et al., 2013).  
Experimental Models of IBD 
Over the past decades, there has been a surge of experimental models for 
inflammatory bowel disease based on genetic or environmental manipulations. Though 
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no one animal model exactly reproduces human IBD, they each have pathological aspects 
that mimic human IBD and can help to inquire about the etiology and potential 
therapeutics for these diseases (Elson et al., 1995).  One of the most widely used models 
for IBD is the dextran sulfate sodium (DSS) experimental model. The DSS model is 
commonly used due to its simplicity and similar histological (monocyte infiltration, 
mucosa ulcerations and erosion) and clinical (weight loss, diarrhea, lethargy etc.) 
pathology to human IBD, though extreme precaution must be paid to several parameters 
including, compound molecular weight, concentration, exposure time (Yan et al., 2009), 
intestinal flora and animal species (Karlsson et al., 2007) and strain (Mahler et al., 1998), 
all parameters that can alter disease presentation (Perse  & Cerar, 2012).  The DSS model 
was first postulated by Okayasu et al. (1990) and consists of oral administration of this 
salt for short consecutive time period (5-7 days) resulting in acute inflammation or in 
cycles consisting of an acute administration followed by a recovery period (10-21 days) 
resulting in a more chronic inflammatory profile.  DSS exposure reliably results in 
diarrhea, bloody stool, weight loss, colonic crypt damage, colon hyperplasia, immune cell 
infiltration to the colon mucosa including leukocytes and lymphocytes (Yan et al., 2009), 
mucin depletion (Qualls et al., 2006), shortening of the colon (Okayasu et al., 1990; 
Dieleman et al., 1998; Bento et al., 2012) and muscle wall thickening (Larsson et al., 
2006). Though DSS-induced colitis has been reported to affect multiple areas of the GI 
tract, most studies observed greater damage to the distal colon (the most posterior part of 
the colon) with little damage to the proximal colon (Dieleman et al., 1998; Mahler et al., 
1998; Yan et al., 2009). 
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In line with Kleinewietfeld et al. data pointing to high salt content as a risk factor 
for the development of immune diseases due to increased permeability, Yan et al. (2009) 
observed that DSS, a salt, increases colon epithelium permeability allowing for labeled 
DSS molecules and bacteria to infiltrate the colonic mucosa. This DSS-induced colonic 
epithelium permeability allows for immune cell infiltration and damage to colonic crypts.  
Cell infiltrates in this model consist of -activated lymphocytes, macrophages and 
neutrophils (Dieleman et al., 1998; Yan et al., 2009; Bento et al., 2012).  The high 
neutrophil activity translates into elevated levels of the enzyme myeloperoxidase (MPO), 
which is commonly used as a marker for neutrophil activity and a hallmark of DSS-
induced colitis. Though it is possible that these immune cells may drive DSS-induced 
colitis, it has also been demonstrated that the complete absence of these phagocytic cells 
results in worse pathology (Qualls et al., 2006). Therefore it appears that DSS 
administration results in permeable colonic epithelium allowing for bacteria and 
potentially other pathogen infiltration into the colon mucosa. This in turns initiates an 
immune response mainly driven by phagocytes, which then exacerbates and results in the 
recruitment of cytokine producing lymphocytes. DSS-induced colitis is characterized by 
both a Th1 (IL-1β, IFN-γ, IL-12) and Th2 (IL-4, IL-10) cytokine profile (Dieleman et al., 
1998). This magnified immune response then translates into colonic microstructure 
damage including aberration of mucus producing cells and colonic crypt structures. The 
importance of the colonic epithelium permeability in the DSS model becomes apparent 
when considering the fact that during recovery periods, a time point when DSS molecules 
are not present in the animals, epithelium permeability is resolved (Yan et al., 2009). 
	  	  
25	  
In addition to being simplistic and mimicking human disease, the DSS model of 
induced colitis is advantageous in that it has been validated with drugs currently being 
used for the treatment of human IBD. It has been reported that treatment of DSS-induced 
colitis with currently conventional drugs (and in equivalent human dose ranges) for the 
treatment of human IBD such as sulfasalazine, olsalazine (Axeksson et al., 1998), 
cyclosporine A, methotrexate, anti-IL-12p40 and CD3 antibodies (Melgar et al., 2008) 
ameliorates DSS-induced colitis albeit to different degrees. Furthermore, it was reported 
that validation treatments were more often efficacious after the disease had been 
established from some time (chronic colitis) than during the most acute phases (Axeksson 
et al., 1998).  Taken together, these data suggest that though several experimental models 
for human IBD exist, DSS is a good model for the assessment of potential therapeutic 
agents and it is often amongst the top model of choice due to its simplicity and similarity 
to human IBD.  
Pain-Related Measures and the DSS Model 
 Though DSS induced colitis has been reliably shown to very closely mimic 
human IBD parameters including colonic inflammation, weight loss and bloody stool, 
studies looking at visceral pain, which is a symptom often reported by human patients 
(Baumgart and Carding, 2007a) are scarce in this model. Most of the available literature 
looking at DSS-induced (and other experimental models of colitis) visceral pain has 
focused on measuring visceral hypersensitivity (VHS) in response to colorectal distention 
(CRD). However, the results from CRD in the DSS model are not in accord with data 
generated from other colon inflammation models that suggest increased nociception 
during colonic inflammation (Kamp et al., 2003; Bercik et al., 2004; Larsson et al., 
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2006).  Larsson et al. (2006) showed that DSS-induced colitis does not affect VHS in 
response to CRD at either acute or chronic inflammatory phases. These same authors then 
sought to determine if psychological stress (either before or after DSS administration) can 
trigger VHS in DSS-induced colitis and observed that only a transient hyperalgesia 
during acute colitis (Larsson et al., 2009). In contrast to these findings, Chen et al. (2013) 
reported that although DSS does not alter VHS in response to CRD, the paring of DSS-
induced inflammation with psychological stress does result in visceral hypersensitivity. 
Hence, these data suggest a potential exacerbation of the nociceptive component of IBD 
by psychological stress.  Though other behavioral paradigms have been used in the DSS 
model, those usually focus on assessing anxiety and depression (Painsipp et al., 2011) 
and not pain-related behavior. It is therefore clear that more emphasis should be directed 
at assessing visceral nociception in experimental models of colitis and particularly in the 
DSS model.  
Neuropeptide Y and the DSS Model 
With increasing evidence that NPY and its receptors are involved in the 
neuroimmune crosstalk (Prod’homme et al., 2006; Wheway et al., 2007b), there is a 
growing line of research interested in assessing the involvement of NPY in human 
inflammatory diseases using animal models, in particular, the role of NPY in DSS-
induced colitis. Over the last decade, there have been a handful of reports presenting data 
that suggest a key role for NPY and its Y1 receptor in experimental colitis.  
The role of NPY in colonic motility and secretion is well established in both 
human (Cox et al., 2001; Cox et al., 2007) and mice (Tough et al., 2011; 
Chandrasekharan et al., 2008) during non-inflamed states. Klompus et al. (2010) sought 
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to determine if the antisecretory effects of NPY are altered with DSS administration. 
These authors provided further support that NPY application to murine distal but not 
proximal colon results in inhibition of ion transport across the colonic epithelium 
(antisecretory effect), an effect that is not likely under direct neurogenic control as 
application of tetrodotoxin (TTX) does not alter these results.  Using pharmacological 
agents, it was shown that NPY’s inhibitory effects on ion transport are mediated largely 
via the Y1 with a small contribution from the Y2 receptor.  In DSS-induced inflamed 
colons, both the proximal and distal colons failed to respond to NPY stimulation 
suggesting a loss of NPY-mediated inhibitory control during experimental colitis. This 
observation was accompanied with decreased levels of Y1 mRNA in colon tissue and 
decreased Y1 protein expression in the colon epithelium. In addition and in line with the 
lack of proximal colon responsiveness to NPY application, proximal colon segments 
express less Y1 mRNA (10-fold less) than the distal colon.  These data suggest that the 
NPY system plays an important role in regulating colonic ion transport, which is 
dysregulated in DSS-induced colitis and may account for the observed dehydration and 
weight loss observed in these animals.  
In addition to a role for NPY in colon secretion, there is also a growing body of 
literature providing evidence for an interaction between NPY signaling and the immune 
system in DSS-induced colitis. In vitro, NPY induces the production of neuronal nitric 
oxide synthase (nNOS), a marker for oxidative stress, and the inflammatory cytokine 
TNF-α.  In vivo, DSS administration induces an increase in the expression of NPY that is 
as high as a 20-fold as well as a significant increase in nNOS in enteric ganglia from the 
murine distal colon (Chandrasekharan et al., 2008; Pang et al., 2010).  Making use of 
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mice genetically altered to not express the NPY gene (NPY-/-), it has been shown that 
these mice do not demonstrate the DSS-induced nNOS increases suggesting that NPY 
regulates oxidative stress in the DSS model. In addition, NPY-/- mice were shown to be 
resistant to DSS-induced colitis as evident from decreased clinical and histological scores 
along with decreased MPO activity in these mice. In line with the decreased MPO 
activity, NPY-/- mice had less neutrophil infiltration suggesting that neutrophil 
mobilization in DSS-induced colitis is regulated by NPY (Chandrasekharan et al., 2008). 
The importance of NPY signaling in the progression of DSS-induced colitis has also been 
determined by preventing NPY signaling after disease development by preventing its 
transcription using antisense oligodeoxynucleotides (ODN).  In line with the findings 
from Chandrasekharan et al., NPY ODN treatment after acute colitis development results 
in attenuation of DSS-induced colitis.  NPY ODN reversed clinical and histological 
scores as well as decreasing MPO activity and TNF-α expression (Pang et al., 2010). The 
fact that ODN treatment was initiated after acute inflammation was in place provides 
strong evidence for the idea that NPY is one of the major drivers of DSS-induced 
pathology. 
With these observations in mind, it is apparent that NPY signaling plays a key 
role in experimental colitis; the question then is, via which of its five known receptors 
does NPY exacerbate DSS-induced colitis. The limited literature currently available 
using receptor specific small molecule antagonists and mice genetically altered to not 
express the Y1 receptor (Y1-/-) suggests a strong role for this receptor in experimental 
colitis. Hassani et al. (2004) observed that DSS-induced colitis was attenuated in Y1-/- 
mice as determined by the clinical and histological scores. In addition, in Y1-/- mice, 
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DSS-induced weight loss, though not eliminated, followed a slower course and these 
mice recovered faster than wild type mice. A similar pattern was observed using a Y1 
receptor antagonist for the duration of the disease. The involvement of the Y1 receptor 
was corroborated by Wheway et al. (2005) who also observed attenuation of DSS-
induced colitis in Y1-/- mice, likely driven by decreased IFN-γ production by Y1-/- mice.  
Furthermore, these authors elucidated a previously unknown bimodal role of NPY 
signaling via Y1 in immunity.  Y1-/- mice had smaller spleens with decreased numbers of 
mature B-cells, CD8+ T –cells and other effector T-cell populations. In line with altered 
immune cell expression in mice lacking Y1 were observations that APC cells in these 
mice and T-cells are functionally defective. Antigen presentation abilities are impaired in 
macrophages and dendritic cells from Y1-/- mice as evident from their inability to 
activate T-cells and to induce the production IL-12 expression upon stimulation. 
Similarly, T-cell function from Y1-/- mice is altered.  T cells from these mice were 
hyperresponsive to stimulation. Transplantation of Y1-/- T-cells to a RAG-/- mice who 
lack mature B and T-cells induces a more rapid and aggressive colitis. This role of Y1 in 
immunity is further supported by observations that dendritic, natural killer, T, B cells and 
macrophages all express the functional Y1 receptor (Wheway et al., 2005). This series of 
findings complement those of Chandrasekharan et al. (2008) and Pang et al. (2010) in 
providing evidence for the importance of NPY signaling in the development and 
progression of experimental colitis and further implicate the Y1 receptor as playing a 
crucial role in neuroimmune inflammation. 
Though it is clear that NPY signaling via Y1 plays an important role in 
neuroimmune inflammation, there is very limited information about the role of its other 
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receptors, in particular, the role of Y2 and Y5 receptors signaling, which has been 
implicated to play key roles in immune cell regulation (Dimitrijevic et al., 2005; Bedoui 
et al., 2008; Mitic et al., 2011). With increasingly available pharmacological agents and 
genetic manipulations specifically targeting these receptors, it is possible to determine 
their potential role in mediating NPY’s effects on the neuroimmune crosstalk.  
To date, there are no available reports assessing the role of the Y2 receptor in 
DSS-induced colitis even though several reports indicate that these receptors are 
expressed in colon tissue. This paper seeks to replicate the findings that Y1 receptor 
antagonism has beneficial effects on DSS-induced colitis and looks to extend these 
findings to the assessment of any potential role of the Y2 receptor in this model. The Y2 
receptor was selected over the Y5 receptor, which has also been implicated in immune 
processes due to the fact that Y2 but not the Y5 receptors have been demonstrated to be 




SPECIFIC AIMS AND RATIONALE 
Specific Aim 1: To assess disease progression and the regulation of NPY in the DSS-
induced model of colitis across time. 
The disease severity and colonic inflammation in the DSS-induced model of 
colitis is contingent upon [among other things] the concentration of DSS, time of 
exposure and recovery period. The progression of colonic inflammation across time (4, 7 
and 10 days) will be assessed using body weight, distal colon histological assessment, 
MPO and cytokine protein expression. In addition, NPY protein expression levels will be 
determined at each time point to determine the potential involvement of NPY in this 
model. Lastly, general open field activity will be assessed as an indicator of disease-
related discomfort. 
Specific Aim 2: To determine the role of peripheral NPY via its Y1 receptor in the 
mouse model of DSS-induced colitis. 
 NPY fibers comprise a significant component of the sympathetic nervous 
system innervation of the distal colon and NPY receptors are expressed on immune cells.  
Based on this potential neuroimmune interaction and the reports suggesting inflammation 
mediated via Y1 receptors, the role of Y1 in 7-day DSS-induced colitis will be assessed. 
Once daily subcutaneous injections of the selective Y1 receptor antagonist BIBP-3226 at 
1mg/kg or 3mg/kg will be administered for peripheral Y1 receptor inhibition. Colon 




The potential involvement of NPY via its Y1 receptor may be differential between 
a chronic inflammatory state and during disease recovery periods. To address this 
question, colon histology, cytokine and NPY protein levels and general open field 
behavior will be assessed at a chronic inflammatory stage (7-day DSS) and during a 
recovery period (7-day DSS with a 3-day recovery). To assess the potential involvement 
of NPY, BIBP 3226 (Sigma-Aldrich) will be administered subcutaneously once daily at 
1mg/kg or 3mg/kg. 
Specific Aim 3: To determine the role of peripheral NPY via its Y2 receptor in the 
mouse model of DSS-induced colitis. 
 NPY Y2 receptors are autoreceptors reportedly expressed on immune cells 
and playing substantial roles during immune responses. To assess the potential 
involvement of the Y2 receptor in the DSS-induced model of colitis, BIIE-0246 (Tocris), 
a selective Y2 receptor antagonist will be administered subcutaneously once daily at 
10mg/kg.  Colon histology, cytokine and NPY protein levels and general open field 
behavior will be assessed at a chronic inflammatory stage (7-day DSS) and during a 
recovery period (7-day DSS with a 3-day recovery). 
Specific Aim 4:  To evaluate the possibility that NPY plays a role in the 
pathophysiology of DSS-induced colitis via its Y1 and Y2 receptors in a pathology-
stage dependent manner. 
Pilot data from our laboratory suggests a potential differential effect of the Y1 and 
Y2 receptors at the different disease stages. It appears that the Y1 receptors plays a major 
role during the acute inflammatory state and the Y2 receptor appears to be most important 
during the recovery phase of the disease. To further study these effects, a factorial design 
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will be conducted with a experimental group receiving daily subcutaneous injections of 
BIBP-3226 at 3mg/kg for the first 7 days while the animals are exposed to DSS followed 
by BIIE-0246 subcutaneous injections at 10mg/kg for the remaining 3 days of recovery.  
Specific Aim 5: To assess DSS-induced gene expression changes, identify a DSS-
induced genetic meta-signature from multiple independent studies and compare this 
to genetic profiles generated from human IBD patient samples.  
 The DSS-model of inflammatory bowel disease is one of the most common used 
experimental animals models to study human IBD due to its relative simplicity and robust 
similarity in pathological presentation to human disease. First, it will be necessary to 
determine if the potential DSS-induced gene alterations are reliable enough so that a DSS 
genetic meta-signature can be computed. Should this be the case, it would be useful, for 
translational purposes, to determine if these similarities between the DSS model and 
human IBD are also observed at the genetic level.  This will be addressed by comparing 
the potential DSS-induced genetic meta-signature to genetic profiles from human Crohn’s 
and Ulcerative Colitis patients. To address these questions, colon samples from four 
independent DSS studies will be genetically profiled and compared to develop a DSS 
genetic meta-signature. This meta-signature will then be compared to genetic profile 






C57Bl/6 adult male mice (Jackson Labs) between 16-20 weeks of age and 
weighing on average 26 grams were used for these experiments. Animals were randomly 
assigned to control and experimental conditions. Animals were housed in groups of 3-5 
per cage in a 12:12 hour light:dark cycle (lights on at 7:00) and were provided with food 
and water ad libitum.  All animals were acclimated to the housing colony and water 
bottles for at least one week before treatment initiation. All procedures were conducted in 
full compliance with the Regeneron Pharmaceuticals, Inc. Institutional Animal Care and 
Use Committee regulations. 
DSS Preparation and Colitis Induction 
Dextran Sodium Sulfate (Average molecular weight 9,000-20,000, Sigma-
Aldrich) was mixed for at least two hours in distilled water to yield a 4% DSS solution 
(e.g. 40g of DSS in every 1 liter of distilled water). This solution was placed in 250mL 
glass bottles with metal spouts and was given to experimental animals ad libitum as a 
replacement for drinking water. Control mice received tap water in similar glass 
containers. Fluids were replenished as needed for the duration of the experiments. The 
acute inflammatory model consisted administration of 4% DSS for 7 consecutive days. 
The recovery model consisted of the acute inflammatory model treatment plus a 3-day 





All animals were weighed once daily for the duration of the experiments. A 
plastic container was placed on a calibrated Ohaus CS200 scale (Ohaus Corporation, NJ), 
the scale was then equilibrated at 0 grams and the animals were placed in the container. 
Body weight was recorded to the nearest tenth of a gram. Animal health was carefully 
monitored, and if weight loss was greater than 25% of starting body weight, or if animals 
appeared to be in poor health, they were immediately euthanized.   
Pharmacological Treatment 
Y1 Receptor Antagonism — 
Systemic peripheral NPY Y1 receptor antagonism was achieved by once daily 
subcutaneous injection of the selective Y1 inhibitor BIBP 3226 (Sigma Aldrich) 
reconstituted in distilled water to a final injectable dose of 1mg/kg or 3mg/kg. Control 
animals received a vehicle (dH20) injection instead.  
Y2 Receptor Antagonism — 
Systemic peripheral NPY Y2 receptor antagonism was achieved by one daily 
subcutaneous injection of the selective Y2 inhibitor BIIE 0246 (Tocris). For one 
experiment, BIIE 0246 was reconstituted in 100% DMSO and diluted with distilled water 
to a 50% DMSO solution. For all subsequent experiments, BIIE 0246 was reconstituted 
in a 1mL of 100% dimethyl sulfoxide (DMSO) and then diluted in distilled water to a 
12.5% DMSO solution with a final injectable dose of 10mg/kg. Control animals received 
a vehicle (50% or 12.5% DMSO in dH20 accordingly) injection instead.  
Open Field 
On the last day of each experiment, animals were placed in a smart frame open 
field system configured with the automated tracking software for Windows (Microsoft) 
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called Motor Monitor (Kinder Scientific). This 16’’ (length) x 16’’ (width) x 15’’ (height) 
inch Plexiglas open field chamber was encompassed by two horizontal laser beam 
detection frames.  The lower frame rested 3/4’’ and the upper frame was 2½’’ inches 
from the chamber floor. Each frame contained 16 beams per side (times 4 sides) that were 
1’’ inch apart. Eight animals counterbalanced across experimental conditions were tested 
for 60 minutes each in the field. The automated software recorded responses in five 
minute intervals and a total count for each measure for the 60 minutes was calculated by 
summing the twelve five minute intervals for each measure. The following measures 
were collected: basic movements (operationally defined as any horizontal beam cross), 
immobility time (operationally defined as a lack of horizontal and vertical beam crosses), 
fine movements (operationally defined as changes in body position not meeting criteria 
for ambulation, includes grooming and head movements), X+Y axis ambulation 
(operationally defined as a complete relocation of the animal’s body), rears (operationally 
defined as vertical beam crosses), rearing time (the time spent crossing vertical beams), 
rest time (operationally defined as a lack of beam crosses lasting longer than 15 seconds), 
total distance traveled (calculated from known distances between beams and total beam 
crosses), normalized rears (defined as the ratio of total rears to X+Y ambulation) and 
normalized rear duration (defined as the ratio of time spent rearing to total rears).  
Euthanasia and Tissue Collection 
Animals were euthanized by carbon dioxide (CO2) asphyxiation. Blood samples 
were collected using the cardiac puncture method. Collected blood samples were 
immediately placed in serum separator tubes (Becton, Dickinson and Company), kept on 
wet ice for the length of the sacrifice, spun in an centrifuge (Eppendorf, model 5415R) at 
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13,200 revolutions per minute and 4° C for 20 minutes.  The resulting serum 
(supernatant) was collected in 1.5mL Eppendorf tubes and stored at -80° C. The large 
intestine and cecum were identified, surgically removed, cleaned in a neutral PBS 
solution and dried on an absorbent tissue.  The large colon was then divided in half and 
labeled as proximal (closest to the cecum) or distal (closest to the anus). For the time 
course characterization experiment, the proximal and distal colons were then subdivided 
into two approximately equal parts. The most proximal and most distal segments were 
placed into tissue embedding cassettes (VWR) and sunk in a 10% formalin neutral 
buffered solution for fixation.  The inner segments were flash frozen in 200mL of 2-
methylbutane  (Fisher Scientific) for immunoassay analyses and stored at -80° C. For all 
subsequent experiments, only the distal colon was collected always keeping the most 
distal 1-1.5cm of tissue for histology and the most proximal 1-1.5cm of tissue for 
immunoassays. For experiments where gene profiling was conducted, the next proximal 
1-1.5cm of tissue was collected and placed in 5ml RNAlater tubes (Qiagen) stored 
overnight at 4° C and then transferred to -20° C until processed.  
 
 
Gross Anatomical Measures 
Colon and cecum were collected, cleaned, dried and positioned flat while 
avoiding stretching on a dissecting board with an engraved ruler (Fisher Scientific) to 
measure the full length of the colon and cecum in centimeters. Next, the colon was placed 
on a calibrated scale that recorded weights to the nearest hundredth of a gram. The same 





Proximal and distal colon samples in embedding cassettes were immersed in 10% 
formalin neutral buffered for at least 24 hours. The samples were washed at least three 
times with phosphate buffered saline (PBS) and immersed in 70% alcohol until processed 
for paraffin embedding. Samples were placed in a metal rack cassette holder and then in 
the chamber of an automated tissue processor (TBS, model ATP1) and allowed to process 
overnight. The processing procedure consisted of repeated and increasing gradients of 
alcohol concentrations (70,95 and 100%), two xylenes and two wax immersions at 58° C.  
Samples were then placed in the liquid paraffin chamber of a tissue-embedding center 
(TBS, TEC-120) and completely embedded in paraffin. Once embedded, all samples 
were placed on a frozen stage for at least an hour for paraffin solidification.  
Paraffin embedded tissue blocks were then individually placed and secured to a 
microtome cassette holder (Leica, Model RM 2165).  Colon sample were sectioned at 
thickness of 7µm. Recently cut tissue ribbons were placed in a warm water bath and 
mounted from there onto HistoBond coated slides (VWR).  At least three slides, each 
with four or more sections, were collected per animal. Once completely dry, slides were 
stored in slide boxes until stained.  
Immunoassays 
Colon samples used for immunoassays were first pulverized and then 
homogenized in a buffer containing 150mM NaCl, 20mM Tris, pH 7.5, and 1% TritonX 
and protease inhibitor tablets (1 tablet for every 25mL of buffer).  For pulverization, 
samples were removed from the -80° C freezer and placed on dry iced. The Eppendorf 
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tubes were then opened one at a time and the tissue was placed in the tissue compartment 
of an ice-cold stainless steel Bessman tissue pulverizer mortar (Spectrum Labs). Using a 
lead hammer, the tissue was completely pulverized (hammering about 8 times per 
sample). Following pulverization, the mortar tissue compartment was placed above a 
10mL falcon round bottom tube sitting on dry ice and inverted for tissue transference. 
Any tissue that did not transfer from the mortar was scooped with a dry ice-cold spatula 
and placed in the tube.  Once the pulverized tissue was transferred into the 10mL tube, it 
was left on dry ice to prevent protein degradation and awaiting homogenization. 
Pulverized samples in 10mL falcon tubes were removed from dry ice for buffer 
addition. 1mL of the homogenization buffer was added to the pulverized tissue and 
placed on wet ice. All tissue samples were kept in wet ice awaiting homogenization. Each 
10mL falcon tube containing the sample and buffer was then placed into a 50mL beaker 
filled with wet ice to keep the sample from degrading during the homogenization process. 
Using a dispensing ULTRA-TURRAX T-8 (IKA) instrument, the tissue was 
homogenized in three 10-second intervals with 10 second waiting periods in between 
when the probe was placed in wet ice to prevent excessive heating. When the third 
homogenization period was concluded, the homogenate was placed back on wet ice and 
allowed to sit until the solution settled (when bubbles disappeared). The homogenate was 
then transferred into 1.5mL Eppendorf tubes and centrifuged at 4°C and 1400 revolutions 
per minute (RPM) for a 20 minute period. Homogenized samples were separated in 
aliquots to prevent repeated freeze-thaw cycles and protein degradation. A small volume 
(20µL) aliquot was placed on wet ice for protein analysis using a Pierce bicinchoninic 
acid (BCA) protein assay kit (Thermo Scientific). 
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 The BCA protein assay kit was used following the manufacturer’s protocol. 
Briefly, 25ųL of standards (ranging from 25-2000ųg/mL) and unknown samples were 
added to a non-binding 96-well round-bottom clear plate in duplicates. 200ųL of working 
reagent (50 parts reagent A: 1 part reagent B) were added to each well and mixed 
thoroughly for 30 seconds on a plate shaker. The plate was then placed in an oven at 
37°C and allowed to incubate for 30 minutes. Following incubation, the plate was 
allowed to reach room temperature and then read in a spectrophotometer at a wavelength 
of 562nm providing a total protein concentration in milligrams for each sample. The 
remaining aliquot samples were stored at -80°C for future immunoassay analyses. 
The homogenized colon aliquots were then used to quantify different proteins of 
interest including neuropeptide Y, MPO, and inflammatory cytokines (GM-CSF, IFN-γ, 
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 [p40/p70] and TNF-α).  
 
Genetic Profile 
Barcoded distal colon samples submerged in 5ml RNAlater tubes were removed 
from the -20° C storage and trimmed to a total weight of 33mg. After weighing, tissue 
samples were placed under the hood and transferred to 4ml round bottom tubes 
containing 1ml of TRIzol solution. A plastic tissue cutter was placed into each sample 
tube for tissue homogenization using an Omni AH96 homogenizing workstation (Omni 
International). Samples were homogenized at 20,000 rpm for a period of two minutes 
with the first minute consisting of an oscillating pattern for a more complete 
homogenization. After homogenization, the tubes were capped and stored at -20° C until 
RNA extraction. RNA extraction was done using the MagMax Total RNA Isolation kit 
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(Life Technologies) and following the suppliers provided protocol. Next, the resulting 
RNA was quantified using a standard protocol. Briefly, 2µl of RNase free water was 
added to each sample and placed in a Nanodrop 8000 spectrophotometer (Thermo 
Scientific) for quantification.  Lastly, RNA quality was determined using a QIAxcel RNA 
quality control kit (Qiagen) following the manufacturer’s protocol.  
Tissue Analysis 
Histology 
All colon samples were first stained with hematoxylin and eosin (H&E) for 
pathological assessment (see protocol in supplement), cover-slipped and allowed to dry 
over night.  All excess adhesive was removed from dried slides using a glass cleaning 
solution (50:50 Windex-dH2O solution). Cleaned slides were then placed in the slide 
rack compartments (hotels) of an automated imager (Leica, Model SL801). The imager 
was set to scan all slides up to the maximum magnification of 40X. The resulting scanned 
images were uploaded to an Internet-based network provider 
(http://slidepath/dih/login.php) from where digital images were capture of each colon 
sample.  At least 4 images for each colon were captured and digitally stored.  Using the 
publically available software Image J (NIH), five length measurements of each of the 
different anatomical areas of interest (colon muscle layers and colon crypts) of the colon 
were recorded. With 4 images per sample, a total of 20 length measurements were 
collected for each measure for each animal. 
Histopathological Analysis 
H&E stained distal colon sections were scored by an experimenter blind to 
treatment conditions using a modified scale from that used by T. ten Hove et al., 2002. At 
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least four different images from each animal along different levels of the distal colon 
were scored to obtain an average score per animal. Tissue was scored for the following 
criteria: a) percent of area involved on a scale of 0-4 where 0=0%, 1=0-10%, 2=10-20%, 
3=20-50% and 4=>50%, b) erosion and ulceration, c) crypt loss, d) number of follicle 
aggregates, e) monocyte infiltration, f) edema and g) goblet cell loss with b-g being 
scored on a 0-3 scale where 0=none, 1=weak, 2=moderate and 3=severe.  
Immunoassay 
All protein expression assays were conducted using commercially available 
assays and in accordance with the provided manufacturer protocols. NPY (Phoenix 
Pharmaceuticals) and MPO (Hycult Biotech) colon expression levels were quantified 
using an enzyme-linked immunosorbent assay (ELISA). Multiple inflammatory cytokine 
expression levels were quantified in single samples by making use of the multiplexing 
capabilities of a 10-Plex Mouse magnetic capture bead cytokine panel Luminex 
(Invitrogen). 
RNAseq Read Mapping 
Sequenced reads in Illumina Hiseq2000 image files (BCL files) were converted to 
FASTQ format via Illumina Casava 1.8.2. Reads were decoded based on their barcodes 
and merged for each individual samples. The overall read quality per sample was 
evaluated with FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) to 
retain only samples with sufficient quality.  Subsequently, a two-step hierarchical 
mapping strategy was employed to retrieve the raw read counts mapped to each gene. 
Reads in each sample were first mapped against mouse transcriptome 
(http://data/ncbi/GBK/mouse) using Bowtie (http://bowtie-
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bio.sourceforge.net/index.shtml) with two allowed mismatches. For each gene, reads 
mapped to the sense-strand exons of the gene were identified and counted. The resulting 
unmapped reads were then mapped against the genomic sequence of each gene (gDNA) 
by Bowtie using the same mapping parameters. The reads mapped to the sense-strand 
introns were also added to the counts for each gene. 
Statistical Analysis 
All quantitative measures and graphical representations were conducted using 
either the Statistical Package for the Social Sciences (SPSS, Version 20 for Mac) or 
Graphpad Prism (Prism 6b for Mac OS X) unless otherwise specified. Any data value 
that fell 2 or more standard deviations from the mean in either direction was considered 
an outlier and removed from statistical analysis.  Two or three-way Factorial analyses of 
variance (ANOVAs) were conducted for each measure using either a fully independent or 
mixed Factorial ANOVAs as appropriate. All statistical analyses were conducted at an 
alpha level of .05 for statistical significance. Post-hoc analyses were conducted to probe 
significant main effects or interactions using either Tukey tests, Sidak tests, or a 
Bonferroni tests, as appropriate. All graphs are expressed as group means ± the standard 
error of the mean (SEM). 
Statistical Analysis of Differentially Expressed RNA  
Read counts summarized at gene level represented the raw gene expression 
measures. An empirical minimum read count of 10 was applied to flag the “absence” and 
“presence” of genes in each sample, assuming the quantitation of a gene with less than 10 
mapped reads is not reliable. We normalized the raw gene expression in each sample by 
global scaling to match the median library size (i.e. the total number of mapped reads) as 
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well as the 75% quartile of the gene-level read counts across all samples, as described in 
previous studies [BMC Bioinformatics 2010, 11:94]. For each comparison between two 
groups of samples, we first eliminated genes that were not flagged as “presence” in all 
samples of the higher expressing group, resulting in on average about 13,000 out of total 
35,161 genes for subsequent analysis. Next, fold changes associated with the comparison 
were calculated as the ratio between the arithmetic mean expressions in the two groups. 
The statistical significance (p-value) of the differential expressions was assessed under 
negative binomial distribution models using DESeq package (version 1.6, Genome 
Biology 2010, 11:R106). At the end, we selected genes with fold changes no less than 1.5 
in either up or down directions with p-values of at most 0.01 as the significantly 
perturbed gene signatures. The final number of signatures in the present work range from 






SPECIFIC AIM METHODS AND RESULTS 
Specific Aim I: To assess disease progression and the regulation of NPY in 
the DSS-induced model of colitis across time. 
The DSS model of colitis is an animal model often used and well characterized in 
the literature. However, from experiment to experiment, there are variations in DSS used, 
the concentration of DSS and the time of exposure. In general, the model is characterized 
by distal colon shrinkage and microscopic damage including immune cell infiltration, 
crypt structure disorganization, muscle wall thickening and increased expression of 
inflammatory mediators. All these parameters however, can potentially be altered by 
differences in protocols, yielding differential results across experiments. The current 
experiment was designed to assess the progression of DSS-induced disease at three 
commonly used DSS exposure time point, including recovery periods. In addition, based 
on some reports indicating sympathetic involvement in immune diseases such as SLE and 
RA as indicated by elevated serum levels of NPY (Harle et al., 2006) as well as elevated 
colon expression of NPY in patients suffering from Crohn’s disease (Belai et al., 1997), 
colon NPY levels were assessed for all animals in this experiment to determine any 
potential regulation of NPY in DSS-induced disease. It was hypothesized that colon NPY 
protein levels would be increased in DSS treated animals indicating the involvement of 
the SNS in this model. Additionally, all open field behavioral measures specified in the 
methods section were collected at each time point to determine any potential DSS-
induced behavioral signature including the animal’s discomfort level. It was hypothesized 
that mice treated with DSS would show behavioral alterations suggestive of general 
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discomfort such as decreased locomotion and decreased general movement. In addition, 
rearing behavior was measured as a potential indicator of visceral pain with the reasoning 
that rearing requires stretching of the viscera, a behavior that is expected to be decreased 




















Experiment 1  
Aim and Design 
 The aim of this experiment was to characterize the DSS-induced disease 
progression using 3 different time courses. Model characterization included the 
assessment of colon tissue damage, the quantification of inflammatory cytokine, MPO 
and NPY at each time point studied. In addition, open field behavior was studied to 
determine the potential DSS signature on behavior. The time points studied were: 4, 7 
and 10 days. Animals in the 4-day condition were exposed to DSS the entire time. The 7-
day condition consisted of two group, one receiving DSS for 4 days and allowed to 
recover on water for 3 extra days and a group receiving 7-days of consecutive DSS 
exposure. Animals in the 10-day condition received 7-days of DSS exposure followed by 
a 3 day recovery period. All the characteristic landmarks of DSS-induced disease 
including weight loss, colon and cecum length and width, histological score and cytokine 
profile were assessed at each time point for every group. There was a control group 
administered regular drinking water for each time point with the exception of the day 7 
groups. The 7-day control group served as control for both the 7-day DSS only and the 4-
day DSS plus recovery groups. Data points from the 7-day control group were duplicated 
to have an even number of groups in order to compute the appropriate statistical analyses. 
A design table summarizing the different treatment conditions is depicted below. 
	  
4	  Day	  	   4	  Day	  +	  3	  Day	  Recovery	  (7	  Day)	   7	  Day	  	  
7	  Day	  +	  3	  Day	  Recovery	  
(10	  Day)	  
Control	  (H2O)	   6	   8*	   8*	   8	  
4%	  DSS	   10	   10	   10	   10	  




DSS Treatment Induces a Progressive Pattern of Weigh Loss 
 DSS treatment induces a rapid and steady decrease in body weight with leveling 
off only observed in the 10-recovery group after replacement of DSS with regular 
drinking water (see Figure 1). DSS treated mice had significantly greater weight loss at 
terminal time points than control mice in all disease time courses assessed: day 4 
(F(1,14)=30.236; p <.001), day 7 recovery group (F(1,16)=198.713; p <.001), day 7 DSS 
only (F(1,16)=89.522; p <.001) and at day 10 (F(1,14)=103.945; p <.001). These findings 
are in line with the available literature providing support for the observation that DSS 
induces weight loss. In addition however, these findings add to the available literature the 
observation that adding a recovery period after 4 days of DSS treatment does not prevent 
further weight loss and that adding a recovery period following 7 days of exposure to 





Figure 1.  DSS induces rapid and progressive weight loss. Animals treated with DSS 
showed significant weight loss compared to control mice. Recovery from DSS does not 
prevent weight loss after a 4-day exposure to DSS but does halt weight loss following 7 
days of exposure. Data presented as mean ± SEM. 
DSS Induces Colon and Cecum Shrinkage and Cecum Weight Loss 
 Treatment with DSS results in colon and cecum tissue shrinkage at all disease 
time points studied (see Figure 2). Colons from animals treated with DSS were 
significantly shorter than colons from control mice (F(1,59)=40.768; p <.001) across all 
times studied (F(1,59)=0.490; p =.690). Colon weight however was not significantly 
changed by DSS treatment (F(1,57)=2.510; p =.119). Ceca from DSS	   treated mice were 
Body Weight Percent Change
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significantly shorter (F(1,58)=185.106; p <.001) and weighed significantly less 
(F(1,59)=4.526; p =.038) than ceca from control mice at all times studied. Taken 
together, these results demonstrate that the DSS-induced colon and cecum shrinkage is 
present by the fourth day from DSS treatment initiation and does not resolve with the 
instillation of a 3-day recovery period. 	   	  
	  
Figure 2. DSS treatment results in colon (A) and cecum shrinkage (C) and an 
overall decrease in cecum (D) but not colon weight. DSS-induced tissue shrinkage and 
weight loss was observed at all times studied.  Data presented as mean ± SEM. ** 




























































































































































































DSS Induces Colon Muscle Wall Thickening and Mucosal Crypt Shortening 
 DSS treatment results in distal colon tissue damage including colon muscle wall 
thickening. Animals treated with DSS had a significantly thicker colon muscle wall in 
comparison to control mice (F(1,54)=47.577; p <.001). Since the distal colon muscle wall 
is made up of two smooth muscle layers (muscularis interna or circular and muscularis 
externa or longitudinal), a refined analysis was conducted and revealed significant 
thickening of both the circular (F(1,54)=53.735; p <.001) and the longitudinal (F(1, 
54)=24.963; p <.001) muscle layers in DSS treated mice, an effect that was consistent at 
all time points assayed (F(3,54)=0.952; p =.422). These findings corroborate at the 
microscopic level similar findings reported in the literature but using magnetic resonance 
imaging (MRI) as the assessment tool. It is therefore apparent that DSS induces colon 
muscle wall thickening (see Figure 3 and 4) potentially as a result of edema. 
 DDS treatment significantly alters the microstructure of the colon mucosa by 
shortening distal colon crypts. Animals treated with DSS had significantly shorter colon 
crypts than control mice (F(1,58)=7.281; p =.009), with this effect consistently observed 
at all times studied (F(3,58)=1.143; p =.340). Anecdotal observations of these tissues 
stained with H&E suggested that this DSS-induced crypt shortening could be the result of 
immune cell infiltration to the mucosa inducing non-specific immune cell phagocytosis 
of mucosal enteric cells, This cascade could be the result of bacterial penetration into the 
mucosa following DSS-induced permeability or damage to the surface epithelium 
membrane.  In addition, DSS damaged colon tissue can vary in its histological 
appearance between groups, which may be the result of different degrees of edema. This 




Figure 3. DSS exposure results in significant colon tissue damage. DSS-induced colon 
damage includes muscle wall thickening, colon mucosa shortening and crypt structure 
damage and immune cell infiltration. Representative micrographs (10X) of distal colon 
samples are shown for each time point studied. Representative sections from animals 
receiving water (A) or 4% DSS (B) for 4 days. Representative sections from animals 
receiving water (C), 4% DSS for 4 days and 3 days of water (d) and 4% DSS for 7 days 
(E). Representative sections from animals receiving water (F) and 4% DSS for 7 days 
followed by 3 days on water (G). Scale bars = 100µm.  
A B 






Figure 4. DSS induces significant mucosal crypt shortening (B) and colon muscle 
wall thickening (A) affecting both the circular (C) and longitudinal (D) smooth 
muscle layers.  These DSS-induced microstructural changes did not vary across the 
different disease times studied. Data presented as mean ± SEM. 
** (p<.01) indicates a statistically significant main effect of DSS. 
DSS Induces a Significant Distal Colon Upregulation of MPO Protein 
MPO, an enzyme abundantly expressed by activated neutrophils, is highly 
expressed in the distal colon in response to DSS (see Figure 5). Animals treated with DSS 
had significantly greater colon MPO protein expression than control mice (F(1, 
58)=7.647; p = .008) and this effect was similarly observed across all disease time points 


























































































































































































(F(3,58)=1.025; p =.388). These results are in accord with a large body of literature and 
indicative of a strong neutrophil involvement in this inflammatory disease model. 
	  
Figure 5. DSS induces significant mean increases in distal colon MPO expression.  
These increases in MPO are observed at each disease time point studied. Data presented 
as mean ± SEM. ** (p<.01) indicates a statistically significant main effect of DSS. 
 DSS Induces Distal Colon Upregulation of Both Pro and Anti-Inflammatory 
Cytokines  
DSS induces an inflammatory profile composed of both pro and anti-
inflammatory cytokine with IL-1β, IL-6, IL-12, TNF-α, IL-2 and IL-4 all being reliably 
expressed at detectable levels in the distal colon.  DSS treated mice expressed 
significantly more protein for the cytokines mentioned above than control mice except for 


























































IL-1β and IL-6 which did not reach statistical significance but showed a slight statistical 
trend to be elevated with DSS treatment (see Table 1). These elevated cytokines in the 
colon were similarly observed at all disease time points studied. Table 1 shows the 
calculated concentrations for each cytokine assayed and the associated p value only for 
those cytokines whose protein expression was reliably detected. Values for the other 
cytokines are reported using detectable protein expression in only some animals and 
hence should be interpreted with caution. For this reason, the statistical p values for these 
















DSS-­‐Induced	  Cytokine	  Profile	  















IL-­‐1β	   24.54	   55.35	   25.96	   181.00	   118.30	   17.66	   1090.00	   0.102	  
SEM	  ±	   4.04	   7.43	   2.37	   48.62	   34.22	   1.79	   628.30	  
	  
IL-­‐6	   31.15	   63.81	   32.90	   48.77	   39.35	   21.54	   362.10	   0.103	  
SEM	  ±	   5.12	   6.74	   3.01	   4.55	   4.72	   2.64	   185.40	  
	  
IL-­‐12	   8.01	   14.81	   8.46	   14.37	   19.74	   5.54	   16.11	   <	  .001	  
SEM	  ±	   1.32	   1.99	   0.77	   1.65	   5.14	   0.68	   3.98	  
	  
GM-­‐CSF	   19.99	   49.64	   21.11	   31.30	   25.25	   13.82	   21.92	   N/A	  
SEM	  ±	   3.29	   13.33	   1.93	   2.92	   3.03	   1.69	   2.42	  
	  
IFN-­‐γ	   17.63	   32.58	   18.63	   27.61	   22.86	   12.19	   19.62	   N/A	  
SEM	  ±	   2.90	   4.38	   1.71	   2.57	   2.61	   1.49	   2.07	  
	  
TNF-­‐α	   24.98	   48.05	   26.39	   39.11	   33.17	   17.27	   29.25	   <	  .001	  
SEM	  ±	   4.11	   5.40	   2.42	   3.65	   3.79	   2.12	   3.38	  
	  
IL-­‐2	   9.04	   13.70	   7.83	   11.61	   9.55	   7.23	   9.28	   <	  .001	  
SEM	  ±	   0.82	   1.84	   0.72	   1.08	   1.10	   0.55	   1.26	  
	  
IL-­‐4	   47.32	   87.43	   49.98	   74.08	   59.76	   32.71	   51.90	   <	  .001	  
SEM	  ±	   7.78	   11.74	   4.58	   6.90	   7.16	   4.01	   5.73	  
	  
IL-­‐10	   47.90	   92.15	   50.60	   75.00	   60.51	   33.12	   52.54	   N/A	  
SEM	  ±	   7.88	   10.36	   4.63	   6.99	   7.25	   4.06	   5.80	  
	  
IL-­‐5	   26.75	   51.45	   28.25	   41.88	   33.79	   18.49	   29.34	   N/A	  
SEM	  ±	   4.40	   5.79	   2.59	   3.90	   4.05	   2.27	   3.24	  
	  Table 1.  DSS induces a cytokine inflammatory response resulting in elevated distal 
colon pro and anti-inflammatory cytokine expression. All cytokine concentrations are 
expressed as group mean in pg/ng of total sample protein. p values refer to the main 
effect of DSS independent of treatment. No statistically significant interactions were 
observed for treatment by time. 
NPY Protein Expression in the Distal Colon is Significantly Increased in Response 
to DSS Treatment 
Treatment with DSS results in significant increases in distal colon NPY protein 
expression (see Figure 6). DSS treated mice had significantly greater concentrations of 
NPY protein in the distal colon than control groups (F(1,61)=12.723; p < .001) and this 
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effect was observed at all disease time points studied (F(3,61)=0.355; p =.785). This 
observed DSS-induced upregulation of the sympathetic neuromodulator NPY provides 
support for the idea of increased sympathetic involvement during inflammatory disease.  	  
 
Figure 6. DSS induces a significant upregulation of NPY protein in the distal colon. 
This significant upregulation NPY was observed at all disease time points studied. Data 
presented as mean ± SEM. ** (p<.01) indicates a statistically significant main effect of 
DSS. 
DSS Induces Significantly Alterations in General Movement, Locomotion and Pain-
Related Behaviors in the Open Field  
DSS treatment significantly altered all open field behavioral measures assessed 
except for total rest time (F(1,57)=0.613; p =.437). DSS treated mice showed significant 



























































decreases in total locomotion and general movement behaviors including basic 
movements (F(1, 57)=31.653; p <.001), fine movements (F(1,58)=74.785; p <.001), X-Y 
axis ambulation (F(1,58)=21.911; p <.001), total distance traveled (F(1,58)=20.047; p 
<.001) and significantly increased the total time animals spent immobile (F(1,54)=8.597; 
p =.005).  All these DSS-induced behavioral changes showed statistically significant 
interactions with disease time point except for immobility.  All interactions followed the 
same pattern such that DSS treatment did not significantly alter open field behavior in the 
4-day group but significantly altered behavior for the 7 day, and in some cases for the 10-
day, DSS groups (see Figures 7-11.) 
Visceral pain-related behaviors were observed in DSS treated compared to control 
mice. DSS treatment significantly decreased the total number of rears (F(1,58)=55.548; p 
<.001) and the total time animal spent rearing (F(1,56)=93.601; p <.001). Similar to what 
was observed with general movements and locomotion, DSS treatment resulted in 
decreased rearing (F(3,58)=4.838; p =.005) and total time spent rearing (F(3,56)=5.242; p 
=.003) in all time disease time points except on day 4 post treatment initiation. In order to 
rule out the possibility that the observed decreases in rearing and rearing time in DSS 
treated mice were due to general sickness-related discomfort, these two measures were 
normalized to total ambulation and total rears respectively. Normalization of rears was 
done by dividing the total number of rears by total X-Y axis ambulation, similarly, the 
average duration per rear was calculated from the ratio of total rearing time by total 
number of rears. Statistical analysis of the ratios revealed that DSS treated mice reared 
significantly less (F(3,57)=53.452; p < .001) and the average duration per rear was 
significantly shorter than that of control mice (F(3,57)=34.337; p < .001), see Figure 9. In 
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line with the observation before normalizing rearing, decreases in rearing were observed 
at all disease time points except for day 4 (F(3,57)=4.126; p = .010). Mean rear duration 
however, showed that DSS-induced decreases in rearing duration were observed at all 
disease time points including at day 4. Taken together, this data suggest that even though 
inflammation is present after 4 days of DSS treatment, a DSS-induced behavioral profile 
has not developed by this time point but is present in all subsequent disease time points 
studied. Furthermore, the normalized rearing ratios appear to be a more sensitive measure 
than total counts to identify visceral pain. 	  
	  
Figure 7. DSS induces significant decreases in general movement behaviors in the 
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movements measured. DSS decreased the total number of basic and fine movements at all 
time points studied except at day 4. Data presented as mean ± SEM. 
** (p<.01), * (p<.01) indicates a statistically significant main effect of DSS. 
	  
Figure 8. DSS significantly decreases total ambulation and distance traveled in the 
open field. Mean total counts (A, C) and counts per 5-minute blocks (B, D) for 
locomotion measures. DSS treatment significantly decreases ambulation distance traveled 
in the 7-day groups but for the 4 and 10-day groups. Data presented as mean ± SEM. ** 
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Figure 9. DSS does not alter the total time animals spent resting for 15 seconds or 
more but significantly increases the total time spent immobile. Mean total (A, C) and 
per 5-minute blocks (B, D) time spent resting and immobile. DSS treatment does not 
affect resting time but significantly increases immobile time in the 7-day DSS-only 
group. Data presented as mean ± SEM. ** (p<.01), * (p<.01) indicates a statistically 
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Figure 10. DSS significantly decreases total rears and time spent rearing. Mean total 
(A, C) and per 5-minute blocks (B, D) rearing counts and time. Animals treated with DSS 
reared significantly less and spent significantly less time rearing than control mice at all 
disease time points assessed except at day 4. Data presented as mean ± SEM. ** (p<.01), 
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Figure 11. Normalized rears and rearing duration revealed significant decreases 
induced by DSS treatment. Mean total (A,C) and per 5 minute blocks (B,D) rearing 
counts normalized to ambulation and rearing time normalized to total. DSS treated mice 
reared less with respect to overall movement at all time points except day 4. The average 
duration per rear was significantly reduced by DSS treatment at all time points assessed. 
Data presented as mean ± SEM. ** (p<.01), * (p<.01) indicates a statistically significant 
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Specific Aim II: To determine the role of peripheral NPY signaling via its Y1 
receptor in the mouse model of DSS-induced colitis. 
The role of NPY in immune and inflammatory disease is well established 
(Wheway et al., 2007b), particularly in inflammation with neurogenic components 
(Naveilhan et al., 2001). Though 3 receptors for NPY have been consistently observed in 
the immune system, namely, Y1,2 and Y5 (Bedoui et al. 2008; Dimitrievic et al.,2008), at 
this point it is not clear how each of these receptors contributes to the involvement of 
NPY in inflammation. Naveilhan et al. (2001) conducted a series of experiments to 
ascertain the involvement of Y1 in different types of inflammation (neurogenic, non-
neurogenic and mixed). These authors concluded that NPY Y1 signaling is both required 
and sufficient to induce neurogenic inflammation. Similarly and specific to experimental 
IBD, Y1 has been implicated to play a key role in experimental colitis potentially by 
activating antigen presenting cells (Wheway et al., 2005) as well as reports that Y1 
antagonism or NPY gene knock-out attenuates DSS-induced colitis (Hassani et al., 2004). 
Hence, the elevated levels of distal colon NPY observed in the previous experiment and 
elsewhere in the literature along with reports supporting the involvement of Y1 in 
inflammation led to the assessment of the effect of systemic peripheral Y1 antagonism in 
the DSS model of colitis using both an acute inflammatory model where DSS is 
continuously given for 7 days and a recovery model where 3 DSS is withdrawn and 
replaced with regular drinking water for 3 days after the acute inflammatory phase. It was 






Aim and Design 
To assess if systemic peripheral Y1 receptor antagonism attenuates DSS-induced 
disease parameters including tissue damage, cytokine, MPO and NPY expression and 
open field behavior during the acute inflammatory phase. Due to the limited literature 
available on daily systemic administration of the selective Y1 antagonist BIBP-3226, for 
this experiment, a safe dose of 1 mg/kg was chosen based on unpublished dose response 
studies conducted by the author. Animals were randomly assigned to one of four groups: 
water-vehicle, water-BIBP 3226, DSS-Vehicle or DSS-BIBP 3226 where the vehicle was 
distilled water (dH2O).  All animals received a once daily subcutaneous injection around 
the same time of day for the length of the experiment (7 days). This first exploratory 
experiment with BIBP 3226 did not include a recovery phase group. All statistical 
analyses for this experiment were computed as described in the general methods. The 
specific experimental design is depicted in the table below.  
	  
Vehicle	  (dH2O)	   BIBP	  3226	  (1mg/kg)	  
Control	  (H2O)	   10	   10	  
4%	  DSS	   10	   10	  
	  
Results 
Y1 Receptor Antagonism at 1 mg/kg Slows Down and Significantly Improves DSS-
induced Body Weight Loss at the Terminal Time Point 
Similar to the observations from Experiment 1 and in the literature, DSS induced 
significant weigh loss. DSS treated mice showed significantly more weight loss than 
control mice (F(1,36)=202.745; p <.001). The observed DSS-induced body weight loss is 
first observed on day 4 post DSS administration when all animal in the DSS groups loss 
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significantly more weight than control mice (F(1,21)=25.208; p <.001). Treatment with 
the Y1 receptor antagonism significantly attenuated DSS-induced body weight loss after 5 
days of DSS exposure and this protective effect persevered until day 7, the terminal time 
point for this experiment (F(1,36)=4.672; p =.037), see Figure 12.  
	  
Figure 12. DSS induces severe and progressive weight loss, an effect that is 
attenuated by Y1 receptor antagonism. Animals exposed to DSS loss significantly 
more weight than control mice starting at day 4 post DSS initiation. BIBP 3226 treatment 
significantly slows down DSS-induced weight loss and significantly attenuates this effect 
at the terminal time point. Data presented as mean ± SEM. 
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DSS-induced Colon and Cecum Shrinkage is not Significantly Affected by Y1 
Receptor Antagonism at 1 mg/kg  
	   In line with the findings from Experiment 1, DSS exposure results in colon and 
cecum shrinkage and this effect is not attenuated by Y1 receptor antagonism (see Figure 
13). Animals exposed to DSS had colons that were significantly shorter (F(1,35)=39.811; 
p <.001) and weighed significantly more (F(1,35)=18.968; p <.001) than colons from 
control mice. Similar to the effects observed in the colon, cecum animals exposed to DSS 
were significantly shorter (F(1,36)=63.540; p <.001) and weighing significantly less 
(F(1,36)=10.410; p <.003) than cecum from control mice. These findings are in 
agreement with those from Experiment 1 and provide further evidence that DSS induces 
both colon and cecum shrinkage. Treatment with the Y1 receptor antagonist did not 
prevent DSS-induced colon (F(1,35)=0.117; p =.735) or cecum (F(1,36)=0.277; p =.602) 
shrinkage, see Figure 12. The observation that animals exposed to DSS demonstrated 
signs of colon tissue atrophy yet had colons that weighed significantly more than those of 
control mice potentially indicates greater fluid retention and may be indicative of edema. 
However, this speculation was not directly assessed. 




Figure 13. Exposure to DSS results in colon (A) and cecum shrinkage (C), increased 
colon weight (B) and decreased cecum weight (D). Treatment with a Y1 receptor 
antagonist did not prevent these effects. Data presented as mean ± SEM. ** (p<.01), 
indicates a statistically significant main effect of DSS. 
Y1 Receptor Antagonism at 1mg/kg Does Not Significantly Alter DSS-induced Colon 
Muscle Wall Thickening and Mucosa Crypt Shortening  
 As observed in Experiment 1, DSS exposure results in significant colon wall 
thickening and mucosa crypt shortening (see Figures 14 and 15). Animals treated with 
DSS had colon muscle walls that were significantly thicker than those of control mice 
(F(1,30)=10.275; p =.003). Upon closer examination, it was observed that both the 



































































layers making up the distal colon wall were significantly thickened. BIBP 3226 treatment 
did not attenuate these effects of DSS. In addition, DSS-induced shortening of distal 
colon mucosa crypts (F(1,35)=47.590; p <.001) and this effect was not significantly 
altered by the Y1 receptor antagonist (F(1,35)=3.511; p =.069), see Figure 13. The effects 
of DSS on colon muscle wall and mucosa crypt observed in Experiment 1 were replicated 
in this experiment providing further evidence for this effect. In light that these effects 
may be due to edema, it is not surprising that Y1 receptor antagonism, which is expected 
to act on immune cell functioning, does not alter these observations. 
	  
Figure 14. Exposure to DSS results in significant colon tissue damage that is not 
attenuated by Y1 receptor antagonism. Representative micrographs (10X) of a non-
treated control animal (A), a control animal treated with the Y1 antagonist (B), a non-
A B 
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treated DSS animal (C) and a DSS animal treated with the Y1 receptor antagonist (D). 
Scale bar = 100µm. 
	  
Figure 15. Y1 receptor antagonism does not attenuate DSS-induced mucosal crypt 
shortening (B), full colon muscle wall (A), circular (C) or longitudinal (D) smooth 
muscle layers thickening. Data presented as mean ± SEM. ** (p<.01), indicates a 
statistically significant main effect of DSS. 
 Y1 Antagonism at 1 mg/kg Attenuates DSS-Induced Distal Colon 
MPO Protein Overexpression 
Distal colon MPO protein quantification revealed that DSS induces neutrophil 
activity as was also observed in Experiment 1. DSS exposure significantly increased 
distal colon MPO protein expression (F(1,30)=95.612; p < .001), an effect that was 
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significantly decreased with Y1 receptor antagonist Treatment (see Figure 16). Animals 
treated with the Y1 receptor antagonist had significantly less MPO expression than those 
treated with the vehicle (F(1,30)=6.252; p =.018) and this reduction in MPO expression 
was mainly driven by the effect of the antagonist in DSS treated mice (F(1,30)=6.524; p 
=.016). These observations suggest that Y1 signaling inhibition significantly reduces the 
expression of MPO, thereby potentially tampering with the neutrophil-mediated 
inflammatory response to DSS and hence implicating NPY signaling as playing an 
important role in this experimental model of IBD. 
	  
Figure 16. Y1 receptor antagonism reduces DSS-induced MPO expression in the 
mouse distal colon. DSS treated animals expressed significantly more MPO than control 
mice. BIBP 3226 treatment significantly decreased MPO expression in DSS treated mice. 
Data presented as mean ± SEM.** (p<.01), * (p<.01) indicates a statistically significant 



























main effect of DSS. $ (p<.05), indicates a significant interaction of BIBP 3226 treatment 
with DSS 
Exposure to DSS Results in Elevated Levels of Inflammatory Cytokines in the Distal 
Colon, an Effect Not Altered by Y1 Receptor Antagonism at 1 mg/kg  
 Animals exposed to DSS showed increased levels of all cytokines assessed except 
for IL-10, which was not in the detectable range for any sample (see Table 2). This DSS-
induced cytokine profile is in line with the findings from Experiment 1 and extends those 
findings to include the upregulation of GM-CSF, IL-5 and IFN-γ. Y1 receptor antagonism 
did not significantly regulate DSS-induced cytokine increases. On the other hand, 
animals treated with this antagonist showed significantly higher levels of TNF-α 
(F(1,35)=7.060; p =.012) and IL-5(F(1,35)=5.362; p =.027). However, this was a general 
effect and not specific to DSS treated mice. Taken together, this data corroborate the 
DSS-induced cytokine profile and suggest that NPY signaling has the potential to 
modulate cytokine expression. 	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DSS Induced Cytokine Profile and the Effect of Y1 Receptor Antagonism 
Cytokine	   H2O-­‐Vehicle	   H2O-­‐BIBP	  3226	   DSS-­‐Vehicle	   DSS-­‐BIBP	  3226	   p	  Value	  
IL-­‐1β	   6.412904 8.610449 39.03891 29.70756 **	  
SEM	  ±	   0.6362674 0.8019347 16.07987 6.434397 
	  IL-­‐6	   14.94639 13.73548 23.13976 20.24673 *	  
SEM	  ±	   2.191921 1.322243 5.86987 2.978675 
	  IL-­‐12	   2.749034 2.642764 18.77273 14.58442 **	  
SEM	  ±	   0.3272806 0.223564 3.580395 1.610096 
	  GM-­‐CSF	   5.171335 6.513018 9.179712 11.21258 **	  
SEM	  ±	   0.5699411 0.5895221 0.9753283 1.33567 
	  IFN-­‐γ	   6.91067 9.43618 59.72564 43.23656 **	  
SEM	  ±	   1.21056 1.383273 24.08662 9.853886 
	  TNF-­‐α	   4.83397 6.389729 9.653385 15.52484 **	  $	  
SEM	  ±	   0.4586454 0.5439156 0.4229044 2.596539 
	  IL-­‐2	   8.177305 9.040475 12.95407 10.21786 .152	  
SEM	  ±	   0.9012746 0.8504746 3.376863 1.576425 
	  IL-­‐4	   17.39358 16.51094 52.58372 39.96121 *	  
SEM	  ±	   2.340864 1.580286 20.63793 6.502727 
	  
IL-­‐10	   11.76378 14.47214 17.12872 21.59708 N/A	  
SEM	  ±	   1.133051 1.057769 2.433275 2.351359 
	  IL-­‐5	   6.744294 9.239133 9.689588 12.05901 **	  $	  
SEM	  ±	   0.6437144 0.8285941 1.301592 1.312912 
	  Table 2. DSS exposure results in increased expression of pro and anti-inflammatory 
cytokines in the distal colon, an effect not regulated by Y1 receptor antagonism. 
Mean distal colon cytokine protein expression is presented in pg/mg of total sample 
protein. ** (p<.01), * (p<.01) and p values indicate a significant main effect of DSS. $ 
indicates a statistically significant main effect of BIBP 3226 treatment. 
DSS-Induced Distal Colon NPY Protein Upregulation is not Significantly Changed 
by Y1 Receptor Antagonism at 1 mg/kg  
 Similar to the observations from Experiment 1, exposure to DSS resulted in 
significant increases in distal colon NPY expression in mice (see Figure 17). DSS treated 
mice showed significantly greater levels of colon NPY protein than control mice 
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(F(1,34)=33.214; p <.001). Treatment with the Y1 receptor antagonist BIBP 3226 did not 
significantly altered this observation (F(1,34)=1.882; p =.179) These observations 
provide further support for the direct involvement of the sympathetic neuromodulator 
NPY in this model of inflammatory disease. Y1 receptor antagonism did not significantly 
regulate colon NPY expression, a potential indication that other Y receptors are available 
for NPY signaling in the colon. 
	  
Figure 17. Exposure to DSS results in increased colon expression of NPY. Y1 
Receptor antagonism does not alter this observation. Data presented as mean ± SEM. 
** (p<.01), indicates a statistically significant main effect of DSS. 
 
 




























Y1 Receptor Antagonism at 1 mg/kg Does Not Significantly Alter DSS-induced 
Behavioral Changes in the Open Field  
Consistent with the findings from Experiment 1, DSS administration significantly 
altered all open field behavior measures assessed (see Figures 18-22). DSS treated mice 
demonstrated significant decreases in general movements including basic (F(1,36)=20.63; 
p <.001) and fine movements (F(1,36)=25.89; p <.001) when compared to control 
animals. These animals also demonstrated significant decreases in general locomotion 
including less movement along the X-Y axis (F(1,34)=46.640; p <.001) and total distance 
traveled (F(1,33)=55.43; p <.001) as well as increases in total rest time (F(1,36)=5.073; p 
=.031) and time spent immobile (F(1,35)=11.05; p =.002). Visceral pain-related measures 
including rearing (F(1,35)=91.12; p <.001), rearing time ((F(1,34)=104.50; p <.001), 
normalized number of rears to overall ambulation, (F(1,35)=42.400; p <.001) and 
normalized rearing time to total rears (F(1,36)=27.970; p <.001) were all significantly 
decreased in DSS treated mice when compared to control mice.  Peripheral Y1 receptor 





Figure 18. DSS exposure significantly decreased general movement in the open field. 
Y1 receptor antagonism does not alter these observations. Mean total counts (A, C) and 
counts per 5-minute blocks (B, D) for basic and fine movements. DSS treatment 
significantly decreases the total count of basic and fine movements. Data presented as 
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Figure 19. DSS exposure significantly decreased overall locomotion in the open field. 
Y1 receptor antagonism does not alter these observations. Mean total counts (A, C) and 
counts per 5-minute blocks (B, D) for locomotion. DSS treatment significantly decreases 
both X-Y ambulation and total traveled distance. Data presented as mean ± SEM. ** 
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Figure 20. DSS exposure significantly increases the time animals spent immobile 
and resting in the open field. Y1 receptor antagonism does not alter these behaviors. 
Mean total (A, C) and per 5-minute blocks (B, D) time spent resting and immobile. DSS 
treated mice spent significantly more time resting and immobile than control mice.  Data 
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Figure 21. DSS exposure significantly decreases the occurrences and duration of 
rearing behavior in the open field. Y1 antagonism did not alter these observations. 
Mean total (A, C) and per 5-minute blocks (B, D) rearing counts and time in the open 
field. DSS treated mice showed significantly less occurrences and less time spent rearing 
compared to control mice. Data presented as mean ± SEM. ** (p<.01), indicate a 







































































Figure 22. After normalizing rearing behavior with overall activity, DSS exposure 
significantly reduces these behaviors. Y1 antagonism does not alter these observations. 
Mean total (A, C) and per 5 minute blocks (B, D) rears normalized to ambulation and 
rearing time normalized to total rears in the open field. DSS treatment significantly 
decreases rearing counts and time normalized to overall X-Y ambulation. Data presented 

























































































Aim and Design 
The observation from Experiment 2 that systemic Y1 receptor antagonism with 
BIBP 3226 at 1mg/kg significantly decreases DSS-induced MPO increases in the distal 
colon suggests that NPY signaling via Y1 plays an important role in regulating neutrophil 
activity in DSS-induced inflammation. In addition, Y1 receptor antagonism at 1mg/kg of 
BIBP 3226 attenuates one clinical manifestation of DSS induced colitis, namely, weight 
loss. Together, these observations provide support for a potential involvement of the 
sympathetic neuromodulator NPY in DSS-induced colitis, specifically its signaling via 
the Y1 receptor. In order to further assess the role of NPY signaling via its Y1 receptor in 
this experimental model of IBD, the current experiment was designed to replicate 
Experiment 2 at the higher concentration of the antagonist BIBP 3226 of 3mg/kg and 
further to determine the role of Y1 antagonism at this higher concentration not only in the 
acute inflammatory model but also after a 3-day recovery period when animals are placed 
back on regular drinking water while still receiving the antagonist treatment. Data from 
Experiment 1 provides sufficient evidence that at this time point, DSS-induced bowel 
inflammation, general and pain-related behavioral abnormalities are still observed. To 
address these questions, two experiments were designed and executed concurrently with 
the specific designs described in the tables below. By the end of both experiments, all 
animals from the acute model survived until the terminal time point whereas 5 animals 
from the DSS vehicle recovery group had died by their terminal time point. Hence, 
statistical analysis for this group was carried out with a maximal sample size of 5. All 
statistical analyses for these experiments were computed as a 2X2 factorial ANOVA or 
	  	  
82	  
as a 3 way mixed Factorial ANOVAs (when adding a repeated measures variable) as 
appropriate. 
 7-Day Acute Inflammation Model 
	  
Vehicle	  (dH2O)	   BIBP	  3226	  (3mg/kg)	  
Control	  (H2O)	   10	   10	  
4%	  DSS	   10	   10	  	  
10-Day Recovery Model 
	  
Vehicle	  (dH2O)	   BIBP	  3226	  (3mg/kg)	  
Control	  (H2O)	   10	   10	  
4%	  DSS	   10	   10	  
	  
Results 
Y1 Receptor Antagonism at 3 mg/kg Slows Down and Significantly Improves DSS-
induced Body Weight Loss at the Terminal Time Point for Both the Acute 
Inflammatory and Recovery Models 
 Similar to the observations from Experiment 1 and Experiment 2, DSS induces a 
progressive weight loss pattern that alleviates upon withdrawal (see Figure 23). Animals 
exposed to DSS showed significant weight loss in both the acute inflammatory 
(F(1,36)=183.935; p <.001) and recovery models (F(1,30)=286.178; p <.001). In the 
acute inflammation model, BIBP 3226 treatment at 3mg/kg significantly reduced DSS 
induced weight loss at the terminal time point (F(1,36)=4.248; p = .047). Similarly, in the 
recovery model, animals exposed to DSS and treated with BIBP 3226 at 3mg/kg showed 
significantly less weight loss than those receiving the vehicle injection (F(1,30)=7.842; p 
=.009). These observations replicate the findings from Experiment 2 indicating a 
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protective effect of Y1 receptor antagonism in the pathological weight loss induced by 
DSS. 
	  
Figure 23. DSS induces a progressive pattern of weight loss in both models with 
weight leveling off when DSS is withdrawn in the recovery model. Y1 receptor 
antagonism significantly attenuates this effect. Mean percent body weight change 
across time in the acute inflammation model (A) and in the recovery model (B). Data 
presented as mean ± SEM.  
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DSS-induced Colon and Cecum Shrinkage, Tissue Weight and Colon 
Histopathological Damage Are Not Significantly Altered by Y1 Receptor 
Antagonism at 3mg/kg 
Treatment with the Y1 Receptor Antagonist at 3mg/kg does not attenuate DSS-induced 
histopathological damage, tissue shrinkage or weight changes (see Figures 24- 26).  
Animals exposed to DSS had significantly more histopathological damage in both the 
acute F(1,35)=506.67; p <.001) and recovery periods F(1,34)=310.57; p <.001) than 
water treated mice and colons that were significantly shorter than those of control mice in 
both the acute inflammatory (F(1,36)=28.36; p <.001) and recovery models 
(F(1,31)=21.85; p <.001). Y1 receptor antagonism did not significantly altered this 
observation at the acute nor recovery time points. Colon weight was not significantly 
different between animals exposed to DSS and control mice in the acute inflammatory 
model (F(1,34)=1.672; p =.205). In the recovery model however, colons from animals 
exposed to DSS were significantly heavier than those from control mice (F(1,30)=33.65; 
p <.001). Y1 receptor antagonism did not affect colon weight in either the acute 
(F(1,34=0.902; p =.349) or recovery models (F(1,30)=2.743; p =.108).  
Cecum length was significantly decreased in animals exposed to DSS in both the 
acute (F(1,36)=18.99; p <.001) and recovery models (F(1,29)=8.302; p <.007) while no 
main effect of DSS was observed for cecum weight in either the acute (F(1,35)=1.313; p 
=.260) or recovery models (F(1,31)=0.043; p =.837). Y1 receptor antagonism did not 
significantly change any of these DSS-induced effects for either model but significantly 




Figure 24. DSS exposure induces colon and cecum shrinkage, an effect not 
attenuated by Y1 receptor antagonism. Mean dry colon and cecum length following 









































































































































recovery (F,H) phases. DSS induces significant colon and cecum shrinkage at both time 
points and increases colon weight following the recovery period. Y1 receptor antagonism 
significantly decreases cecum weight following the recovery period in control but not 
DSS mice. Data presented as mean ± SEM. ** (p<.01), indicate a significant main effect 
of DSS. 
Y1 receptor Antagonism at 3 mg/kg Does Not Significantly Alter DSS-
Induced Colon Wall Thickening or Crypt Shortening in in Either Model  
Similar to the observation from previous experiments, DSS exposure results in 
significant muscle wall thickening and mucosal crypt shortening (see Figure 27). Animals 
exposed to DSS demonstrated colon muscle wall thickening in both the acute 
(F(1,33)=15.07; p <.001) and recovery (F(1,29)=9.01; p <.001) models. Closer 
examination of the individual muscle layers making up the colon muscle wall revealed 
that both the circular (F(1,33)=31.12; p <.001) and longitudinal  (F(1,34)=13.44; p <.001) 
muscles were significantly thickened by DSS in both models; (F(1,28)=31.82; p <.001) 
and (F(1,29)=12.28; p <.001) for circular and longitudinal muscle layers respectively. In 
the acute model, Y1 receptor antagonism did not significantly affect overall colon wall 
thickness  (F(1,33)=1.895; p =.178) nor the individual circular (F(1,33)=3.176; p =.084) 
or longitudinal (F(1,34)=4.054; p =.052) muscle layers. In the recovery model, animals 
treated with BIBP 3226 had significantly longer colon muscle wall (F(1,29)=6.165; p 
=.019) than control mice and this effect was mainly driven by a significant elongation of 
the longitudinal (F(1,29)=5.683; p =.024) but not the circular (F(1,28)=2.358; p =.136)  
muscle layer and was not specific to DSS treated mice. 
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In line with previous observations, DSS exposure resulted in significantly shorter 
mucosal crypt in the acute model (F(1,33)=39.05; p <.001). In the recovery model 
however, crypt lengths were not significantly different between animals exposed to DSS 
and control mice (F(1,31)=3.886; p <.058) but instead showed a statistical trend towards 
longer crypts than control mice potentially indicating a rebound effect during recovery. 
Y1 receptor antagonism did not have an effect on DSS-induced crypt shortening in either 
the acute (F(1,33)=0.156; p =.695) or recovery (F(1,31)=1.453; p <.237) models. 	  
	  
Figure 25.  DSS exposure in the acute inflammatory model results in significant 
colon tissue damage and Y1 receptor antagonism does not attenuate this effect.  
Representative micrographs (10X) of a non-treated control animal (A), a control animal 
treated with the Y1 antagonist (B), a non-treated DSS animal (C) and a DSS animal 
treated with the Y1 receptor antagonist (D). Scale bar = 100µm. 
A B 
C D 












Figure 26.  DSS exposure in the recovery model results in significant colon tissue 
damage and Y1 receptor antagonism does not attenuate this effect.  Representative 
micrographs (10X) of a non-treated control animal (A), a control animal treated with the 
Y1 antagonist (B), a non-treated DSS animal (C) and a DSS animal treated with the Y1 
receptor antagonist (D). Scale bar = 100µm. 
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Figure 27. DSS exposure results in colon wall thickening and mucosal crypt 
shortening, an effect not significantly altered by Y1 receptor antagonism. Mean distal 
colon muscle wall thickness for the acute inflammatory (A, C, D) and recovery models 











































































































































(E, G, H), and crypt length during acute (B) and recovery periods (F). DSS treatment 
results in significant muscle wall thickening at both time points and BIBP 3226 does not 
alter this effect. Crypt lengths are shortened in the acute but not the recovery phase while 
BIBP 3226 does not alter these DSS-induced effects. Data presented as mean ± SEM. ** 
(p<.01), indicate a significant main effect of DSS. 
A Statistical Trend for Y1 Receptor Antagonism at 3mg/kg to Attenuated 
DSS-Induced Colon MPO Expression is Observed in the Acute inflammatory but 
Not in the Recovery Model 
In line with previous observations, DSS induces a significant increase of MPO in 
the distal colon (see Figure 28). Animals exposed to DSS expressed significantly more 
MPO protein than control mice in both the acute inflammatory (F(1,34)=20.53; p <.001) 
and recovery (F(1,30)=15.82; p <.001) models. This DSS-induced increase in distal colon 
MPO was not significantly altered by Y1 receptor antagonism during acute inflammation 
(F(1,34)=1.706; p =.200) or after recovery (F(1,30)=2.115; p =.156).  However, in the 
acute inflammatory phase, treatment with the antagonist resulted in a slight statistical 





Figure 28. DSS exposure results in significant elevations of MPO in the colon. Y1 
receptor antagonism shows a statistical trend to attenuate this effect in the acute 
inflammatory model. Mean distal colon MPO protein concentrations are expressed as 
ng/mg of total sample protein for animals in the acute inflammatory (A) and recovery (B) 































































models. Data presented as mean ± SEM. ** (p<.01), indicate a significant main effect of 
DSS. 
Y1 Receptor Antagonism at 3mg/kg Results in a Tendency to Decrease DSS-
Induced Distal Colon IL-1β Overexpression in the Acute Inflammatory Model and 
Significantly Decreases this Cytokine in the Recovery Model 
In line with the previous results presented here, DSS exposure significantly 
increased distal colon for IL-1β, IL-6 and IL-12 in the acute inflammatory model and IL-
1β in the recovery model (see Table 3).  Y1 receptor antagonism showed a strong 
statistical tendency to decrease IL-1β expression in DSS treated mice F(1,33)=3.913; p 
=.056) during DSS-induced acute inflammation while no significant changes were 
observed in response to the antagonist for any of the other cytokines assessed in this 
model. Similarly, in the recovery model, Y1 receptor antagonism significantly decreased 
DSS-induced IL-1β expression F(1,30)=6.521; p<.016), see Table 4. Together, these 
findings suggest that Y1 signaling plays a key role in DSS-induced IL-1β overexpression 







Acute Phase Cytokine Profile 
Cytokine	   H2O-­‐Vehicle	   H2O-­‐BIBP	  3226	   DSS-­‐Vehicle	   DSS-­‐BIBP	  3226	   p	  Value	  	  
IL-­‐1β	   16.81386 17.75558 111.3921 49.23142 **	  
SEM	  ±	   2.53687 1.866473 30.17852 12.41497 	  	  
IL-­‐6	   21.37558 22.53742 36.20176 28.68877 *	  
SEM	  ±	   3.21644 2.369141 6.894981 1.969268 
	  IL-­‐12	   5.489641 5.797109 15.98026 12.24084 **	  
SEM	  ±	   0.8282755 0.6093939 2.456585 2.001906 
	  GM-­‐CSF	   13.69475 14.46177 17.55511 17.06275 N/A	  
SEM	  ±	   2.06626 1.520226 2.955812 1.330563 
	  IFN-­‐γ	   12.08015 12.75674 15.48537 15.05107 N/A	  
SEM	  ±	   1.822649 1.340993 2.607324 1.17369 
	  TNF-­‐α	   17.11477 18.07334 22.51349 21.32387 0.104	  
SEM	  ±	   2.582271 1.899875 3.486941 1.662847 
	  IL-­‐2	   4.87424 6.921898 6.510254 6.327665 N/A	  
SEM	  ±	   0.5344833 1.183025 1.096153 0.4934348 
	  IL-­‐4	   71.53068 49.06963 77.74019 68.17538 N/A	  
SEM	  ±	   15.62074 5.61604 26.38842 10.12326 
	  IL-­‐10	   32.82042 34.65865 42.07205 40.89208 N/A	  
SEM	  ±	   4.951936 3.643329 7.083812 3.188787 
	  IL-­‐5	   18.32571 19.35211 23.49148 22.83263 N/A	  
SEM	  ±	   2.764979 2.0343 3.955339 1.780501 
	  Table 3.  Mean distal colon cytokine protein expression measured using a Multiplex 
assay and standardized to total sample protein (pg/mg). DSS significantly upregulates 
the proinflammatory cytokines Il-1β, IL-6, and IL-12 during the acute inflammatory 
phase. BIBP 3226 does did not have a significant effect on cytokine expression but 
showed a tendency to decrease Il-1β expression in DSS treated mice. ** (p<.01), * 




Recovery Phase Cytokine Profile 
Cytokine	   H2O-­‐Vehicle	   H2O-­‐BIBP	  3226	   DSS-­‐Vehicle	   DSS-­‐BIBP	  3226	   p	  Value	  	  
IL-­‐1β	   20.81488 12.12715 196.1769 39.95261 **	  $$	  &	  
SEM	  ±	   1.794794 0.9519817 95.92606 12.64534 
	  IL-­‐6	   26.42064 15.39316 18.89595 15.96787 .110	  $$	  
SEM	  ±	   2.278159 1.208364 2.370359 2.09306 
	  IL-­‐12	   6.287168 3.867739 6.275491 8.533562 0.078	  
SEM	  ±	   0.5421203 0.3027516 0.5749277 2.003764 
	  GM-­‐CSF	   16.95355 9.877457 10.61518 11.48305 N/A	  
SEM	  ±	   1.461845 0.775381 1.720463 1.881096 
	  IFN-­‐γ	   14.95474 8.712912 10.33061 8.967675 N/A	  
SEM	  ±	   1.289494 0.683964 1.522139 1.321398 
	  TNF-­‐α	   21.18739 12.34417 15.75459 13.14435 .183	  $$	  
SEM	  ±	   1.826914 0.9690183 1.754815 1.732826 
	  IL-­‐2	   9.621325 5.346669 5.14487 5.227454 0.079	  
SEM	  ±	   1.459621 0.9728884 0.6052965 1.095078 
	  IL-­‐4	   103.4952 28.71417 36.37644 48.15194 N/A	  
SEM	  ±	   19.27814 4.16338 7.086813 11.54405 
	  IL-­‐10	   40.63036 23.67202 28.06713 24.46825 N/A	  
SEM	  ±	   3.503413 1.858255 4.135484 3.214549 
	  IL-­‐5	   22.6865 13.21758 15.67165 13.29341 N/A	  
SEM	  ±	   1.956177 1.037581 2.309102 1.963935 
	  Table 4.  Mean distal colon cytokine protein expression measured using a Multiplex 
assay and standardized to total sample protein (pg/mg). DSS significantly upregulates 
Il-1β and shows strong statistical tendencies to increase other cytokines. BIBP 3226 
significantly decreases Il-1β expression in DSS treated mice while decreasing GM-CSF, 
IL2 and IL-4 for animals in the control water group. 
** (p<.01) and p values indicate a statistically significant main effect of DSS. $ indicates 
main effect of BIBP 3226. & (p<.05) indicates a significant interaction between 
treatments. 
 
Y1 Receptor Antagonism at 3mg/kg Does Not Significantly Alter DSS-
Induced Distal Colon NPY Protein Overexpression in either Model Assessed 
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In line with the observations from previous studies discussed, animals exposed to 
DSS had significantly greater NPY protein expression in the distal colon in both the acute 
inflammatory (F(1,35)=25.45; p <.001) and recovery (F(1,30)=10.95; p <.001) models 
(see Figure 29). These DSS-induced distal colon NPY protein elevations are not 
significantly altered by BIBP 3226 in the acute (F(1,35)=0.346; p =.560) or recovery 
(F(1,30)=2.313; p =.139) models, see Figure 25. These findings provide further support 
for the involvement of NPY in DSS-induced inflammation and suggest the potential 




Figure 29. Mean distal colon NPY protein concentration measured by ELISA and 
standardized to total sample protein (ng/mg). DSS treatment significantly increased 
distal colon NPY protein expression at both acute and recovery phases. Y1 receptor 
























































antagonism does not alter these observations. Data presented as mean ± SEM. ** (p<.01), 
indicate a significant main effect of DSS. 
Y1 Receptor Antagonism at 3mg/kg Does Not Significantly Alter the DSS-
Induced Behavioral Profile in the Open Field in Either Model 
In line with the findings from Experiments 1 and 2, animals exposed to DSS 
showed significant behavioral alterations in both the acute inflammatory and recovery 
models for all behavioral measures assessed in the open field except for total time spent 
resting in the acute (F(1,36)=3.190; p =.083) and recovery (F(1,30)=1.285; p =.266) 
models (see Figures 30-34). General movements are significantly decreased in DSS 
treated mice in comparison to control mice. In the acute phase, both basic 
(F(1,36)=16.23; p <.001) and fine movements (F(1,36)=53.13; p <.001) are significantly 
decreased in DSS treated mice. A similar observation was made during the recovery 
phase for both basic (F(1,30)=26.65; p <.001) and fine movements (F(1,31)=41.58; p 
<.001).  
Locomotion was also significantly reduced by DSS administration. During the 
acute phase, DSS exposure induced significant decreases in X-Y ambulation 
(F(1,35)=18.00; p <.001), total distance traveled (F(1,36)=20.66; p <.001) and 
immobility (F(1,35)=11.56; p <.001). Similar observations were made for X-Y 
ambulation (F(1,29)=27.85; p <.001), distance traveled (F(1,30)=30.59; p <.001) and 
immobility (F(1,30)=38.45; p <.001) for animals in the recovery model.  
DSS induced visceral pain-related behavioral changes at both time points. Rearing 
behavior was significantly reduced in DSS treated mice in both the acute inflammatory 
(F(1,36)=83.18; p <.001) and recovery (F(1,30)=56.19; p <.001)  models. In line with 
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these observations, the total time spent rearing was also significantly decreased in 
animals exposed to DSS in both the acute (F(1,36)=121.7; p <.001) and recovery 
(F(1,30)=61.41; p <.001) models. These same behaviors assessed while normalizing 
rearing behavior to total ambulation and rearing time to total rears support the 
observation that DSS induces pain-like states. With the normalized data, DSS treated 
animals in the acute inflammatory (F(1,34)=59.60; p <.001) and recovery 
(F(1,31)=17.70; p <.001) models reared significantly less than control mice and spent 
significantly less time per rear, (F(1,36)=42.790; p <.001) and (F(1,31)=62.68; p <.001) 
for acute and recovery respectively. Y1 receptor antagonism did not significantly alter 
any of the DSS-induced behavioral changes. These results corroborate the findings from 
Experiment 2, which suggests that Y1 signaling may not play a significant role in DSS-




Figure 30. DSS exposure results in significant decreased in general movements in 
the open field. Y1 receptor antagonism does not alter these observations. Mean basic 
and fine movement total (A,C,E,G) and per 5-minute block (B,D,F,H) counts in the acute 




























































































































H2O-Veh H2O-BIIE 0246 DSS-Veh DSS-BIIE 0246
Basic Movements















































fine movements. Data presented as mean ± SEM. ** (p<.01), indicate a significant main 
effect of DSS. 
	  
Figure 31. DSS exposure results in significant decreases in locomotor activity in the 
open field. Y1 receptor antagonism does not alter these observations. Mean X-Y 

































































































































































































counts in the acute and recovery models. DSS treatment significantly decreases both X-Y 
ambulation and distance traveled at both time points. Data presented as mean ± SEM. ** 
(p<.01), indicate a significant main effect of DSS. 
	  
Figure 32. DSS exposure results in significant increases in immobility time in the 























































































































































































immobility (A,C,E,G) time and per 5-minute block (B,D,F,H) counts in the acute and 
recovery phases in the open field. DSS does not significantly alter rest time but does 
increase total immobility time. Data presented as mean ± SEM. ** (p<.01), indicate a 













































































































































































Figure 33. DSS exposure significantly decreases total number of rears and rearing 
time. Y1 receptor antagonism does not alter these observations.  Mean number of 
rears and rearing time (A,C,E,G) and per 5-minute block (B,D,F,H) counts in the acute 
and recovery phases in the open field. Data presented as mean ± SEM. ** (p<.01), 


















































































































































































Figure 34. DSS-Induced significantly decreases reduced normalized rearing and 
rearing time. Y1 receptor antagonism does not alter these observations.  Mean 
number of rears and rearing time (A,C,E,G) and per 5-minute block (B,D,F,H) counts 
normalized to overall ambulation in the acute and recovery phases in the open field. Data 




Specific Aim 3: To determine the role of peripheral NPY via its Y2 receptor in the 
mouse model of DSS-induced colitis. 
Up until this point, Experiment 1 provided an in depth characterization of the DSS 
model of colitis at 3 different disease time points with the inclusion of recovery periods. 
Experiment 1 corroborated the current experimental disease landmarks reported in the 
literature including elevated levels of MPO, cytokines, microscopic damage to the colon 
epithelium and body weight loss. In addition, Experiment 1 provided a microscopic 
pathological characterization of DSS-induced damage not readily available in the 
literature including colon crypt length, colon muscle wall thickness including changes in 
the specific smooth muscle layers making up the colon wall as well as DSS-induced 
behavioral profile in the open field. Experiments 2 and 3 sought to determine the effect of 
NPY Y1 receptor antagonism on DSS induced colitis along all the previously mentioned 
variables. Findings from Experiments 2 and 3 suggested that NPY signaling via its Y1 
receptor plays an important role in this experimental model of human inflammatory 
disease. Specifically, it was observed that Y1 receptor signaling inhibition results in 
significantly less body weight loss as well as decreased inflammatory cytokine and MPO 
expression in the distal colon. These observations were most often observed in the acute 
inflammatory model than following the recovery period suggesting what appears to be a 
specific involvement of Y1 signaling in the development of DSS-induced acute colon 
inflammation. These experiments provide strong evidence for the involvement of NPY in 
neuroimmune mediated inflammation but it is also apparent that Y1 signaling is not the 
sole mechanism of NPY’s involvement. In light of these observations and the well 
publicized role of Y2 receptors in immunity, the studies in Experiment 4 are aimed at 
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unveiling the potential involvement of NPY signaling via its Y2 receptor in the DSS 
experimental model of colitis.  
Experiment 4 
Aim and Design 
To study the role of the Y2 receptor in DSS-induced inflammation and pain-
related behavior, the small molecule selective Y2 receptor antagonist BIIE 0246 given 
once daily via subcutaneous injections at a dose of 10mg/kg during the length of the 
experiment. Because BIIE 0246 is not soluble in water but rather ethanol or DMSO, both 
of which have the capacity to alter behavior on their own, the first study was designed 
with the highest concentration of diluent (DMSO) available in the literature as a gauge 
for subsequent studies within this experiment.  
For this first study, BIIE 0246 was reconstituted in 100% DMSO for the stock 
solution and then diluted in a 50:50 ratio of dH2O to DMSO to obtain an injectable 
solution of 50% DMSO and a dose of 10mg of BIIE 0246 per kg of mouse weight. The 
recovery model was used to assess any potential detrimental effects of this compound 
across the longer model (10-day administration period). Briefly, the control group 
received drinking water for 10 days whereas the experimental group received 4% DSS 
for 7 days then animals were changed to drinking water for the following 3 days. Due to 
higher than expected mortality rates in the DSS groups for this study, only body weight 
and behavior was assessed. The specific experimental designed is depicted in the table 
below. All statistical analyses for this experiment were computed as independent samples 
t-test or as a 3 way mixed Factorial ANOVAs (when adding a repeated measures 




Vehicle	  (50%	  DMSO)	   BIIE	  0246	  (10mg/kg)	  
Control	  (H2O)	   10	   10	  
4%	  DSS	   10	   10	  
	  
Results 
BIIE 0246 Reconstituted in 50% DMSO as well as 50% DMSO Alone Exacerbate 
DSS-Induced Weight Loss and Increase Death Rate in DSS Treated Mice 
 In line with previous observation, DSS exposure results in significant body weight 
loss compared to mice provided with regular drinking water (see Figure 35). Similar to 
previous experiment, significant DSS-induced body weight loss is observed as early as 
day 4 post DSS administration (F(1,35)=21.621; p <.001) and continued to decrease 
throughout the length of the experiment. However, unlike the previous recovery 
experiment, mice exposed to DSS did not show body weight leveling following initiation 
of the recovery phase. In fact, by day 7 post DSS exposure (DSS withdrawal day), only 8 
out of 20 DSS treated animals survived (5 from DSS-BIIE 0246 group) while 17 animals 
from the water control groups were still alive.  By day 8 post DSS administration (day 1 
of recovery), the remaining DSS mice were humanely sacrificed as they continued to 
loose weight below the critical point of 25% body weight loss and that experimental leg 
was concluded. Both water control groups were maintained and weight daily to assess the 
role any potential detrimental effects of DMSO in body weight. As seen in Figure 31, 
though there were weight variations in these groups, no obvious detrimental effect of 
DMSO was observed in these mice. These findings suggest that a 50% DMSO solution is 
lethal for DSS treated mice and call for a lower DMSO concentration for future 




Figure 35. 50% DMSO is lethal for animals exposed to DSS. Mean percent body 
weight change across time in the recovery model of DSS-induced colitis. DSS treated 
mice experience significant body weight loss as early as day 4 post DSS exposure and 
continue to loose weight even when tap water is reinstalled in the presence of 50% 
DMSO. Water control groups maintain body weight throughout the length of the 
experiment with minimal fluctuation. Data presented as mean ± SEM.  
BIIE 0246 Reconstituted in 50% DMSO Does Not Significantly Alter Open Field 
Behaviors Compared to 50% DMSO-Alone Control Groups 
 Due to high mortality rates in the DSS treated groups, only the two water control 
(water-50% DSMO and water-BIIE 0246 in 50% DMSO) groups were assessed in the 
open field. General movements in the open field were not affected by  
Percent Body Weight Change



















BIIE 0246 reconstituted in 50% DMSO in comparison to the vehicle (50% DMSO-alone) 
group (see Figures 36-40), this was true for basic movements (t(14)=0.527; p=.606) and 
fine movements (t(14)=0.421; p=.680).  Similarly, measures of locomotion did not differ 
significantly between these two groups. Animals from both groups showed similar X-Y 
ambulation patterns (t(14)=0.747; p=.468), traveled similar total distances (t(14)=0.551; 
p=.591), had similar total resting time (t(13)=0.626; p=.542) as well as total time spent 
immobile (t(14)=0.103; p=.919).  In addition, these two groups did not differ 
significantly in the visceral pain-related measures assessed including total rearing counts 
(t(14)=1.431; p=.175), rearing time (t(14)=1.308; p=.212), and no difference was 
observed when these two measures normalized to overall ambulation (t(13)=0.605; 
p=.556) and total rears (t(14)=0.770; p=.454) respectively. Though there is no significant 
difference between the 50% DMSO and BIIE 0246 in 50% DMSO groups, it is worth 
noting that all values for each measure assessed appear to be at very low levels in 
comparison to the values from control animals in previous experiments which is in line 
with the reported numbing properties of DMSO. 




Figure 36. BIIE 0216 in 50% DMSO does not significantly alter general movement 
behaviors in the open field. Mean total counts (A, C) and counts per 5-minute blocks 
(B, D) for general movements measures. BIIE 0246 treated animals did not differ 
significantly from control groups for either measure of general movement. Data presented 
as mean ± SEM.  
 
Basic Movements




























































Veh (50% DMSO) BIIE 0246 (10mg/kg)
Fine  Movements




















Figure 37. BIIE 0216 in 50% DMSO does not significantly alter general locomotion 
behaviors in the open field. Mean total counts (A, C) and counts per 5-minute blocks 
(B, D) for locomotion. BIIE 0246 treated animals did not differ significantly from control 
groups for either measure of locomotion. Data presented as mean ± SEM.  
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Figure 38. BIIE 0216 in 50% DMSO does not significantly total rest and immobility 
time in the open field. Mean total (A, C) and per 5-minute blocks (B, D) time spent 
resting and immobile. BIIE 0246 does not alter resting time or time spent immobile 
when compared to animals in the vehicle group. Data presented as mean ± SEM.  	  
Total  Rest Time


















































































Figure 39. BIIE 0216 in 50% DMSO does not significantly alter general rearing 
behaviors in the open field. Mean total (A, C) and per 5-minute blocks (B, D) rearing 
counts and time. BIIE 0246 treated mice showed similar number of rears and time rearing 
as animals from the vehicle group. Data presented as mean ± SEM.  
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Figure 40. BIIE 0216 in 50% DMSO does not significantly alter normalized rearing 
behaviors in the open field. Mean total (A, C) and per 5 minute blocks (B, D) rears 
normalized to ambulation and rearing time normalized to total rears. Normalizing 
for overall ambulation, BIIE -0246 treated mice did not differ significantly from animals 


































































































 The study from Experiment 4 demonstrated that administration of BIIE 0246 
diluted in 50% DMSO or 50% DMSO alone results in high mortality rates for animals 
exposed to DSS. In addition, though no significant differences were observed in 
behavioral patterns between animals injected with 50% DMSO alone or the Y2 blocker 
diluted in this solution, post hoc observations suggest that generally, animals treated with 
50% DMSO showed decreased activity in the open field (half values for most measures) 
in comparison to values from control animals in all previous experiments. These 
observations suggest that treatment with a 50% DMSO solution is detrimental for animals 
exposed to DSS and dampers overall activity in the open field, findings which are 
suggestive of a “numbing effect” of DMSO at a concentration of 50%. In order to address 
this issue, different dilution of BIIE 0246 were made at varying degrees of DMSO 
concentrations to assess the lowest DMSO concentration that would maintain the Y2 
antagonist in solution. The DMSO concentrations assessed were 50%, 25%, 12.5% and 
6.25% after letting the solutions sit for over 72 hours. BIIE 0246 was completely in 
solution at all concentration except at the lowest where some crystals were still visible. 
Based on these observations the 12.5% concentration was selected. A pilot study was 
designed to determine if a12.5% DMSO solution injected daily subcutaneously would 
also induced the higher mortality rates in mice exposed to DSS mice as was observed 
with the 50% DMSO solution. Since this was a pilot study, only percent weight change 
and open field behaviors were assessed. This pilot study design is depicted in the table 





dH2O	   12.5%	  DMSO	  
4%	  DSS	   5	   5	  
	  
Results 
A 12.5% DMSO Solution Administered to Mice Exposed to DSS Results in Nearly 
Indistinguishable Body Weight Loss Patterns Compared to Control Mice 
 Daily subcutaneous injection of 12.5% DMSO to DSS treated mice does not 
induced the high mortality rate observed when a 50% DMSO solution is administered nor 
does it exacerbate body weight loss (see Figure 41). In fact, both groups showed percent 
body weight changes that were in line with the previously observed DSS-induced weight 
loss patterns but no significant difference was observed between the groups across the 7 
day period (F(1,8)=0.586; p=.466).  
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 Figure 41. Mean percent body weight change across time in the acute model of 
DSS-induced colitis. Treatment with a 12.5% DMSO solution does not alter DSS-
induced body weight loss. Data presented as mean ± SEM.  
A 12.5% DMSO solution Administered to Mice Exposed to DSS Does Not Alter 
DSS-Induced Behavioral Changes in the Open Field  
 Administration of a 12.5% DMSO solution to mice exposed to DSS does not 
significantly alter general movements, locomotion or pain-related behaviors in the open 
field (see Figures 42-46). In DSS treated mice, total basic (t(8)=0.620; p=.552) and fine 
(t(8)=1.366; p=.210) movements are not significantly different between vehicle (dH2O) 
or 12.5% DMSO treated animals. Similarly, measures of locomotion including X-Y 
ambulation (t(8)=0.466; p=.654), total distance traveled (t(8)=0.711; p=.497), total time 
spent resting (t(8)=0.377; p=.716) and total immobility time (t(8)=1.337; p=.218) were 
not significantly different between these groups. In addition, these groups also did not 
differ in pain-related measures including total rears (t(8)=0.626; p=.549), total rearing 
time (t(8)=1.073; p=.315) even after normalizing rearing to overall ambulation 




Figure 42. 12.5% does not significantly alter DSS-induced changes in general 
movements in the open field. Mean total counts (A, C) and counts per 5-minute blocks 
(B, D) for general movements measures. DSS treated mice injected with 12.5% DMSO 
do not differ significantly in general movements from control mice receiving the vehicle 
injection. Data presented as mean ± SEM. 
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Figure 43. 12.5% does not significantly alter DSS-induced changes in general 
locomotion in the open field. Mean total counts (A, C) and counts per 5-minute blocks 
(B, D) for locomotion. DSS treated mice injected with 12.5% DMSO do not show 
significant differences from control mice in overall locomotion. Data presented as mean 
± SEM.  	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Figure 44. 12.5% does not significantly alter DSS-induced changes in rest and 
immobility times in the open field. Mean total (A, C) and per 5-minute blocks (B, D) 
time spent resting and immobile. Injections of 12.5% DMSO to DSS treated mice does 
not significantly alter total rest time or immobility compare to control mice. Data 
presented as mean ± SEM. 	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Figure 45. 12.5% does not significantly alter DSS-induced changes in rearing 
behaviors in the open field. Mean total (A, C) and per 5-minute blocks (B, D) rearing 
counts and time. DSS treated mice injected with 12.5% DMSO do not show differential 
rearing patterns compared to control mice. Data presented as mean ± SEM.  	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Figure 46. 12.5% does not significantly alter DSS-induced changes in normalized 
rearing behavior in the open field. Mean total (A, C) and per 5 minute blocks (B, D) 
rearing normalized to ambulation and rearing time normalized to total rears. 12.5% 
DMSO injections do not alter rearing behavior even when normalizing to overall 


















































































Both previous studies sought to determine the optimal concentration of DMSO to 
reconstitute the Y2 receptor antagonism BIIE 0246 while not affecting mortality in DSS 
treated mice or behavior when administered systemically for long periods of time. The 
data from these studies suggests that DMSO at high concentrations (50%) increases 
mortality rates in DSS treated mice and affects behavior in both water and DSS treated 
mice via what appears to be a “numbing-like effect”. At the lower concentration of 
DMSO (12.5%) where BIIE 0246 is still maintained in solution for long periods of time, 
mortality in DSS treated mice is unaffected as well as behaviors in the open field. Based 
on this data, the role o NPY signaling via its Y2 receptor in the DSS model of colitis in 
both the acute inflammatory and recovery models was assessed in a similar design to Y1 
in Experiment 3. Briefly, for the acute inflammatory model, experimental animals 
received 4% DSS in their drinking water for 7 days at which point they were tested in the 
open field and sacrificed for tissue collection.  For the recovery model, animals were 
allowed a 3-day recovery period after the acute inflammatory phase. All animals in the 
experimental group received the Y2 antagonist for the duration of the experiment.  The 
specific designs are depicted in the table below. All statistical analyses for these 
experiments were computed as a 2X2 factorial ANOVA or as 3 way mixed Factorial 
ANOVAs as appropriate. One animal from each DSS group in the acute model died in 
the course of the experiment while none did in the recovery model. Data from dead 





7-Day Acute Inflammatory Model 
	  
Vehicle	  (dH2O)	   BIIE	  0246	  (10mg/kg)	  
Control	  (H2O)	   10	   10	  
4%	  DSS	   10	   10	  	  
10-Day Recovery Model 
	  
Vehicle	  (dH2O)	   BIIE	  0246	  (10mg/kg)	  
Control	  (H2O)	   10	   10	  
4%	  DSS	   10	   10	  
	  
Results 
Y2 Receptor Antagonism Slows Down DSS induced Weight Loss and Significantly 
Improves Terminal Weight in DSS Treated Mice in Both the Acute Inflammatory 
and Recovery Models 
 As observed in all previous experiments, administration of DSS to mice caused 
significant weight loss in both the acute (F(1,34)=638.65; p <.001) and recovery models 
(F(1,36)=281.39; p <.001) compared to their respective control groups (see Figure 47). 
Y2 receptor antagonism results in a slower weight loss pattern in animals exposed to DSS 
and significantly improves terminal body weight for these mice in both the acute 
(F(1,34)=8.88; p =.005) and recovery (F(1,36)=11.25; p =.002) models while showing no 




Figure 47. DSS induces a progressive pattern of weight loss in both models with 
weight leveling off after DSS withdrawal in the recovery model. Y2 receptor 
antagonism significantly attenuates this effect. Mean percent body weight change 
across time in the acute inflammation model (A) and in the recovery model (B). Y2 
receptor antagonism slows down DSS-induced weight loss and significantly improves 
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body weight a both terminal points. Data presented as mean ± SEM. ** (p<.01), indicate 
a significant difference between DSS groups. 
Y2 Receptor Antagonism at 10mg/kg Does not Alter DSS-induced Histopathological 
damage, Colon and Cecum Shrinkage or Tissue Weight Changes in the Acute 
Inflammatory Model But Does Alter Tissue Weight in the Recovery Phase 
 Similar to the observations from previous studies, DSS administration results in 
significant colon and cecum shrinkage and weight loss at both stages of disease (see 
Figure 48). Animals exposed to DSS had greater histopathological damage than control 
mice at the acute F(1,36)=491.723; p <.001) and recovery periods F(1,36)=149.25; p 
<.001) and colons that were significantly shorter in both the acute (F(1,33)=58.720; p 
<.001) and recovery phases (F(1,36)=6.635; p =.014) compared to colons from control 
mice. Y2 antagonism did not significantly change these observations. Colon weight was 
not significantly altered in the acute phase (F(1,33)=0.2919; p =.593) but was 
significantly increased in mice exposed to DSS in the recovery model  (F(1,35)=5.334; p 
=.027). 
 Cecum from mice exposed to DSS were significantly shorter than those of control 
mice in both the acute (F(1,34)=42.820; p <.001) and recovery (F(1,36)=53.480; p <.001) 
models. Y2 antagonism did not alter these observations at either time point. Cecum 
weight was significantly decreased by DSS administration in both the acute 
(F(1,34)=12.75; p <.001)  and recovery (F(1,36)=8.631; p =.005)  models.  Y2 




Figure 48. DSS induces colon and cecum shrinkage and tissue weight change in both 
models. Y2 receptor antagonism does not alter these observations. Mean dry colon 
and cecum length following acute (A,C) and recovery (E,G) phases and mean weight  
following acute (B,D) and recovery (F,H) phases. Data presented as mean ± SEM. ** 










































































































































Y2 Receptor Antagonism Does Not Significantly Alter DSS-Induced Colon Wall 
Thickening or Mucosa Crypt Shortening in either Model Assessed 
In line with previous observations, DSS induces significant colon muscle wall 
thickening and mucosa crypt shortening (see Figures 49-51). Animals exposed to DSS 
had significantly thicker colon muscle walls than control mice in both the acute 
(F(1,31)=15.400; p <.001) and recovery (F(1,31)=8.887; p =.006) models. Examination 
of the individual smooth muscle layers making up the colon wall revealed significant 
thickening of both the circular (F(1,30)=34.49; p <.001) and longitudinal (F(1,31)=4.668; 
p =.039) muscle layers in the acute inflammatory model. For the recovery model, colon 
muscle wall thickness was mainly driven by thickening of the circular (F(1,32)=6.083; p 
=.019) but not the longitudinal (F(1,31)=0.349; p =.559) muscle layer. Y2 receptor 
antagonism did not have an effect on DSS-induced colon wall thickening in either model.  
 Animals exposed to DSS had significantly shorter mucosal crypts in the acute 
(F(1,32)=4.736; p =.037) model but significantly longer crypts in the recovery 
(F(1,34)=6.407; p =.016) model. Y2 receptor antagonism did not have an effect in DSS-
induced crypt shortening during the acute inflammatory (F(1,32)=0.012; p =.915) or 




Figure 49.  DSS exposure in the acute inflammatory model results in significant 
colon tissue damage and Y2 receptor antagonism does not attenuate this effect.  
Representative micrographs (10X) of a non-treated control animal (A), a control animal 
treated with the Y2 antagonist (B), a non-treated DSS animal (C) and a DSS animal 
treated with the Y2 receptor antagonist (D). Scale bar = 100µm. 
A B 
C D 












Figure 50.  DSS exposure in the recovery model results in significant colon tissue 
damage and Y2 receptor antagonism does not attenuate this effect.  Representative 
micrographs (10X) of a non-treated control animal (A), a control animal treated with the 
Y2 antagonist (B), a non-treated DSS animal (C) and a DSS animal treated with the Y2 
receptor antagonist (D). Scale bar = 100µm. 	   	  
A B 
C D 












Figure 51.  DSS induces significant colon wall thickening and mucosa crypt 
shortening. Y2 receptor antagonism does not alter these observations. Mean full 
distal colon muscle length and specific muscle layers for the acute (A, C, D) and recovery 
phases (E, G, H), and crypt length during acute (B) and recovery periods (F). Data 






































































































































presented as mean ± SEM. ** (p<.01), * (p<.05) indicate a significant main effect of 
DSS. 
Y2 Receptor Antagonism Does Not Significantly Alter DSS-Induced Distal Colon 
MPO Protein Expression in the Acute Inflammatory Model but Shows A Statistical 
Tendency To Attenuate This Effect in the Recovery Model 
In line with observations from all previous experiments presented here, exposure 
to DSS significantly increases distal colon MPO protein expression (see Figure 52). MPO 
protein was significantly overexpressed in DSS treated mice in both the acute 
(F(1,31)=34.370; p <.001) and recovery (F(1,33)=19.140; p <.001) phases. Y2 receptor 
antagonism does not alter DSS-induced distal colon MPO increases in the acute 
inflammatory model (F(1,31)=0.148; p =.703) but shows a statistical tendency to 





Figure 52. DSS induces significant upregulation of distal colon MPO in both models. 
Y2 receptor antagonism does not significantly alter these observations. Mean distal 
colon MPO protein concentration expressed in ng/mg of total sample protein for animals 
in the acute inflammatory (A) and recovery (B) models. Y2 receptor antagonism does not 
alter DSS-induced increases in distal colon MPO expression in the acute inflammatory 
model but shows a strong statistical tendency to decrease MPO expression in the 
recovery model. Data presented as mean ± SEM. ** (p<.01), indicate a significant main 
effect of DSS. 

























































Y2 Receptor Antagonism Does Not Alter DSS-Induced Distal Colon Cytokine 
Increases in Either Model 
 In line with previous findings, DSS exposure induced significant increases in 
distal colon cytokine expression in the acute inflammatory model (see Tables 5 and 6). In 
the recovery model however, DSS did not increase distal colon cytokine expression with 
only a slight trend to increase IL-1β observed. In fact, from all the cytokines assessed, 
only IL-1β, IL-6 and IL-12 demonstrated consistent detectable protein expression in both 
models with only very few animals showing protein expression for the other cytokines. 
When expression was below the detectable range, animals were assigned the lowest 
detectable limit value for those cytokines. Y2 receptor antagonism did not have an effect 
on distal colon cytokine expression in either model.  
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0246	   p	  Value	  	  
IL-­‐1β	   12.1913 12.91618 28.71229 25.16299 **	  
SEM	  ±	   1.220933 1.148731 2.942573 3.270066 
	  IL-­‐6	   23.79725 25.2122 56.04599 46.88763 **	  
SEM	  ±	   2.383244 2.242306 5.743862 6.968401 
	  IL-­‐12	   15.4746 16.39469 36.44493 30.48954 **	  
SEM	  ±	   1.549748 1.458101 3.735051 4.531331 
	  GM-­‐CSF	   3.980398 4.217067 9.374419 7.842565 N/A	  
SEM	  ±	   0.3986284 0.3750548 0.9607353 1.165556 
	  IFN-­‐γ	   9.929709 10.52012 23.38592 19.56447 N/A	  	  
SEM	  ±	   0.9944394 0.9356313 2.396701 2.907656 
	  TNF-­‐α	   13.2875 14.07756 31.29402 26.18032 N/A	  	  
SEM	  ±	   1.330716 1.252021 3.207161 3.890899 
	  IL-­‐2	   8.759005 9.279802 20.62873 17.25784 N/A	  	  
SEM	  ±	   0.8771958 0.825321 2.114132 2.564846 
	  IL-­‐4	   12.40948 13.14733 29.22613 24.45035 N/A	  	  
SEM	  ±	   1.242783 1.169288 2.995234 3.633791 
	  IL-­‐10	   3.6824 3.901351 8.672591 7.25542 N/A	  	  
SEM	  ±	   0.3687846 0.3469758 0.8888087 1.078295 
	  IL-­‐5	   23.50457 24.90212 55.3567 46.31097 N/A	  	  
SEM	  ±	   2.353933 2.214729 5.67322 6.882699 
	  Table 5.  DSS induces significant increases in distal colon cytokine expression. Y2 
receptor antagonism does not significantly alter these observations. Mean distal 
colon cytokine protein expressed as pg/mg of total sample protein Animals exposed to 
DSS showed significant increases in IL-1β, IL-6 and IL-12. 













0246	   p	  Value	  	  
IL-­‐1β	   16.17513 15.09252 38.59196 50.44469 p	  =.106	  
SEM	  ±	   1.741578 1.375928 9.246645 34.39629 
	  IL-­‐6	   31.57364 29.46039 28.64425 31.29384 p	  =	  .238	  
SEM	  ±	   3.399535 2.685793 2.866773 2.833243 
	  IL-­‐12	   20.53134 19.15716 31.93923 21.62598 p	  =	  .855	  
SEM	  ±	   2.21061 1.746486 11.16141 2.641546 
	  GM-­‐CSF	   5.2811 4.927632 4.791121 5.234301 N/A	  	  
SEM	  ±	   0.5686164 0.4492337 0.479505 0.4738966 
	  IFN-­‐γ	   13.17451 12.29273 11.95218 13.05776 N/A	  	  
SEM	  ±	   1.4185 1.120682 1.196198 1.182207 
	  TNF-­‐α	   17.62955 16.44959 15.99389 17.47333 N/A	  	  
SEM	  ±	   1.898175 1.499648 1.6007 1.581978 
	  IL-­‐2	   11.62124 10.84343 10.54303 11.51826 N/A	  	  
SEM	  ±	   1.25126 0.9885543 1.055167 1.042826 
	  IL-­‐4	   16.46461 15.36262 14.93703 16.3187 N/A	  	  
SEM	  ±	   1.772745 1.400552 1.494927 1.477442 
	  IL-­‐10	   4.885724 4.558718 4.432428 4.842428 N/A	  	  
SEM	  ±	   0.5260462 0.4156012 0.4436063 0.4384177 
	  IL-­‐5	   31.18532 29.09806 28.29196 30.90897 N/A	  	  
SEM	  ±	   3.357725 2.652761 2.831516 2.798397 
	  Table 6.  DSS did not significantly increase distal colon cytokine expression in the 
recovery model. Mean distal colon cytokine protein expressed in pg/mg of total sample 
protein 
Y2 Receptor Antagonism Does Not Significantly Alter DSS-Induced Distal Colon 
Increases in NPY Protein Expression at either Disease Time Point 
 As previously observed, exposure to DSS results in a significant upregulation of 
distal colon NPY protein expression (see Figure 53), an effect that was observed at both 
the acute inflammatory (F(1,33)=19.440; p <.001) and recovery (F(1,34)=11.160; p 
<.002) phases. Treatment with BIIE 0246 does not alter distal colon NPY protein 
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expression in neither the acute (F(1,33)=2.421; p =.129) nor recovery (F(1,34)=2.547; p 
=.120) models.  
	  
Figure 53. DSS induces significant increases of NPY in the distal colon in both 
models. Mean distal colon NPY protein concentration expressed in ng/mg of total sample 
protein. DSS treatment induces distal colon NPY protein upregulation in both the acute 
and recovery models. Y2 receptor antagonism does not significantly alter these 
observations but shows a statistical tendency to decrease NPY expression in DSS treated 




















































mice. Data presented as mean ± SEM. ** (p<.01), indicate a significant main effect of 
DSS. 
Y2 Receptor Antagonism Does Not Significantly Alter DSS-Induced Behavioral 
Changes in the Open Field  
 Similar to the observations from previous experiments, DSS exposure 
significantly alters all behavioral measures assessed in the open field in both models 
except for total rest time at both time points and total distance traveled and X-Y 
ambulation in the recovery model (see Figures 54-58). DSS significantly alters general 
movement at both time points in the open field. Basic movements were significantly 
decreased in mice exposed to DSS in the acute inflammatory (F(1,34)=22.160; p <.001) 
and recovery (F(1,36)=4.127; p =.500) models. Similarly, fine movements were 
significantly decreased in mice exposed to DSS in comparison to control mice in both the 
acute (F(1,34)=29.860; p <.001) and recovery (F(1,36)=16.910; p <.001) models. Y2 
receptor antagonism did not significantly changes these DSS-induced behavioral changes 
in the acute inflammatory model but showed a slight statistical tendency to increase fine 
movements in these mice (F(1,36)=2.860; p =.100). 
 Locomotion in the open field was also significantly decreased in animals exposed 
to DSS when compared to control mice. DSS treated mice showed significantly less X-Y 
ambulation in the acute inflammatory model (F(1,32)=69.720; p <.001) and a statistical 
tendency in the same direction was observed for recovery model (F(1,36)=3.308; p 
=.077). Similarly, the total distance traveled was significantly decreased in animals 
exposed to DSS in the acute inflammatory model (F(1,32)=70.410; p <.001) but for 
animals in the recovery model (F(1,35)=1.939; p =.173). Though no significant effect of 
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DSS was observed in total time spent resting, there was however an effect of this 
treatment in total time spent immobile. DSS treated mice spent significantly more time 
immobile than control mice in both the acute inflammatory (F(1,33)=25.250; p <.001) 
and recovery (F(1,34)=5.185; p =.029) models. Y2 receptor antagonism did not 
significantly alter these DSS-induced behavioral changes in either model. 
Visceral pain-related behaviors were significantly induced by DSS as seen in all 
previous experiments in both the acute inflammatory and recovery models.  Total rearing 
counts were significantly decreased in mice exposed to DSS compared to control mice 
both during acute inflammation (F(1,31)=114.700; p <.001) and recovery 
(F(1,35)=39.030; p <.001). Similarly, the total amount of time animals spent rearing was 
significantly decreased in DSS treated mice during acute inflammation (F(1,31)=114.700; 
p <.001) and recovery (F(1,31)=114.700; p <.001). Analyzing the effects of DSS on 
rearing behavior normalized to the animal’s total X-Y ambulation resulted in similar 
findings. Rearing counts normalized to total X-Y ambulation revealed significant 
decreases in rearing in the acute inflammatory (F(1,32)=65.990; p <.001) and recovery 
(F(1,35)=35.090; p <.001) models. Rearing time normalized to total rears was also 
decreased in mice exposed to DSS in both the acute inflammatory (F(1,34)=30.070; p 
<.001) and recovery (F(1,36)=80.490; p <.001) models.  
Y2 receptor antagonism did not significantly affect DSS induced rearing or 
rearing time but it showed strong statistical trends to increase overall total rearing 
(F(1,31)=4.082; p =.052) and total rearing time (F(1,32)=3.637; p =.066) in the acute 
inflammatory model. Normalizing total rears to total ambulation revealed a significant 
effect of BIIE 0246 on rearing. Overall, animals treated with the antagonist showed 
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significantly more rearing than animals receiving the vehicle solution (F(1,32)=7.673; p 
<.009).  Though not statistically significant, the statistical tendency for BIIE 0246 to 
increase rearing duration was also observed after normalizing for total rears 
(F(1,34)=3.439; p =.072). In the recovery model, BIIE 0246 did not have a significant 
effect on total rears (F(1,35)=0.207; p =.652) or total rearing time (F(1,36)=0.038; p 
=.847). This observation was also seen after normalizing total rears by ambulation 
(F(1,35)=1.648; p =.207). However, when total rearing time was normalized to total 
rears, an effect of BIIE 0246 was revealed.  Overall, treatment with the Y2 receptor 






Figure 54. DSS induces significant decreases in general movements in the open field. 
Y2 receptor antagonism does not alter these observations. Mean basic and fine 
movement total (A,C,E,G) and per 5-minute block (B,D,F,H) counts in the acute and 
recovery models. Data presented as mean ± SEM. ** (p<.01), indicate a significant main 








































































































H2O-Veh H2O-BIIE 0246 DSS-Veh DSS-BIIE 0246
Fine Movements


























H2O-Veh H2O-BIIE 0246 DSS-Veh DSS-BIIE 0246
Basic Movements




















































Figure 55. DSS induces significant decreases in general locomotion in the open field. 
Y2 receptor antagonism does not alter these observations. Mean X-Y ambulation and 
































































































































































































and recovery models. Data presented as mean ± SEM. ** (p<.01), indicate a significant 
main effect of DSS. 
	  
Figure 56. DSS does not alter rest time but significantly increases immobility in the 
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immobility (A,C,E,G) time and per 5-minute block (B,D,F,H) counts in the acute and 
recovery models. Data presented as mean ± SEM 
	  
Figure 57. DSS induces significant decreases in rearing behavior in the open field. 
Y2 receptor antagonism does not alter these observations. Mean number of rears and 








































































































































































recovery models. Data presented as mean ± SEM. ** (p<.01), indicate a significant main 
effect of DSS. 
	  
Figure 58. DSS induces significant decreases in normalized rearing behavior in the 

















































































































































































normalized rears and rearing time (A,C,E,G) and per 5-minute block (B,D,F,H) counts in 
the acute and recovery models. Data presented as mean ± SEM. ** (p<.01), indicate a 




Specific Aim 4:  To evaluate the possibility that NPY plays a role in the 
pathophysiology of DSS-induced colitis via its Y1 and Y2 receptors in a pathology-
stage dependent manner. 
Experiments 3 and 6 sought to determine any potential involvement of NPY 
signaling via its Y1 and Y2 receptors in modulating several parameters associated with 
DSS-induced colitis. When looking at the data collectively, it is apparent that blocking 
either receptor does not result in any robust disease modification. However, upon closer 
examination, there appears to be a slight pattern such that the effects of each antagonist 
appears to have greater effects in one time course model over the other. That is, the 
tendencies for Y1 receptor antagonism with BIBP 3226 to alter DSS-induced effects more 
often occurred in the acute inflammatory model and were nearly nonexistent in the 
recovery model. Y2 receptor antagonism on the other hand showed slight tendencies to 
alter DSS-induced effects in the recovery but not in the acute inflammatory model.  
Experiment 7 
Aim and Design 
Based on these observations, the current studies were designed to replicate the 
potential effects of each antagonist given alone, but to also determine whether the effects 
would be enhanced if both antagonists were given in combination in the acute and 
recovery models.  An additional experiment tested the combination of the Y1 receptor 
antagonist given for the first 7 days and the Y2 receptor antagonist given during the 3 
recovery days, hereafter referred to as the mixed treatment. All animals in these studies 
received 4% DSS for 7 days. All measures assessed in the previous experiments were 
also collected for these studies. These three different studies were conducted concurrently 
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and each experimental design is depicted in the tables below. All statistical analyses for 
these experiments were computed as 2X2 factorial ANOVAs or as 3 way mixed Factorial 
ANOVAs (when adding a repeated measures variable) as appropriate. 
7-Day Acute Inflammatory Model Combination Treatment 
	  
12.5%	  DMSO	   BIIE	  0246	  (10mg/kg)	  
dH2O	   10	   10	  
BIBP	  3226	  (3mg/kg)	   10	   10	  
 
10-Day Recovery Model Combination Treatment 
	  
12.5%	  DMSO	   BIIE	  0246	  (10mg/kg)	  
dH2O	   10	   10	  
BIBP	  3226	  (3mg/kg)	   10	   10	  
 
10-Day Recovery Model Mixed Treatment 
	   12.5%	  DMSO	  
BIIE	  0246	  (10mg/kg)	  
Days	  8-­‐10	  Only	  
dH2O	   10	   10	  
BIBP	  3226	  (3mg/kg)	  
Days	  1-­‐7	  Only	   10	   10	  
 
Results 
Y1 and Y2 Combined and Mixed Receptor Antagonism Treatments Do Not 
Significantly Improve DSS-induced Terminal Weight Loss 
All animals in these studies were exposed to DSS and showed the typical pattern 
of weight loss observed in previous experiments (see Figure 59). In the acute 
inflammatory model, animals treated with the Y1 receptor antagonist had significantly 
more weight loss at the terminal point than animals receiving the dH2O vehicle injection 
(F(1,35)=8.484; p=.006), an effect that may be driven by the co-administration of BIBP 
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3226 with 12.5% DMSO as this group experienced the greatest weight loss among the 
groups. The Y2 receptor antagonist on the other hand showed a protective effect in DSS-
induced body weight loss when given alone which is in line with observations from 
previous experiments. Animals treated with the Y2 receptor antagonist had lost 
significantly less weight at the terminal point of the acute model than animals treated 
with the 12.5% DMSO vehicle solution (F(1,35)=10.749; p =.002). The combination 
treatment of the two antagonists did not improved terminal body weight. Co-treatment 
with the Y1 and Y2 receptor antagonists ((F(1,30)=0.974; p =.331) or either antagonist- 
alone  did not prevent or alleviate DSS-induced body weight loss at the terminal point in 
the recovery model((F(1,30)=0.038; p =.846 and (F(1,30)=1.445; p =.239) for BIBP 3226 
and BIIE 0246 respectively). Similarly, in the recovery model, mixed antagonist 
treatment did not significantly improve terminal body weight (F(1,24)=0.113; p =.740). 
In this same model, animals treated with BIBP 3226 only during the acute inflammatory 
phase did not improve body weight (F(1,24)=0.007; p =.933). Similarly, animals only 
receiving BIIE 0246 treatment during the recovery phase did not show body weight 




Figure 59. DSS induces significant body weight loss that is not attenuated by Y1 and 
Y2 receptor antagonist combination or mixed treatment. Mean percent body weight 
change across time in the acute inflammation model (A) and in the recovery model (B) 
with Y1 and Y2 receptor antagonist combination treatment and mixed treatment in the 
recovery model (C). Data presented as mean ± SEM.  
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Y1 and Y2 Combined and Mixed Receptor Antagonist Treatment Did Not 
Attenuate DSS-Induced Histopathological damage, Colon and Cecum 
Shrinkage or Weight Change 
 Y1 and Y2 combined in the acute F(1,39)=0.046; p =.831), recovery 
F(1,33)=0.001; p =.994) and mixed F(1,26)=1.826; p =.190) receptor antagonism does 
not attenuate DSS-induced histopathological damage. Combination treatment of BIBP 
3226 and BIIE 0246 did not significantly improve DSS-induced colon shrinkage or 
weight change in either the acute inflammatory or recovery models (see Figure 60). 
However, animals treated with the Y1 receptor antagonist has significantly larger colons 
than those not treated with the antagonists (control) (F(1,35)=6.451; p=.016). There was 
no interaction or significant main effects of either antagonist in either the combined or 





Figure 60. Treatment with the Y1 receptor antagonist significantly attenuates DSS-
induced colon shrinkage in the acute inflammatory model. Mean colon length in the 
acute inflammatory model with antagonist co-treatment (A) and colon length and weight 
in the recovery model with antagonist co-treatment (B,C) and mixed treatment (D, E). 
Distal Colon Length





















































































Data presented as mean ± SEM. $ (p<.05), indicates a significant main effect of BIBP 
3226. 
Neither Combined nor Mixed Y1 and Y2 Receptor Antagonism Significantly Alter 
DSS-Induced Colon Muscle Wall Thickness or Mucosa Crypt Length 
 The combination or mixed treatment with BIBP 3226 and BIIE 0246 in either the 
acute inflammatory or recovery models did not significantly alter DSS-induced changes 
in colon muscle thickness and crypt lengths (see Figures 61-64). However, the Y1 
receptor antagonist alone did have significant effects on these measures in both the 
combined and mixed treatments in the recovery model. In the recovery model where 
animals were co-administered BIBP 3226 and BIIE 0236, animals treated with the Y1 
receptor antagonist had significantly shorter colon crypts (F(1,28)=7.508; p =.011). A 
slight statistical tendency in the same direction was observed with BIIE 0246 treated 
mice (F(1,28=3.165; p =.086) in the same model, however, the individual effects of these 
treatments did not interact to produce a synergistic effect (F(1,28)=1.054; p =.313). A 
similar tendency for the Y1 receptor antagonist to decrease crypt length was also 
observed in the acute inflammatory model (F(1,34=3.085; p =.088).  This negative effect 
of the Y1 receptor antagonist was not observed in any previous experiments as well as in 
the mixed recovery model. A major difference between the experiments where the 
antagonist had detrimental effects from the other experiments not showing this effect is 
the co-administration of the antagonist with 12.5% DMSO. It is therefore speculated that 
BIB6 3226 can exacerbate DSS-induce mucosal crypt damage when administered along 
with 12.5% DMSO.  
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Co-administration of the antagonists at either the acute inflammatory or recovery 
models did not significantly alter DSS-induced colon muscle wall thickening. In the 
recovery model mixed antagonist treatment however, treatment with the Y1 receptor 
antagonist resulted in significantly thicker colon walls (F(1,22)=8.341; p <.009). Analysis 
of the two muscular layers making up the colon wall revealed that this effect was 
observed in both muscles but only significantly increased in the circular layer 
(F(1,21)=8.949; p <.007) with strong statistical trend in the same direction for the 
longitudinal muscle (F(1,22)=4.009; p =.058), see Figure 55.  
	  
Figure 61.  Combined receptor antagonist treatment in the acute inflammatory 
model does not attenuate DSS-induced colon tissue damage.  Representative 
micrographs (10X) of a control animal receiving both vehicles (A), an animal co-treated 
with the Y1 receptor antagonist and 12.5% DMSO (B), an animal co-treated with the Y2 
A B 
C D 




















receptor antagonist and dH2O (C) and an animal co-treated with the Y1 and Y2 receptor 
antagonist (D). Scale bar = 100µm. 
	  
Figure 62. Combined receptor antagonist treatment in the recovery model does not 
attenuate DSS-induced colon tissue damage.  Representative micrographs (10X) of a 
control animal receiving both vehicles (A), an animal co-treated with the Y1 receptor 
antagonist and 12.5% DMSO (B), an animal co-treated with the Y2 receptor antagonist 
and dH2O (C) and an animal co-treated with the Y1 and Y2 receptor antagonist (D). Scale 
bar = 100µm. 
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Figure 63.  Mixed receptor antagonist treatment in the recovery model does not 
attenuate DSS-induced colon tissue damage.  Representative micrographs (10X) of a 
control animal receiving dH2O for the first 7 days post DSS treatment and then 12.5% for 
the last 3 days (A), an animal treated with the Y1 receptor antagonist for the first 7 days 
and then 12.5% DMSO for the next 3 days (B), an animal receiving dH2O for the first 7 
days followed by 3 day treatment with the Y2 receptor antagonist (C) and an animal 
treated with the Y1 receptor antagonist for the first 7 days and then treated with the Y2 
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Figure 64. Treatment with the Y1 receptor antagonist does not attenuate DSS-
induced colon wall thickening or colon mucosal shortening. Mean length for the full 
muscle, circular muscle layer, longitudinal muscle layer and colon crypt for the 
antagonist co-treatment in the acute inflammatory model (A,B,C,D), recovery model 
(E.F,G,H) and the mixed antagonist treatment in the recovery model (I,J,K,L). Data 
presented as mean ± SEM. $ (p<.05), indicate a significant main effect of BIBP 3226. 
Y1 and Y2 Receptor Antagonist Combined But Not Mixed Treatment 
Significantly Reduces DSS-Induced MPO Expression 
In the acute inflammatory model, treatment with the Y2 receptor antagonist alone 
and in combination with the Y1 receptor antagonist but not the Y1 receptor antagonist 
alone significantly regulated DSS-induced MPO activity in the distal colon (see Figure 
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65).  Treatment with the Y1 receptor antagonist did not significantly reduce DSS-induced 
distal colon MPO protein expression in either of the combination treatment studies, 
potentially as a result of 12.5% DMSO being co-administered, especially since it did 
decrease MPO activity in the mixed model in which DMSO was not a present at the same 
time as this antagonist. In the acute inflammatory model with antagonist co-treatment, Y1 
receptor antagonism did not significantly reduced DSS-induced MPO activity in the 
distal colon (F(1,31)=1.123; p =.298) while treatment with BIIE 0246 significantly 
lowered colon MPO as previously observed (F(1,31)=12.800; p <.001).  Additionally, 
there was a statistically significant interaction between BIBP 3226 and BIIE 0246 
(F(1,31)=20.310; p <.001) such that the combination of the two antagonists resulted in 
lower levels of distal colon MPO expression than control, however, not to the same 
extent as when the Y2 antagonist was given alone, potentially due to the interaction of 
BIBP 3226 with the diluent of the Y2 antagonist, DMSO.  This pattern was not observed 
for the combination treatment in the recovery model where neither Y1 receptor 
antagonism (F(1,25)=0.271; p =.608), Y2 receptor antagonism (F(1,25)=1.788; p =.193) 
nor the combination of the antagonist (F(1,25)=2.281; p =.144) significantly lowered 
DSS-induced colon MPO increases. Mixed antagonist treatment in the recovery models 
showed a different pattern from the combination treatment. In this model, treatment with 
BIBP 3226 significantly reduced DSS-induced distal colon MPO (F(1,20)=5.600; p 
=.028) while BIIE 0246 did not significantly reduce MPO (F(1,20)=0.773; p =.390)  and 
no statistical interaction was observed between the treatments (F(1,20)=0.025; p =.876).  
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Figure 65. Y1 and Y2 receptor antagonism significantly decreased DSS-induced 
MPO expression in the acute inflammatory combination and recovery mixed 
treatment models. Mean distal colon MPO protein concentration expressed as ng/mg of 
total sample protein in the acute inflammatory combined treatment (A) and recovery 
models (B) and in the mixed treatment recovery model (C). Data presented as mean ± 
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SEM. $ (p<.01), indicate a significant main effect of BIBP 3226, ## (p<05) indicates a 
significant main effect of BIIE 0246, && (p<.01) indicates a significant interaction. 
Y1 and Y2 Receptor Antagonism Significantly Alters DSS-Induced Cytokine 
Expression in The Different Models Assessed 
In line with previous experiments, the most consistently overexpressed cytokines 
as a result of DSS treatment across all three studies presented here were IL-1β, IL-6 and 
IL-12 with all other cytokines assessed showing detectable expression by some but not all 
animals across groups (see Tables 7-9). Those cytokines not reliably detected were not 
further considered for statistical analysis. Y1 receptor antagonism in the acute 
inflammatory model significantly decreased IL-1β (F(1,34)=14.250; p <.001), IL-6 
(F(1,32)=8.752; p <.005) and IL-12 (F(1,34)=11.320; p <.001) and IFN-γ 
(F(1,33)=4.228; p =.048) while Y2 receptor antagonism did not significantly alter these 
parameters and no statistically significant interactions were observed. In the combined 
treatment recovery model, neither antagonist alone significantly altered DSS-induced 
cytokine increases however, the combination treated group showed significantly higher 
levels of IL-12 than the BIBP 3226 only treated group (F(1,29)=5.619; p =.025). A 
similar pattern was observed in the mixed treatment recovery model where the group 
receiving the two antagonists treatment showed significantly higher levels of IL-6 














BIIE	  0246	   p	  Value	  	  
IL-­‐1β	   61.66454 19.32007 38.82283 10.53401 $$	  
SEM	  ±	   10.83197 2.564893 19.98997 5.290589 
	  IL-­‐6	   19.57324 7.861765 30.18776 13.09013 $$	  
SEM	  ±	   5.347001 1.51712 6.214503 4.402872 
	  IL-­‐12	   8.517302 7.212255 11.01538 6.969213 $$	  
SEM	  ±	   1.090968 0.4932252 0.8444362 0.5695934 
	  GM-­‐CSF	   2.077117 2.979582 3.763218 2.906909 
	  SEM	  ±	   0.210106 0.314608 0.2240324 0.2716612 
	  IFN-­‐γ	   5.590724 3.156591 3.850645 2.56492 $	  
SEM	  ±	   1.446105 0.5714674 0.6810818 0.2397011 
	  TNF-­‐α	   3.670629 3.724477 6.835872 3.633637 
	  SEM	  ±	   0.8107994 0.3932601 1.789882 0.3395766 
	  IL-­‐2	   1.151388 1.640268 1.397372 1.124982 
	  SEM	  ±	   0.2551826 0.2588252 0.08318856 0.1107706 
	  IL-­‐4	   12.57823 14.4209 10.31475 7.780679 
	  SEM	  ±	   4.061615 2.711801 1.811472 1.09863 
	  IL-­‐10	   4.446502 7.142232 9.020656 6.968033 
	  SEM	  ±	   0.1747277 0.7541342 0.5370187 0.651188 
	  IL-­‐5	   2.087123 3.308212 4.178279 3.227525 
	  SEM	  ±	   0.07655985 0.3493075 0.2487418 0.3016238 
	  Table 7. DSS induces high expression of proinflammatory cytokines, an affect 
attenuated by Y1 receptor antagonism. Mean distal colon cytokine protein expressed in 
pg/mg of total sample protein. Y1 receptor antagonism significantly reduced the DSS-













BIIE	  0246	   p	  Value	  	  
IL-­‐1β	   19.46865 15.03577 19.89867 22.12957 
	  SEM	  ±	   5.389221 3.084194 5.149453 7.425405 
	  IL-­‐6	   6.286328 12.91425 7.380291 9.356112 
	  SEM	  ±	   0.9886978 4.089577 2.4152 3.733945 
	  IL-­‐12	   3.829141 3.11536 3.193594 3.895256 &	  
SEM	  ±	   0.352316 0.2263972 0.4116167 0.1629352 
	  GM-­‐CSF	   2.758362 2.59429 2.505818 3.071163 
	  SEM	  ±	   0.2250092 0.2697039 0.3105747 0.5597374 
	  IFN-­‐γ	   2.971449 2.389466 2.431589 3.742927 
	  SEM	  ±	   0.4434862 0.2274419 0.3876333 1.097927 
	  TNF-­‐α	   3.403571 3.315825 2.663352 3.637766 
	  SEM	  ±	   0.2661769 0.3729112 0.2162924 0.3494514 
	  IL-­‐2	   2.084114 1.071782 1.61623 1.140395 
	  SEM	  ±	   0.7469973 0.1224032 0.3444654 0.2078436 
	  IL-­‐4	   6.312579 9.448304 5.771636 8.382463 
	  SEM	  ±	   0.5611678 1.795414 0.828419 1.420596 
	  IL-­‐10	   6.393204 6.119045 5.107368 6.015457 
	  SEM	  ±	   0.4920276 0.6842989 0.4147725 0.32489 
	  IL-­‐5	   2.961269 2.834282 2.365683 2.7863 
	  SEM	  ±	   0.2279023 0.3169605 0.1921186 0.1504859 
	  @ indicates a statistically significant treatment interaction 
Table 8.  DSS induced IL-12 overexpression is reduced by Y1 and Y2 individual 
antagonism but not by the combined treatment. Mean distal colon cytokine protein 
expressed in pg/mg of total sample protein. & (p<.05) indicates a statistically significant 
















BIIE	  0246	   p	  Value	  	  
IL-­‐1β	   60.22211 24.51561 12.38273 39.73563 
	  SEM	  ±	   29.50554 5.574846 2.860512 10.16161 
	  IL-­‐6	   44.6055 27.19553 41.34873 93.07986 &	  
SEM	  ±	   9.421685 8.554129 15.35994 23.0463 
	  IL-­‐12	   6.528814 3.56979 6.486959 4.919911 
	  SEM	  ±	   2.08333 0.395603 3.01691 1.081882 
	  GM-­‐CSF	   3.273211 2.544295 2.744133 4.66033 
	  SEM	  ±	   0.5371742 0.2275783 0.3424135 1.018321 
	  IFN-­‐γ	   9.308407 8.007323 8.674153 11.88347 
	  SEM	  ±	   1.596975 0.6199697 1.676293 2.159724 
	  TNF-­‐α	   3.98167 3.13962 3.55355 5.751453 
	  SEM	  ±	   0.7397287 0.294562 0.6330321 1.673399 
	  IL-­‐2	   2.343013 1.799714 1.82722 2.361475 
	  SEM	  ±	   0.4187236 0.150451 0.1640779 0.3427137 
	  IL-­‐4	   48.09686 36.02352 38.48457 63.62238 
	  SEM	  ±	   7.531342 2.813155 2.348049 12.38571 
	  IL-­‐10	   7.43712 6.020683 6.420942 6.731996 
	  SEM	  ±	   1.440345 0.5648661 0.9282776 0.8677065 
	  IL-­‐5	   3.538993 2.877455 3.017874 4.223739 
	  SEM	  ±	   0.6496154 0.2403002 0.3991517 0.7393572 
	  @ indicates a statistically significant treatment interaction 
Table 9.  Y1 and Y2 receptor antagonist co-treatment increases the DSS-induced 
expression of IL-6 in the recovery mixed treatment model. Mean distal colon cytokine 
protein expressed in pg/mg of total sample protein. & (p<.05) indicates a statistically 




Y1 and Y2 Receptor Antagonism Combined Treatment Significantly Alter Distal 
Colon NPY protein Expression in the Acute Inflammatory Model 
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 Y1 and Y2 receptor antagonism did not significantly alter distal colon NPY protein 
expression in either one of the recovery models but significantly changed this expression 
in the combined treatment acute inflammatory model (see Figure 66).  Neither BIBP 
3226 (F(1,31)=0.574; p =.454) nor BIIE 0246 (F(1,31)=1.300; p =.263) alone 
significantly altered NPY protein expression in the distal colon. However, these 
treatments showed a statistically significant interaction such that the Y2 antagonist 
significantly increased NPY protein expression but not when co-administered with the Y1 




Figure 66. Y2 receptor antagonism increased distal colon NPY expression but not 
when co-administered with the Y1 receptor antagonist. Mean distal colon NPY protein 
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concentration expressed in ng/mg of total sample protein. Data presented as mean ± 
SEM. &(p<.01), indicate a significant interaction. 
Y1 and Y2 Combined Receptor Antagonism Significantly Alters Pain-Related 
Behavior in the Recovery Model 
Combined Y1 and Y2 receptor antagonism does not significantly alter DSS-
induced behavioral alterations in general movement and locomotion. However, Y2 
receptor antagonism did significantly alter basic movements and X-Y ambulation in the 
mixed treatment recovery model. Y2 receptor antagonism significantly decreased total 
counts of basic movements (F(1,20)=4.595; p =.045) and X-Y ambulation 
(F(120)=6.744; p =.017).  Combined receptor antagonist treatment in the mixed 
antagonist treatment recovery model did not result in significant alterations to DSS-
induced pain-related behaviors whereas antagonist treatment at either time point changed 
visceral pain-related behaviors (see Figures 67-76).  
In the acute inflammatory model, treatment with the Y1 receptor antagonist 
significantly reduced total rearing time (F(1,34)=5.557; p =.024), a finding that is in 
opposition to previous observations and may be due to a potentially detrimental effect of 
BIBP 3226 co-administered with 12.5% DMSO as was observed for other measures. Y2 
receptor antagonism in this same model increased time spent per rear (F(1,34)=13.220; p 
<.001).  
In the combined treatment recovery model, treatment with the Y2 receptor 
antagonist significantly increased total rearing time (F(1,26)=6.079; p =.021) and a 
statistically significant interaction was observed such that the combination treatment 
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group spent significantly more time rearing than the group only treated with the Y1 
receptor antagonist (F(1,26)=10.470; p <.003). Normalized rearing behavior was not 
significantly altered in this model.  Mixed receptor antagonist treatment did not change 
DSS-induced visceral-pain measures in the recovery model. 
	  
	  
Figure 67. Y1 and Y2 receptor antagonism does not alter DSS-induced general 
movement profile in any model. Mean basic (A,B,C) and fine movement (D,E,F) total 
counts in the acute inflammatory and recovery models. Data presented as mean ± SEM.  
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Figure 68. Y1 and Y2 receptor antagonism does not alter DSS-induced general 
movement profile in any model. Mean basic (A,B,C) and fine movement (D,E,F) per 5-
minute block counts in the acute inflammatory and recovery models. Data presented as 
mean ± SEM.  
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Figure 69. Y2 receptor antagonism did not change most DSS-induced effects in 
locomotion but it did decrease ambulation in the mixed model. Mean total X-Y 
ambulation (A,B,C) and distance traveled (D,E,F) in the acute inflammatory and recovery 
model. Data presented as mean ± SEM.  
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Figure 70. DSS-induced locomotion is not altered by Y1 or Y2 receptor antagonism. 
Mean X-Y ambulation (A,B,C) and distance traveled (D,E,F) per 5-minute block counts 
in the acute inflammatory and recovery models. Data presented as mean ± SEM.  
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Figure 71. DSS-induced increased immobility time is not significantly altered by 
either antagonist. Mean total rest time (A,B,C) and time spent immobile (D,E,F) in the 
acute inflammatory and recovery models. Data presented as mean ± SEM.  
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Figure 72. DSS-induced immobility time is not altered by either antagonist. Mean 
rest time (A,B,C) and time spent immobile (D,E,F) per 5-minute block counts in the acute 
inflammatory and recovery models. Data presented as mean ± SEM.  
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Figure 73. Combined Y1 and Y2 receptor antagonism significantly alter DSS-
induced rearing duration decreases. Y1 receptor antagonism resulted in significantly 
shorter rears in the acute inflammatory model while Y1 and Y2 receptor antagonism co-
treatment significantly increased rearing time in the recovery model. Mean total rears 
(A,B,C) and rearing time (D,E,F) in the acute inflammatory and recovery models. Data 
presented as mean ± SEM. $ (p<.05), indicate a significant main effect of BIBP 3226. 
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Figure 74. Combined Y1 and Y2 receptor antagonism significantly alter DSS-
induced decreased rearing duration decreases. Mean rears (A,B,C) and rearing time 
(D,E,F) per 5-minute block counts in the acute inflammatory and recovery models. Data 
presented as mean ± SEM.  
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Figure 75. Y1 receptor antagonism significantly decreases normalized rearing and 
rearing duration in the acute inflammatory model. Mean total rears (A,B,C) and 
rearing time (D,E,F) normalized to ambulation and total rears respectively in the acute 
inflammatory and recovery models. Data presented as mean ± SEM. $ (p<.05), indicate a 











































































































































Figure 76. Y1 receptor antagonism significantly decreases normalized rearing and 
rearing duration in the acute inflammatory model. Mean rears (A,B,C) and rearing 
time (D,E,F) normalized to ambulation and total rears respectively per 5-minute block 
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Specific Aim 5: To assess DSS-induced gene expression changes, identify a DSS-
induced genetic meta-signature from multiple independent studies and compare this 
to genetic profiles generated from human IBD patient samples.  
 The DSS experimental model of human IBD is often used for its simplicity and 
similarity to human pathology for the development of potential therapeutic targets. 
Although the clinical manifestations are similar between the model and human disease, it 
is necessary to determine if these similarities also translate to the genetic level. In order to 
address these questions, distal colon samples from four independent DSS studies 
(samples from Experiments 3 and 6) including from animals treated with the Y1 and Y2 
receptor antagonists, were genetically profiled. Each analysis yielded more than 2500 
genes that were significantly altered in animals exposed to DSS.  These genetic profiles 
along with those from two other independent DSS studies conducted at Regeneron 
Pharmaceuticals, Inc. were cross-referenced to generate a list of genes that are reliably 
changed by DSS exposure. The resulting gene list represents the DSS-induced gene 
expression meta-signature. This gene expression meta-signature was then correlated to 
the gene profile from human IBD patient colon samples to gain clues about the validity of 
the DSS model for human IBD. In addition, the DSS meta-signature was correlated with 
normalized rearing measures collected from Experiments 3 and 6 to determine if a 







Y1 and Y2 Receptor Antagonism Results in Significant Distal Colon Receptor Gene 
Upregulation 
 Exposure to DSS does not induce significant RNA changes for NPY nor for Y1 
and Y2 receptors in the distal colon (see Table 10). Treatments with the specific 
antagonists do not change NPY gene expression but significantly change the gene 
expression for their own target receptor at specific time points. Y1 receptor antagonism 
with BIBP 3226 resulted in a nearly doubled expression of the NPY receptor 1 gene in 
the recovery model but not in the acute model.  Similarly, Y2 receptor antagonism 
resulted in nearly doubled expression of the NPY receptor 2 gene in the acute 
inflammatory model but not during the recovery model. These data provide some 
validation that the two small molecule receptor antagonists used for these experiments are 
specific and reliably antagonizing the correct receptors in animals exposed to DSS.  
	  	   	  	   Acute	  Inflammatory	  Model	   Recovery	  Model	  









Npy1r	   -­‐	   -­‐	   -­‐	   1.82	   -­‐	  
Npy2r	   -­‐	   -­‐	   1.89	   -­‐	   -­‐	  
Table 10. Y1 and Y2 receptor antagonism results in significant receptor gene 
upregulation in the distal colon of DSS treated mice. Fold change values for the 
specific NPY receptors antagonized in Experiments 3 and 6. 
DSS Significantly Alters Distal Colon Gene Expression 
 Exposure to DSS resulted in significant gene regulation in the distal colon 
encompassing on average over 2,500 genes altered including both up and down 
regulation of genes. Due to the vast number of DSS-induced gene alterations, only the top 
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25 genes significantly up and down-regulated for are presented in Tables 10-13.  The 
effect of NPY receptor antagonism on DSS-induced gene expression for these 25 genes is 
included. Collectively analyzing the genes altered by DSS exposure between these 
experiments and 2 additional independent DSS studies conducted at Regeneron 
Pharmaceuticals, Inc. yielded a list of genes significantly expressed in all these studies, a 
DSS-induced genetic meta-signature. Using the publically available gene interaction 
mapping software GeneMania, the connectivity and functional networks of the top 25 
DSS altered genes from each table below were analyzed.  Top 25 upregulated genes from 
Experiment 3, 6 and the meta-signature list showed that these genes are highly co-
expressed, some are co-localized and some have physical interactions. In addition, these 
genes often belonged to similar functional networks falling primarily into 7 functional 
categories: response to bacterium or molecules of bacterial origin, inflammatory 
responses, general chemotaxis, leukocyte chemotaxis, leukocyte migration, neutrophil 
chemotaxis and response to cytokine stimulus.  Analysis of the top 25 down-regulated 
genes showed a lower degree of gene interaction, with those interacting being primarily 
involved in mitochondrial and organelle inner membrane functioning, lipid oxidation and 
fatty acid catabolic processes. See supplement for network depictions.   
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Top 25 Genes Upregulated by DSS From Experiment 3 
	  	   Acute	  Inflammatory	  Model	   Recovery	  Model	  







Gml	   1000.00	   	  	   	  	   	  	  
Mmp8	   230.05	   	  	   181.17	   236.83	  
S100a9	   197.44	   	  	   257.26	   1136.76	  
Chi3l3	   174.44	   6.24	   291.43	   114.12	  
AI747448	   157.34	   163.35	   53.63	   98.92	  
Nos2	   133.76	   34.40	   15.94	   38.86	  
Cxcl5	   107.36	   87.35	   169.92	   175.31	  
Ltf	   105.41	   	  	   	  	   133.05	  
Retnlg	   104.01	   	  	   71.90	   74.71	  
S100a8	   100.69	   	  	   655.51	   241.81	  
Saa3	   96.78	   92.80	   89.83	   228.20	  
Trim10	   63.91	   	  	   	  	   	  	  
Clec4e	   61.97	   121.00	   132.61	   333.75	  
Il1b	   61.63	   18.34	   41.87	   101.08	  
Fpr2	   55.73	   	  	   	  	   33.71	  
Reg3g	   46.34	   164.74	   108.13	   76.96	  
Serpina3m	   45.52	   30.42	   177.41	   113.14	  
Reg3b	   43.23	   248.40	   459.40	   127.66	  
Mmp3	   40.26	   31.82	   25.33	   40.49	  
Cxcl1	   39.85	   27.93	   27.83	   588.86	  
Trem1	   38.20	   16.70	   	  	   110.36	  
Tnfrsf8	   37.85	   15.60	   19.68	   22.07	  
Fam154a	   37.35	   	  	   	  	   	  	  
Lrg1	   32.42	   12.04	   21.54	   39.40	  
Slfn1	   31.59	   9.27	   17.13	   40.28	  
Table 11. Top 25 genes significantly upregulated by DSS exposure. DSS altered genes 
are expressed as fold change from controls and are listed for both the acute inflammatory 
and recovery models. The effect of Y1 receptor antagonism on gene fold change is 





Top 25 Genes Down-regulated by DSS From Experiment 3 
	  	   Acute	  Inflammatory	  Model	   Recovery	  Model	  







Zfp866	   0.6661	   	  	   	  	   	  	  
Lrrc8e	   0.6656	   	  	   	  	   	  	  
Erbb2ip	   0.6654	   	  	   	  	   	  	  
Rab3d	   0.6648	   0.6428	   	  	   	  	  
Phc3	   0.6646	   	  	   	  	   	  	  
Adipor2	   0.6645	   	  	   	  	   	  	  
Cspp1	   0.6643	   	  	   	  	   	  	  
Tspan8	   0.6643	   	  	   	  	   	  	  
Cobl	   0.6643	   	  	   	  	   0.6452	  
Ppargc1b	   0.6640	   0.5381	   	  	   0.5190	  
Cd99l2	   0.6638	   	  	   0.6863	   	  	  
LOC100044751	   0.6636	   	  	   	  	   	  	  
Ccpg1	   0.6635	   0.6524	   	  	   	  	  
LOC100502938	   0.6634	   0.6140	   	  	   	  	  
Rmnd5a	   0.6632	   0.6583	   	  	   	  	  
Rnf167	   0.6627	   0.6201	   0.6296	   	  	  
Cmpk1	   0.6625	   	  	   	  	   	  	  
Tial1	   0.6622	   	  	   	  	   	  	  
Ogt	   0.6619	   	  	   	  	   	  	  
Adk	   0.6615	   	  	   	  	   	  	  
Adi1	   0.6612	   	  	   	  	   0.6201	  
Naip3	   0.6610	   0.5743	   	  	   	  	  
Sort1	   0.6607	   	  	   	  	   	  	  
Zfhx3	   0.6600	   	  	   	  	   0.5319	  
Kidins220	   0.6599	   	  	   	  	   	  	  
Table 12. Top 25 genes significantly downregulated by DSS exposure. DSS altered 
genes are expressed as fold change from controls are listed for both the acute 
inflammatory and recovery models along with the effect of Y1 receptor antagonism on 





Top 25 Genes Upregulated by DSS From Experiment 7 
Table 13. Top 25 genes significantly upregulated by DSS exposure. DSS altered genes 
are expressed as fold change from controls are listed for both the acute inflammatory and 
recovery models along with the effect of Y2 receptor antagonism on gene fold change for 
each model. 
	  	   Acute	  Inflammatory	  Model	   Recovery	  Model	  








S100a8	   2056.82	   198.00	   	  	   52.87	  
Orm2	   1000.00	   	  	   	  	   	  	  
Serpina3m	   1000.00	   101.60	   	  	   	  	  
Il1f9	   1000.00	   	  	   	  	   	  	  
Stfa2l1	   1000.00	   	  	   	  	   	  	  
Cxcl3	   1000.00	   497.13	   	  	   	  	  
Nlrp12	   1000.00	   	  	   	  	   	  	  
Gm5483	   1000.00	   	  	   	  	   	  	  
1100001G20Rik	   970.77	   139.58	   	  	   	  	  
Mmp8	   483.85	   315.17	   	  	   59.76	  
Cxcl5	   472.61	   289.13	   	  	   49.00	  
S100a9	   453.85	   180.21	   	  	   71.46	  
Ngp	   443.45	   	  	   	  	   	  	  
Chi3l3	   428.80	   225.31	   902.90	   	  	  
Il6	   350.48	   1000.00	   	  	   	  	  
Saa3	   325.12	   612.84	   203.87	   81.16	  
AI747448	   267.81	   148.79	   67.00	   43.50	  
Tarm1	   247.80	   	  	   	  	   	  	  
Clec4e	   244.93	   107.74	   	  	   	  	  
Retnlg	   221.12	   68.49	   55.87	   9.88	  
Gml	   199.67	   86.24	   	  	   	  	  
Marco	   162.94	   65.96	   	  	   	  	  
Irg1	   155.02	   80.07	   	  	   	  	  
Reg3b	   122.39	   900.22	   268.21	   99.63	  
Cxcl2	   121.55	   162.29	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Top 25 Genes Down-regulated by DSS From Experiment 7 
	  










2900026A02Rik	   0.6670	   0.5708	  
	   	  Trmt2b	   0.6658	   0.7174	  
	   	  Adi1	   0.6658	  
	   	   	  Tug1	   0.6655	  
	   	   	  Kdm5d	   0.6654	   0.6730	  
	   	  Odc1	   0.6653	  
	   	   	  2810459M11Rik	   0.6652	   0.6681	  
	   	  Depdc6	   0.6652	   0.5936	  
	   	  Etfdh	   0.6651	   0.7209	  
	   	  Pik3c2b	   0.6649	   0.6075	  
	   	  Zbtb7c	   0.6647	   0.5505	  
	   	  Uqcrh	   0.6646	  
	   	   	  BC049349	   0.6646	  
	   	   	  Coq2	   0.6645	  
	   	   	  Pof1b	   0.6645	   0.7196	  
	   	  Ndufs1	   0.6644	   0.7010	  
	   	  Zfp54	   0.6643	  
	   	   	  Scrn3	   0.6641	   0.6816	   0.6989	  
	  Abr	   0.6640	   0.6915	  
	   	  Casd1	   0.6639	   0.6431	  
	   	  Zfp606	   0.6634	  
	   	   	  1110021L09Rik	   0.6624	  
	   	   	  Hibch	   0.6624	   0.6483	  
	   	  Stard7	   0.6624	  
	   	   	  Ppp1r3b	   0.6623	   0.4914	  
	   	  
Table 14. Top 25 genes significantly downregulated by DSS exposure. DSS altered 
genes are expressed as fold change from controls are listed for both the acute 
inflammatory and recovery models along with the effect of Y2 receptor antagonism on 




DSS-Induced Genetic Meta-Signature 
Gene	   Recovery	  Model	  	  
Recovery	  
Model	  	  
Chronic	  DSS	  	  
Model	  
Prolonged	  Recovery	  	  
Model	  
S100a8	   100.69	   2056.82	   145.44	   	  	  
Serpina3m	   45.52	   1000.00	   47.64	   	  	  
Mmp8	   230.05	   483.85	   117.65	   	  	  
S100a9	   197.44	   453.85	   80.81	   94.69	  
Chi3l3	   174.44	   428.80	   50.62	   4.09	  
Cxcl5	   107.36	   472.61	   22.78	   	  	  
Saa3	   96.78	   325.12	   63.79	   39.30	  
AI747448	   157.34	   267.81	   14.92	   247.13	  
Clec4e	   61.97	   244.93	   91.14	   	  	  
irg1	   	  	   155.02	   155.67	   80.95	  
Retnlg	   104.01	   221.12	   79.66	   10.45	  
trem1	   38.20	   54.44	   108.11	   	  	  
Reg3b	   43.23	   122.39	   10.47	   19.60	  
Nos2	   133.76	   43.74	   18.77	   74.78	  
fpr2	   55.73	   69.34	   27.92	   	  	  
chi3l1	   28.00	   97.92	   26.44	   	  	  
Il1b	   61.63	   68.37	   46.71	   16.77	  
Hp	   31.00	   110.61	   15.48	   4.43	  
Mmp3	   40.26	   81.16	   25.61	   8.79	  
Mmp10	   	  	   74.13	   21.64	   13.34	  
Reg3g	   46.34	   51.27	   12.82	   	  	  
Cxcl1	   39.85	   63.51	   32.40	   10.57	  
il1r2	   	  	   29.73	   50.90	   18.94	  
Table 15. DSS-induced genetic meta-signature.   Selected top genes significantly 
altered by DSS exposure in at least 3 out of 4 independent DSS studies. The recovery 
model data are from Experiments 3 and 7 of this dissertation. The chronic model 
consisted of 7 days of DSS exposure followed by 14 days of recovery and then re-
exposure to DSS for 7 more days. The prolonged recovery model consisted of 3% DSS 




The DSS-Model Genetic Meta-Signature Correlates with Human IBD Genetic 
Profiles 
The computed DSS-induced genetic meta-signature was correlated against seven 
genetic studies of colon samples from human patients suffering from Ulcerative Colitis 
and Crohn’s disease. The human studies included colon samples from patients treated 
with infliximab, one of the leading treatments for IBD. Comparisons were made between 
colon samples pre- and post-treatment as well as between patients who responded or did 
not respond to treatment.  In addition, the number of genes that were shared between the 
DSS meta-signature and the human studies are reported with the correlation direction and 
the correlation p value.  
As would be expected if the DSS-model was a valid model for human IBD, 
studies in which patients responded to treatment showed a negative significant correlation 
with the DSS meta-signature.  That is, an effective treatment might be expected to 
decrease the expression of genes upregulated in the DSS meta-signature. Similarly, in 
studies for which treatment was ineffective or studies that compared inflamed versus non-
inflamed tissue, elevated genes associated with IBD would be expected. In these studies, 
the DSS meta-signature showed significant positive correlations indicating that similar 
genes upregulated in IBD were upregulated in the DSS model, see Table 15. Together, 
these data provide strong validation for the DSS experimental model of human IBD. 
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Genes	   p	  Value	  
	  	  
Treatment	  Responders	  (10mg/kg)	  
vs	  
Baseline	  
-­‐	   434	   2.00E-­‐59	  
Study	  1:	  Colon	  Samples	  from	  
Ulcerative	  Colitis	  Patients	  
Treated	  for	  30	  Weeks	  with	  
Infliximab	  
Treatment	  Non-­‐responders	  (5mg/kg)	  
vs	  
Responders	  
+	   261	   1.40E-­‐48	  
	  	  
Treatment	  Non-­‐responses	  (10mg/kg)	  
vs	  
Responders	  
+	   287	   2.30E-­‐45	  
	  	  
















+	   497	   8.90E-­‐55	  
Study	  2:	  Colon	  Mucosa	  
Samples	  from	  IBD	  Patients'	  
First	  Infliximab	  Treatment	  
Ulcerative	  Colitis	  Patients	  
Non-­‐Responders	  Before	  Treatment	  
vs	  
Healthy	  Controls	  






+	   448	   1.10E-­‐40	  
	  	  




-­‐	   362	   6.60E-­‐39	  
	  	  




+	   289	   3.10E-­‐38	  
	  	  




+	   414	   5.20E-­‐36	  
Study	  3:	  Colon	  Biopsy	  Samples	  




+	   464	   1.80E-­‐54	  
Study	  4:	  Colon	  Mucosa	  Sample	  
from	  IBD	  Patients	  
IBD	  Patient	  Inflamed	  Mucosa	  
vs	  
Healthy	  Control	  
+	   406	   4.10E-­‐50	  
Study	  5:	  Inflamed	  and	  Non-­‐
Inflamed	  Colon	  Samples	  






+	   303	   6.40E-­‐44	  
Study	  6:	  Colon	  Mucosa	  and	  
Isolated	  Colonocites	  samples	  




+	   393	   3.00E-­‐40	  
Study	  7:	  	  Colon	  Biopsy	  Samples	  




+	   297	   8.00E-­‐40	  
Table 16.  DSS genetic meta-signature correlated with human IBD studies.	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DSS-induced Gene Changes are Associated with Mouse Pain-Related Measures in 
the Open Field 
 Genes that were significantly altered by DSS exposure in Experiments 3 and 6 are 
significantly associated with the four pain-related measures collected from the same 
animals in the open field, namely, rearing, rearing time, normalized rearing and mean 
rear duration. As is depicted in Table 16, there were a large number of genes that showed 
strong correlation, defines as a Pearson r >.6, with these pain measures. Due to the fact 
that total rearing and total rearing time can be affected by the animals overall activity 
levels and may be more representative of sickness behavior rather than pain, all 
subsequent tables are shown only for the normalized behavior which is proposed to be a 
more accurate measure of pain. 
DSS-Induced Genes Correlate with Pain-Related Behaviors 











































Table 17. Genes that are significantly altered by DSS exposure strongly correlate 
with pain-related measures. For each study from Experiments 3 and 6, the total number 




Top 25 DSS-Induced Genes Correlated with Normalized Rearing Behavior	  
Normalized	  Rearing	  Behavior	  
Acute	  Inflammatory	  Model	   Recovery	  Model	  














Fpr2	   -­‐0.99	   -­‐0.30	   -­‐0.88	   Tppp3	   -­‐0.98	   0.43	   0.16	  
1700017B05Rik	   -­‐0.99	   0.23	   -­‐0.85	   Mylk	   -­‐0.97	   -­‐0.29	   0.70	  
Gpr65	   0.99	   0.17	   -­‐0.85	   Marveld1	   -­‐0.96	   0.00	   0.58	  
Acss1	   0.99	   -­‐0.79	   0.97	   Sycn	   0.95	   -­‐0.72	   -­‐0.03	  
Ptges	   -­‐0.99	   0.08	   -­‐0.75	   Tlr2	   -­‐0.95	   -­‐0.01	   0.75	  
Ccrl2	   -­‐0.99	   0.63	   -­‐0.16	   Wfdc1	   -­‐0.94	   -­‐0.37	   0.40	  
Dpp4	   0.98	   0.60	   0.93	   2010110P09Rik	   0.94	   -­‐0.51	   0.03	  
Alpl	   -­‐0.98	   -­‐0.17	   -­‐0.94	   Eda2r	   0.93	   -­‐0.57	   0.65	  
Nrg1	   -­‐0.98	   -­‐0.40	   -­‐0.71	   Clec3b	   -­‐0.93	   0.56	   0.21	  
Agr3	   0.97	   -­‐0.87	   0.46	   C1qtnf3	   -­‐0.93	   0.81	   0.15	  
Fam13a	   0.97	   -­‐0.85	   0.33	   Ptk6	   0.93	   -­‐0.13	   0.69	  
H1f0	   0.97	   -­‐0.27	   0.92	   1810030J14Rik	   -­‐0.92	   -­‐0.45	   0.20	  
Cpm	   -­‐0.96	   -­‐0.93	   -­‐0.57	   Fndc5	   -­‐0.92	   0.41	   0.34	  
Ly6a	   -­‐0.96	   0.59	   -­‐0.43	   Mkx	   -­‐0.92	   -­‐0.11	   0.35	  
Lama1	   -­‐0.96	   -­‐0.60	   -­‐0.41	   Tnfrsf19	   -­‐0.92	   -­‐0.33	   -­‐0.46	  
Acsl3	   0.96	   -­‐0.78	   0.90	   Il22ra2	   -­‐0.92	   -­‐0.52	   0.10	  
1110017F19Rik	   0.96	   -­‐0.30	   0.89	   Fzd9	   0.92	   -­‐0.24	   0.68	  
Parp3	   -­‐0.95	   0.62	   -­‐0.50	   Ccl6	   -­‐0.92	   -­‐0.06	   0.59	  
Scml2	   0.95	   0.53	   0.71	   Greb1l	   -­‐0.91	   0.31	   -­‐0.91	  
Zfp704	   0.95	   -­‐0.56	   0.78	   Klf12	   0.91	   0.06	   -­‐0.27	  
A430033K04Rik	   0.95	   -­‐0.70	   0.41	   Maob	   -­‐0.91	   -­‐0.60	   -­‐0.10	  
Lilrb4	   -­‐0.95	   -­‐0.56	   -­‐0.56	   Gnat3	   -­‐0.91	   0.03	   0.06	  
Atp8b5	   0.95	   0.29	   -­‐0.52	   LOC100503041	   0.90	   -­‐0.05	   -­‐0.25	  
Hhip	   0.95	   -­‐0.23	   0.09	   Ctse	   0.90	   -­‐0.69	   0.10	  
Zfp612	   0.95	   0.16	   -­‐0.02	   Ecscr	   0.90	   0.10	   -­‐0.41	  
Table 18. Genes significantly altered by DSS exposure correlate strongly with 
visceral pain measures in the open field. The top 25 genes with the greatest significant 
correlation with normalized rearing are shown as well as the effect of the Y1 and Y2 
receptor antagonists on these correlations. 
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Top 25 DSS-Induced Genes Correlated with Normalized Rear Duration 
Normalized	  Rear	  Duration	  
Acute	  Inflammatory	  Model	   Recovery	  Model	  














Serpina3m	   -­‐0.99	   -­‐0.41	   -­‐0.75	   Fcna	   -­‐0.99	   -­‐0.84	   0.25	  
Vcam1	   -­‐0.99	   0.87	   -­‐0.70	   Gsn	   -­‐0.99	   -­‐0.05	   -­‐0.22	  
Pdgfra	   -­‐0.99	   -­‐0.37	   -­‐0.38	   Gm885	   -­‐0.98	   0.20	   -­‐0.29	  
Serpina3n	   -­‐0.99	   0.06	   -­‐0.77	   Itih3	   -­‐0.98	   -­‐0.78	   -­‐0.24	  
Alox5ap	   -­‐0.99	   0.74	   -­‐0.04	   Chi3l3	   -­‐0.98	   -­‐0.91	   -­‐0.43	  
Dusp1	   -­‐0.99	   0.41	   -­‐0.01	   5033406O09Rik	   0.97	   0.59	   0.59	  
Ggt5	   -­‐0.99	   0.69	   -­‐0.82	   Tmem119	   -­‐0.97	   -­‐0.89	   0.66	  
Cp	   -­‐0.99	   0.37	   -­‐0.90	   Ctla2a	   -­‐0.97	   -­‐0.91	   -­‐0.31	  
Cyth4	   -­‐0.99	   0.71	   -­‐0.44	   Axin2	   0.97	   0.29	   0.78	  
B3gnt6	   0.99	   -­‐0.35	   0.28	   C2	   -­‐0.97	   0.20	   -­‐0.23	  
Siglec1	   -­‐0.99	   0.68	   0.03	   2010002N04Rik	   -­‐0.96	   -­‐0.99	   0.25	  
Homer2	   0.99	   -­‐0.13	   -­‐0.30	   Hr	   0.96	   0.42	   0.45	  
Plekhg6	   -­‐0.99	   0.30	   0.82	   Tgfbr2	   -­‐0.96	   -­‐0.92	   -­‐0.27	  
Tcirg1	   -­‐0.99	   0.87	   -­‐0.07	   1500011B03Rik	   -­‐0.96	   -­‐0.94	   -­‐0.78	  
Gm12185	   0.99	   0.44	   -­‐0.17	   Cd163	   -­‐0.95	   -­‐0.89	   0.65	  
Chrd	   -­‐0.99	   0.98	   -­‐0.73	   Lbp	   -­‐0.95	   -­‐0.85	   -­‐0.16	  
Tmem176b	   -­‐0.99	   0.80	   -­‐0.89	   Tmco3	   0.95	   0.81	   0.16	  
Ms4a6d	   -­‐0.98	   0.32	   -­‐0.57	   Inhbb	   -­‐0.95	   -­‐0.93	   -­‐0.19	  
Ccl25	   0.98	   0.47	   -­‐0.01	   Adamts5	   -­‐0.95	   -­‐0.58	   0.36	  
P2ry13	   -­‐0.98	   0.26	   -­‐0.17	   Dio2	   -­‐0.95	   -­‐0.97	   -­‐0.03	  
Ppy	   -­‐0.98	   0.24	   0.37	   Cxcl13	   -­‐0.95	   -­‐0.66	   -­‐0.35	  
Ifitm1	   -­‐0.98	   0.84	   -­‐0.36	   Apoe	   -­‐0.95	   0.02	   0.06	  
Mrc1	   -­‐0.98	   0.20	   -­‐0.82	   Slc39a14	   -­‐0.95	   -­‐0.96	   0.03	  
Hmha1	   -­‐0.98	   0.92	   -­‐0.68	   Lrrc32	   -­‐0.95	   -­‐0.85	   0.36	  
Gpx3	   -­‐0.98	   -­‐0.27	   -­‐0.76	   Zfp759	   0.95	   0.36	   0.09	  
Table 19. Genes significantly altered by DSS exposure correlate strongly with 
visceral pain measures in the open field. The top 25 genes with the greatest significant 
correlation with normalized rear duration are shown as well as the effect of the Y1 and Y2 





The studies presented here were designed to determine the potential role of 
neuropeptide Y on peripheral organ inflammation during an acute inflammatory phase 
and following a recovery phase.  Since the Y1 and Y2 receptors are the most widely 
expressed Y receptors in the immune system, these studies focused on the role of NPY 
signaling via these receptors on DSS-induced bowel inflammation.  
The effects of DSS administration were robust and consistent from experiment to 
experiment. In vivo, the major landmarks of the disease were diarrhea, bloody stool and 
progressive significant weight loss throughout the duration of DSS treatment. DSS-
induced behavioral changes in the open field were also very consistent across 
experiments and included significant decreases in general movements such as grooming, 
locomotion, and rearing, and perhaps more notably, a preferential decrease in rearing 
behaviors relative to general locomotion.  
Post mortem tissue analysis also revealed a clear and consistent DSS profile. DSS 
treated mice had colons that were significantly shorter in size but generally did not differ 
in weight from control animals. The ceca of these animals also shrunk and weighed 
significantly less than that of controls.  Microscopically, DSS caused mucosal structure 
damage including a significant infiltration of immune cells, decreased crypt lengths, and 
significant thickening of the two smooth muscle layers making up the colon wall, and 
increases in submucosal space widths which appear to be a result of edema. This 
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potential increase in tissue fluid may explain why the shorter colons from DSS treated 
mice did not differ in weight from controls.  
The immunoassay profile of the DSS model was also consistent across 
experiments and was largely characterized by significant increases in colon protein 
expression of MPO and the proinflammatory cytokines IL-1β, IL-6, IL-12 and TNF-α as 
well as increases in the anti-inflammatory cytokines IL-2 and IL-4. Furthermore, colon 
protein levels of NPY were consistently elevated in DSS treated mice to levels that were 
significantly greater than control mice.  
Inhibition of NPY signaling via its Y1 receptor resulted in significant regulation of 
some DSS-induced inflammatory and disease parameters. DSS treated mice receiving the 
Y1 antagonist showed a slower rate of weight loss and lost significantly less weight 
overall compared to mice treated with DSS and vehicle.  In addition, Y1 receptor 
inhibition significantly decreased DSS-induced colon MPO protein expression and the 
expression of the proinflammatory cytokine IL-1β.  In contrast, Y1 receptor antagonism 
did not significantly alter DSS-induced tissue shrinkage, colon mucosa damage, muscle 
wall thickening or any behavior assessed in the open field.  
Similar to Y1 antagonism, inhibition of NPY signaling via its Y2 receptors 
resulted in a slower rate of weight loss in DSS treated mice and significantly less weight 
loss at terminal points. Y2 receptor antagonism also significantly decreased colon MPO 
protein expression but did not attenuate changes in cytokine expression in DSS-treated 
mice. In addition, and unlike Y1 receptor antagonism, inhibition of Y2 receptor signaling 
significantly increased the average rear duration in DSS treated mice, suggesting a 
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possible relief of pain-related behavioral changes. Y2 antagonism did not, however, 
prevent DSS-induced tissue shrinkage, colon mucosa damage or colon muscle wall 
thickening, similar to Y1 antagonism.  
In light of the findings that Y1 receptor antagonism inhibits the DSS-induced 
inflammatory cascade but does not alleviate visceral pain-related behavior and Y2 
antagonism only weakly attenuates the inflammatory response but significantly alleviates 
visceral pain-related behavior, particularly in the recovery period, the effect of co-
administration and mixed treatment with the antagonists was assessed. Co-administration 
of the antagonists in the acute inflammatory model did not result in an additive protective 
effect that was different from the effects of each antagonist alone for any of the measures 
assessed. A similar pattern was observed with co-administration of the antagonists in the 
recovery model. None of the measures assessed improved significantly in response to the 
antagonist co-administration except for the total time spent rearing. This measure did not 
improve significantly over Y2 antagonism alone, however, suggesting no advantage to 
concurrent treatment with both Y receptor antagonists.  
The inability of these antagonists to produce a positive additive effect may be 
explained by the mechanism of action of each receptor. That is, inhibition of the Y2 
autoreceptor alone is expected to increase NPY levels by preventing the negative 
feedback signals from action on this receptor. Similarly, inhibition of the Y1 receptor is 
expected to prevent post-synaptic signaling via this receptor, which may cause 
displacement of unbound NPY to its other post-synaptic receptors including the Y2 and 
Y5 receptors.  However, concurrent inhibition of the Y1 and Y2 receptors can potentially 
prevent both the negative feedback mechanism and Y1 post-synaptic signaling possibly 
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diverting most NPY signaling to another receptor type. Because Y5 is the other receptor 
type often observed on immune cells and implicated in the gastrointestinal system, it is 
possible that concurrent inhibition of the Y1 and Y2 receptors results in enhanced Y5 
receptor signaling, leading to the observed detrimental effects.  More work in this area is 
needed to test this hypothesis.  
The DSS model is one of the most commonly used animal models for IBD 
because of its simplicity and similarity in gross pathology to human IBD. That is, after 
about four days of oral exposure to a 4% DSS solution in place of drinking water, 
animals begin to demonstrate marked weight loss, diarrhea, bloody stool and signs of 
visceral discomfort, which is very similar to the human clinical manifestation of IBD. In 
addition to this model’s face validity, the distal colon gene profiling data presented in this 
dissertation supports the use of the DSS model as a potentially valid animal model of 
human IBD. Specifically, the high consistency of the RNA regulation profile in response 
to DSS across several experiments conducted independently leading to the DSS meta-
signature attests to the reliability of the model. Furthermore, the fact that this meta-
signature shows strong correlations with genetic data from human studies using colon 
tissue from UC and Crohn’s disease patients further reinforces the validity of this model.  
In line with the observed genetic profile similarity between the DSS model and 
human IBD, the gene profile data presented here also supports the idea that rearing 
behavior in the open field may be a valid measure to assess visceral pain in mice. It was 
observed that all four rearing measures showed strong and statistically significant 
correlations with DSS-induced gene alterations, an observation that was stronger when 
rearing and rearing time were normalized to ambulation and total rears respectively. 
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Taken together, these results suggest that DSS treatment induces an RNA signature that is 
similar to what is observed in human patients and that this signature strongly correlates 
with DSS-induced visceral pain-related measures in the open field.  
In addition to providing a reliable model for human IBD, the DSS model may also 
be an appropriate model for the study of the cross talk between the CNS and immune 
system. The greatest DSS-induced inflammation was observed in the distal colon, an area 
rich in autonomic innervation, both parasympathetic and sympathetic. Sympathetic fibers 
innervate the two plexuses in the distal colon, the Meissner (or submucosal) plexus and 
the Auerbach (or myenteric) plexus.  These plexuses have many properties similar to 
those of the CNS including the presence of synaptic mechanisms, interneurons, immune 
cells and a small extracellular space for neurotransmitter-mediated communication and 
peptide regulation. This anatomical and functional organization provides the necessary 
platform for a bidirectional communication system between the CNS and the immune.  
Some support for this idea is provided from the current experiments. NPY, an 
abundant neuromodulator often co-released with norepinephrine from sympathetic fibers 
was observed to be significantly increased in response to DSS treatment. Furthermore, 
inhibition of NPY signaling via its Y1 and Y2 receptors significantly toned down the 
immune response to DSS in the colon including decreases in MPO activity and cytokine 
expression suggesting a potential relationship between the sympathetic nervous system 
and the immune system.  
Though the data presented here provide some evidence for an interaction between 
the sympathetic nervous system and the immune system during DSS-induced 
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inflammatory disease, there is still a need to further elucidate the nature of this 
relationship. That is, it is still necessary to understand what is causing the upregulation of 
colon NPY and also what mechanisms the Y1 and Y2 antagonists are using to suppress 
inflammatory signals such as MPO activity and cytokine expression as well as weight 
loss. Similarly, it is of importance to unveil the mechanism by which the Y2 antagonist 
may be alleviating visceral pain in mice.  
Finally, the unexpected and often detrimental effects of co-treatment with both 
antagonists should be further studied. That is, if each antagonist on its own has the ability 
to decrease DSS-induced inflammatory signals, it might be expected that co-treatment 
would have at least an additive effect and perhaps even potentiate the anti-inflammatory 
effects of each antagonist. However, an unexpected detrimental effect was observed for 
some measures in the current studies when both antagonists were combined. One 
potential explanation for this seemingly contradictory result comes from the anecdotal 
observations that DMSO at high concentration increases the vulnerability of mice to 
DSS, potentially making these animals less responsive to the specific antagonists. 
Furthermore, it is also possible that DMSO directly or indirectly interfered with the 
effects of the Y1 receptor antagonist via alterations in immune cell infiltrate caused by 
this chemical. 
Based on the findings presented here, it appears that peripheral NPY may play a 
role in the regulation of colon inflammatory processes, particularly via Y1 receptor 
signaling.  These observations are in line with a growing body of literature that identifies 
peripheral NPY signaling as proinflammatory, an effect mainly mediated via its Y1 
receptor.  This area of research is, however, an area that still needs scrutiny as there are 
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also reports suggesting anti-inflammatory properties of NPY itself. The observation that 
peripheral Y1 receptor antagonism significantly downregulates DSS-induced 
inflammatory markers including MPO and proinflammatory cytokines provides support 
for the former theory rather than the latter.  
Similarly, NPY signaling via the Y2 receptor has been implicated the regulation of 
immune responses. The findings that Y2 receptor antagonism inhibits neutrophil activity 
as determined by decreased expression of MPO provide supports a growing body of 
evidence indicating a direct involvement of Y2 signaling in inflammatory responses. 
Furthermore, the unexpected finding that peripheral Y2 receptor antagonism alleviates 
DSS-induced visceral nociception in mice is contradictory to the well-documented anti-
nociceptive properties of NPY via this receptor in the CNS.  Though much work has been 
done on the role of this receptor in centrally mediated nociception, its peripheral effects 
have received little attention.  A better understanding of the role of this receptor in 
peripheral afferents is needed to more accurately interpret the findings presented here.  
Taken together, the data presented here provide evidence for the direct 
involvement of NPY in the neuroimmune crosstalk during inflammatory disease. The 
observation that NPY protein levels are elevated in inflamed colons is in line with similar 
observation in the serum of human patients suffering from inflammatory disease.  In 
addition, the observation that inhibiting NPY signaling via its Y1 and Y2 receptors 
reduces the inflammatory profile and has anti-nociceptive properties further supports the 
involvement of NPY in inflammatory processes.  
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Hence, it can be theorized that activation of an immune response in this case by 
administration of DSS leads to increases in sympathetic responses as determined by 
increases in NPY expression, which exacerbates the immune response via its peripheral 
Y1 and to a lesser extent, via the Y2 receptors. This increased inflammatory response can 
then be recognized by intrinsic systems including afferent autonomic fibers found in the 
myenteric and mesenteric plexuses, which in turn can relay these inflammatory signals 
back to the CNS completing an inflammatory loop.  In the case of the DSS model, this 
loop will continue to remain active in the presence of this irritant therefore contributing to 
the acute inflammation observed in this model. This is particularly supported by 
observations that upon DSS withdrawal, animals begin to gain back weight and the tissue 
pathology profile begins to reverse, indicating what can potentially be an inhibited 
inflammatory loop in the absence of the irritant.  
In sum, this series of experiments were designed to assess the potential role of 
NPY signaling via its Y1 and Y2 receptors in DSS-induced inflammation and pathology. 
It was observed that Y1 and Y2 receptor inhibition significantly slowed down DSS-
induced weight loss, Y1 inhibition significantly suppressed DSS-induced inflammatory 
mediators including MPO and proinflammatory cytokines, and Y2 inhibition suppressed 
MPO, albeit to a lesser extent than Y1 inhibition. In addition, Y2 signaling inhibition 
attenuated DSS-induced visceral pain-associated behaviors. These findings suggest that 
inhibition of these receptors could cause some alleviation of components of this 
inflammatory pathology albeit to a limited extent. Based on the gene expression signature 
data showing correspondence between DSS and human IBD signatures, these may be 
useful particularly for the treatment of human IBD. 
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Hematoxylin and Eosin (H&E) Staining Protocols 
	  









Hematoxylin and Eosin (H&E) Staining Protocols 
Established in Paraffin Embedded Tissue (Colon and Skin) 	  
Manual	  Progressive	  Method	  	  1.	  	  	  Xylenes,	  3X	   	  	  	  	  	  	  	  	  2min	  each	  	  	  2.	  	  	  100%	  Alcohol	   	  	  	  	  	  	  	  	  10	  Dips	  	  3.	  	  	  95%	  Alcohol,	  2X	   	  	  	  	  	  	  	  	  10	  Dips	  each	  	  4.	  	  	  Tap	  Water	  Rinse	   	  	  	  	  	  	  	  	  	  Rinse	  OH	  off	  	  5.	  	  	  Acidified	  Harris	  	   	  	  	  	  	  	  	  	  1-­‐3	  min	  	  	  	  	  	  	  	  Hematoxylin*	  6.	  	  	  Tap	  Water,	  2X	   	  	  	  	  	  	  	  	  10	  Dips	  Each	  	  7.	  	  	  0.25%	  Ammonia	   	  	  	  	  	  	  	  	  ~20-­‐30sec	  	  	  	  	  	  	  Water	  (dH20)**	  	  8.	  	  	  Tap	  Water,	  2X	   	  	  	  	  	  	  	  	  10	  Dips	  Each	  	  9.	  	  	  Eosin	   	   	  	  	  	  	  	  	  	  10	  Dips	  	  10.	  70%	  Alcohol	   	  	  	  	  	  	  	  	  10	  Dips	  	  11.	  95%	  Alcohol	   	  	  	  	  	  	  	  	  10	  Dips	  	  12.	  100%	  Alcohol,	  3X	  	  	  	  	  	  	  	  10	  Dips	  	  13.	  Alcohol:Xylene	   	  	  	  	  	  	  	  	  	  10	  Dips	  	  14.	  Xylenes,	  3X	   	  	  	  	  	  	  	  	  	  10	  Dips	   	  	  	  	  	  
	  
Manual	  Regressive	  Method	  	  1.	  	  	  Xylenes,	  3X	   	  	  	  	  	  	  	  	  2min	  each	  	  	  2.	  	  	  100%	  Alcohol	   	  	  	  	  	  	  	  	  10	  Dips	  	  3.	  	  	  95%	  Alcohol,	  2X	   	  	  	  	  	  	  	  	  10	  Dips	  Each	  	  4.	  	  	  Tap	  Water	  Rinse	   	  	  	  	  	  	  	  	  	  Rinse	  OH	  off	  	  5.	  	  	  Harris	  Hematoxylin	  	  	  	  	  10-­‐15min	  	  	  6.	  	  	  Tap	  Water,	  2X	   	  	  	  	  	  	  	  	  10	  Dips	  Each	  	  7.	  	  	  1%	  HCl	  in	  70%	  	   	  	  	  	  	  	  	  	  	  5-­‐10	  Dips	  	  	  	  	  	  	  	  Alcohol***	  	  8.	  	  	  Tap	  Water	  Rinse	   	  	  	  	  	  	  	  	  Rinse	  Acid	  	  	  9.	  	  	  0.25%	  Ammonia	   	  	  	  	  	  	  	  	  ~20-­‐30sec	  	  	  	  	  	  	  Water	  (dH20)**	  	  10.	  Tap	  Water,	  2X	   	  	  	  	  	  	  	  	  10	  Dips	  Each	  	  	  	  	  11.	  Eosin	   	   	  	  	  	  	  	  	  	  10	  Dips	  	  12.	  70%	  Alcohol	   	  	  	  	  	  	  	  	  10	  Dips	  	  13.	  95%	  Alcohol	   	  	  	  	  	  	  	  	  10	  Dips	  	  14.	  100%	  Alcohol,	  3X	  	  	  	  	  	  	  	  10	  Dips	  	  15.	  Alcohol:Xylene	   	  	  	  	  	  	  	  	  	  10	  Dips	  16.	  Xylenes,	  3X	   	  	  	  	  	  	  	  	  	  10	  Dips	  
Notes: 
* Acidified Harris Hematoxylin—add 4mL of glacial acetic acid to 96 mL of hematoxylin (e.g. 10mL of 
glacial acetic acid added to 240mL of hematoxylin) 
** 250 ųL of ammonia hydroxide in 100mL of distilled water (e.g. 625ųL of ammonia hydroxide in 250 
mL of dH20)  
*** Add 1mL of hydrochloric acid to 100mL 70% alcohol (e.g. 2.5mL HCl added to 250 mL of 70% 
alcohol) 
Protocol adapted from: Histotechnology-a self instructional text (2009, 3rd ed). Freida L. Carson & Christa Hladik. American Society 
for Clinical Pathology Press. Hong Kong. 
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Experiment 7 Top 25 DSS Upregulated Gene Network 
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